Non-invasive prenatal testing of haemoglobin Bart's Using Fetal DNA from the maternal plasma by SHERRY HO SZE YEE
NON-INVASIVE PRENATAL TESTING OF 
HAEMOGLOBIN BART’S USING FETAL DNA FROM 













NATIONAL UNIVERSITY OF SINGAPORE 
2008 
NON-INVASIVE PRENATAL TESTING OF 
HAEMOGLOBIN BART’S USING FETAL DNA FROM 










A THESIS SUBMITTED FOR THE DEGREE OF  
DOCTOR OF PHILOSOPHY 
DEPARTMENT OF OBSTETRICS AND 
GYNAECOLOGY 
NATIONAL UNIVERSITY OF SINGAPORE 
2008 
ACKNOWLEDGEMENTS 
I undertook this work at the Department of Obstetrics and Gynaecology, Yong 
Loo Lin School of Medicine, National University of Singapore. Firstly, I would 
like to thank my supervisors, A/P Mahesh Choolani, A/P Arijit Biswas and Dr 
Khalil Razvi for their constant support and scientific guidance. I would also 
like to thank A/P Sinuhe Hahn (University of Basel, Switzerland), Jacquie 
Keer (LGC Ltd, UK) and their team members for their friendship and guidance 
in the initial part of this project. I would also like to extend my gratitude 
towards A/P Evelyn Koay (Molecular Diagnosis Centre, NUH), A/P Samuel 
Chong (Department of Paediatrics, NUS) and Dr Jerry Chan for their 
invaluable advice. It has been a great pleasure working with our post-doctoral 
fellows, Dr Sukumar Ponnusamy and Dr Narasimhan Kothandaraman. My 
special thanks to my team members, Dr Nuruddin Binte Mohammed, Dr Qin 
Yan, Zhang Huoming, Zhao Changqing, Fan Yiping, Dr Sonia Baig, Ho Lai 
Meng and Tan Lay Geok who had made research enjoyable. I am most 
grateful to all laboratory, administrative, clinical and nursing staff who had 
been enthusiastic in the recruitment of patients, and patients who participated 
in this study. 
I would like to thank my family: my parents, especially my mother, Gek Khim, 
for her constant faith in me, and my siblings for their love and encouragement. 
Finally, I would like to thank my husband, Dennis Chong, for always being 




TABLE OF CONTENTS     
         
ACKNOWLEDGEMENTS    i
TABLE OF CONTENTS    ii
SUMMARY      v
LIST OF TABLES     vii
LIST OF FIGURES     viii
LIST OF ABBREVIATIONS    xi
Units/ Symbols      xiii
         
CHAPTER 1: INTRODUCTION   1
1.1 Background      1
1.2 Prenatal testing     4
 1.2.1 Prenatal screening    5
  1.2.1.1 Screening for chromosomal disorders 5
  1.2.1.2 Screening for single gene disorders 7
 1.2.2 Prenatal diagnosis    7
  1.2.2.1 8
   
Invasive procedures of prenatal diagnosis 
and their risks  
  1.2.2.2 Laboratory analysis of fetal material 10
1.3 Non-invasive prenatal diagnosis   12
 1.3.1 Fetal cells in maternal blood   13
 1.3.2 Fetal RNA in maternal blood   16
 1.3.3 Fetal DNA in maternal blood   17
  1.3.3.1 Sources of fetal DNA in maternal blood 21
Sensitivity and reproducibility of fetal DNA 23
  
1.3.3.2 
detection in maternal blood   
24
  
1.3.3.3 Preeclampsia - Disease model for 
quantitative analysis of fetal DNA in 
maternal blood  
42
  
1.3.3.4 Thalassaemia - Disease model for 
qualitative analysis of fetal DNA in 
maternal blood  
1.4 DNA molecular technologies   63
 1.4.1 DNA sequencing   63
 1.4.2 Conventional PCR    63
 1.4.3 Quantitative real-time PCR (QRT-PCR)  65
 1.4.4 Quantitative fluorescence PCR (QF-PCR)  70
 1.4.5 Fluorescence in situ hybridisation (FISH)  73
1.5 Experimental aims and hypotheses   78




CHAPTER 2: MATERIALS AND METHODS  80
2.1 Samples      80
 2.1.1 Research ethics board approval   80
 2.1.2 Amniotic fluid     80
 2.1.3 Trophoblast     80
 2.1.4 Fetal blood     81
 2.1.5 Umbilical cord blood   81
 2.1.6 Adult peripheral blood   81
 2.1.7 Cell lines     81
2.2 Deoxyribonucleic acid (DNA) analysis   82
 2.2.1 DNA isolation     82
  2.2.1.1 Amniotic fluid samples  82
  2.2.1.2 Trophoblast samples  82
  2.2.1.3 Blood samples - buffy coats and plasma 83
  2.2.1.4 Cell lines   83
 2.2.2 Conventional PCR    83
 2.2.3 Real-time PCR     84
 
2.2.4 Quantitative fluorescent (QF)-PCR (singleplex and 
multiplex) 87
  2.2.4.1 Microsatellite markers  88
 2.2.5 DNA sequencing    91
2.3 Fluorescence in situ hybridisation (FISH)   92
 2.3.1 FlashFISH     92
2.4 Statistical analysis     98
 2.4.1 PowerStats V12    98
 2.4.2 SPSS      99
         
CHAPTER 3: SENSITIVITY AND SPECIFICITY  100
OF REAL-TIME PCR      
3.1 Introduction      100
3.2 Materials and methods     100
3.3 Results      101
 3.3.1 Qualitative analysis and relative quantitation of APP  101
  gene expression     
 3.3.2 Sensitivities of HBB/APP multiplex QRT-PCR assays 103
 3.3.3 Standard curves    104
3.4 Discussion      105
         
CHAPTER 4: DETECTION OF FETAL DNA FROM  107
MATERNAL PLASMA      
4.1 Introduction      107




4.3 Results      109
4.4 Discussion      119
         
CHAPTER 5: USE OF MICROSATELLITE MARKERS  122
TO IDENTIFY HB BART'S IN FETAL DNA   
5.1 Introduction      122
5.2 Materials and methods     122
5.3 Results      125
 5.3.1 Assessment of maternal DNA contamination  132
 5.3.2 Heterozygosity and PIC   132
5.4 Discussion      133
         
CHAPTER 6: USE OF MICROSATELLITE MARKERS  137
TO EXCLUDE HB BART'S NON-INVASIVELY USING  
FETAL DNA FROM MATERNAL PLASMA   
6.1 Introduction      137
6.2 Materials and methods     138
6.3 Results      139
6.4 Discussion      148
         
CHAPTER 7: COMMENTARY    151
7.1 Introduction      151
7.2 Hypotheses      152
7.3 Findings      152
 7.3.1 Sensitivity and specificity of real-time PCR (QRT-PCR) 152
 7.3.2 Detection of fetal DNA from maternal plasma  153
 7.3.3 Use of microsatellite markers to identify Hb Bart's from  154
  fetal DNA      
 7.3.4 Use of microsatellite markers to exclude Hb Bart's  154
  non-invasively using fetal DNA from maternal plasma  
7.4 Limitations      155
7.5 Directions for future research    159
7.6 Conclusions      160
         








Alpha thalassaemia is the most common inherited monogenic disorder 
amongst haemoglobinopathies in Southeast Asia (SEA). Carriers of double 
alpha-globin gene deletions such as the common -SEA deletion, are at risk of 
carrying fetuses with the fatal haemoglobin (Hb) Bart’s hydrops fetalis. At-risk 
couples are offered prenatal diagnosis for subsequent genetic counselling 
when found to be affected. The risk of procedural-related miscarriages 
associated with prenatal diagnosis is however, unacceptable to some parents. 
Non-invasive techniques will allow at-risk couples to undergo prenatal 
screening with ease. 
The presence of cell-free fetal DNA in the maternal plasma is an alternative 
source of fetal genetic material for non-invasive prenatal testing. In principle, 
any fetal DNA sequence that differs from maternal DNA sequence can be 
identified in maternal plasma. The low level of fetal DNA in the prevailing 
maternal DNA is, however, a technical challenge.  
The aim of this thesis was to develop a highly sensitive and specific analytical 
system to detect fetal-specific markers in the maternal plasma for non-
invasive prenatal testing. I explored the use of polymorphic microsatellite 
markers that may differ between maternal and paternal alleles. This would 
allow the differentiation and identification between fetal paternally-inherited 
alleles from the prevailing maternal alleles in the maternal plasma. 
Quantitative fluorescence polymerase chain reaction (QF-PCR) technique is 




DNA with paternally-inherited microsatellite markers in the maternal plasma. 
This novel strategy was to analyse the specific fetal paternally-inherited 
microsatellite markers that lie within the breakpoints of the common alpha 
thalassaemia double gene deletions using QF-PCR. The detection of these 
fetal paternally-inherited microsatellite markers in the maternal plasma would 
show that the fetus has inherited the unaffected paternal allele and exclude 
the fetus of Hb Bart’s.  
I found that fetal paternally-inherited microsatellite markers can be detected 
and analysed in 10 out of 30 (33.3%) at-risk (n=3) and unaffected (n=7) 
maternal plasma samples using QF-PCR. Hb Bart’s was excluded non-
invasively with 100% accuracy using cell-free fetal DNA in maternal plasma. 
As such, more than one-third (37.5%, 3 out of 8) at-risk mothers carrying 
unaffected fetuses would avoid unnecessary invasive tests that could cause 
miscarriages. The presence of non-specific stutter peaks that mask 
paternally-inherited fetal STRs limits the detection rate.  
In conclusion, I have developed an analytical system for the detection and 
differentiation of small amounts of fetal paternally-inherited alleles from 
prevailing maternal alleles in the maternal plasma. The use of size-
fractionation and single nucleotide polymorphisms (SNPs) within the deleted 
regions may enhance the rate of detection. This non-invasive prenatal 
screening method would allow at-risk mothers carrying unaffected fetuses to 
avoid unnecessary invasive procedures. Hb Bart’s can therefore, be excluded 
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Prenatal diagnosis for chromosomal and monogenic disorders 
involves invasive procedures that carry 0.8-3.0% risks of 
miscarriage (Caughey et al., 2006). This small risk of miscarriage 
can be significant and unacceptable to at-risk couples who decline 
prenatal diagnosis (Sharda and Phadke, 2007). The presence of 
fetal cells and cell-free fetal DNA in the maternal blood offers non-
invasive sources of fetal genetic material for prenatal diagnosis. 
Definitive evidence that fetal cells circulate in the maternal blood 
was shown by Walknowska et al. in 1969 who reported XY 
metaphases in fetal lymphocytes in the peripheral blood of pregnant 
women carrying male fetuses (Walknowska et al., 1969). Fetal cells 
in maternal blood can be useful for non-invasive prenatal diagnosis 
(Kolialexi et al., 2007). However, recovery of rare fetal cells from 
the maternal blood remains a technical challenge and not yet 
clinically practical (Bischoff et al., 2003). Although there were many 
studies in isolating fetal cells from the maternal blood since 1969, 
none of these methods is acceptable for clinical application today 
due to technical challenges in isolating limited number of fetal cells. 
Current strategies for prenatal diagnosis on fetal cells in the 
maternal blood face technical challenges in the enrichment of fetal 
cells from the maternal blood, identification of enriched cells and 
precise analytical methods of these rare fetal cells for accurate 
diagnosis. The limited types of fetal-specific cells in maternal blood, 
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as well as the low frequency of fetal cells trafficking further limit 
clinical applications.  (Bianchi, 1999; Bianchi et al., 1999; Bianchi et 
al., 2002; Bohmer et al., 2002; Schueler et al., 2001; Jackson, 
2003). 
Cell-free fetal DNA in maternal plasma and serum has been shown 
to be potentially useful for non-invasive prenatal diagnosis. Since 
the demonstration of fetal DNA in the maternal plasma and serum 
by Lo et al. in 1997 (Lo et al., 1997), certain neurological disorders 
such as myotonic dystrophies (Amicucci et al., 2000), fetal 
chromosomal aneuploidies (Chen et al., 2001; Dhallan et al. 2007), 
sex-linked disorders (Bianchi et al., 2006; Costa et al., 2002; Wald 
and Morris, 2003; Hyett et al., 2005; Chi et al., 2006; Deng et al., 
2006; Guetta, 2006; Martinhago et al., 2006; Santacroce et al., 
2006; Stanghellini et al., 2006; Illanes et al., 2007), and fetal rhesus 
status (Finning et al., 2002; Lo, 1999; Zhong et al., 2000b; Pertl and 
Bianchi 2001; Zhong et al., 2001c; Finning et al., 2004; Bianchi et 
al., 2005; Hromadnikova et al., 2005; Bianchi et al., 2006; Di 
Simone et al., 2006; Minon et al., 2006; Tsang and Lo, 2007, 
Finning et al., 2007) were diagnosed non-invasively. Exclusion of 
congenital adrenal hyperplasia (CAH) with the detection of 
paternally-inherited genetic traits in maternal plasma was described 
by various groups (Chiu et al., 2002a). In addition, using MS 
analysis of SNPs, Ding et al. (2004) demonstrated that beta-
thalassaemia could be excluded non-invasively (Ding et al., 2004). 
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Increases in cell-free fetal DNA concentrations in the maternal 
plasma and serum had been described in fetal chromosomal 
aneuploidies (Lo et al., 1999a; Zhong et al., 2000a), preterm labour 
(Leung et al., 1998; Shimada et al., 2004), preeclampsia (Sekizawa 
et al., 2002; Shimada et al., 2004), intrauterine growth restriction 
(IUGR) (Lo et al., 1999b; Leung et al., 2001; Lau et al., 2002; 
Zhong et al., 2002; Zhong et al., 2004; Sekizawa et al., 2003), fetal-
maternal haemorrhage (Lau et al., 2000), and polyhydramnios 
(Zhong et al., 2000c). However, application is limited to only 
mothers carrying male fetuses as detection and quantitation is 
based on Y-chromosome specific sequences in the maternal 
plasma (Deng et al., 2006). In theory, fetal DNA sequences that 
differ from maternal DNA sequences can be identified in maternal 
plasma, thus allowing non-invasive prenatal testing of paternally-
inherited genetic diseases.  
The aim of this thesis was to explore the use of polymorphic 
microsatellite markers that differ in sequences between paternal- 
and maternal- inherited fetal alleles that may allow discrimination 
and differentiation between maternal and fetal DNA in the maternal 
plasma. Fetal alleles consist of one maternal-inherited allele and 
one paternal-inherited allele. I hypothesised that the paternal-
inherited fetal allele can be detected and identified amongst the 
maternal alleles in the maternal plasma. I demonstrated that 
paternal-inherited fetal alleles can be differentiated and analysed in 
the maternal plasma using polymorphic microsatellite markers. I 
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proceeded to investigate the usefulness of my strategy in clinical 
applications; in particular, exclusion of Hb Bart’s non-invasively in 
couples with alpha thalassaemia. I showed that Hb Bart’s can be 
excluded non-invasively with the detection of paternally-inherited 
microsatellite markers in the maternal plasma. This strategy allows 
at-risk mothers carrying unaffected fetuses to avoid unnecessary 
invasive prenatal diagnostic procedures and thus, eliminate any 
risks of procedure-related miscarriages. 
1.2 Prenatal testing 
The risk of fetal abnormality is present in every pregnancy. Without 
prenatal diagnosis, 1 in 50 babies are born with serious physical or 
mental handicap and as many as 1 in 30 with some form of 
congenital malformation (Harper, 2001). These may be due to 
structural or chromosomal abnormalities, or single gene disorders. 
Nine in ten of structural or chromosomal abnormalities occur 
spontaneously in low risk pregnancies without family history of 
genetic disorders. Therefore, prenatal screening tests are important 
to both high and low risk populations. Current worldwide prenatal 
testing guides recommend all pregnant women to undergo prenatal 
screening tests regardless of age (American College of 
Obstetricians and Gynecologists Committee statement on Practice 
Bulletins, 2007a). Prenatal screening is more an antenatal risk-
estimation exercise although the development of high-resolution 
ultrasound and the introduction of Down syndrome prenatal 
screening programmes that uses biochemical markers may exclude 
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or even diagnose fetal abnormalities (Chitty, 1998). Many prenatal 
screening tests have high false positive rates that include 
unaffected fetuses while identifying affected fetuses. In order to 
achieve reliable diagnosis of aneuploidy and single gene disorders 
such as thalassaemia, fetal cells and/or fetal DNA has to be 
obtained by invasive procedures such as amniocentesis, chorion 
villus biopsy or fetal blood sampling, for cytogenetic and/or 
molecular analysis. These diagnostic tests are invasive although 
they are highly accurate and are useful in the identification of 
affected fetuses within the high-risk population and/or with positive 
screening results. Current worldwide prenatal testing guides thus 
recommend women at risk of having a fetus with chromosomal 
disorder to undergo invasive testing (American College of 
Obstetricians and Gynecologists Committee statement on Practice 
Bulletins, 2007b). 
1.2.1 Prenatal screening 
In prenatal screening, a positive screening result may lead to 
invasive diagnostic tests that carry risks of procedure-related 
miscarriage (Farrell et al., 1999; Sharda and Phadke, 2007). A 
positive screening result may lead to the option of termination of 
pregnancy which may be unacceptable to some parents due to their 
religious, cultural, ethical and moral views (Harper, 2001). 
1.2.1.1 Screening for chromosomal disorders 
Every pregnant woman is at risk of having a baby with 
chromosomal disorders regardless of family history and maternal 
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age. In prenatal screening for chromosomal disorders, this risk is 
assessed according to the following parameters: (1) nuchal 
translucency measured by ultrasound, which increases in fetuses 
with Down syndrome, (2) neural tube defects (NTD), (3) presence 
of nasal bones assessed by ultrasound where nasal bones are 
absent in the majority of Down syndrome fetuses in the first 
trimester, (4) pregnancy-associated plasma protein A (PAPP-A), 
and (4) Quad screen which measures free beta-subunit of human 
chorionic gonadotrophin (free βhCG) measured in maternal serum, 
alpha-feto protein (AFP), conjugated estriol and inhibin A. PAPP-A 
is reduced and free βhCG is increased in pregnancies of Down 
syndrome fetuses (Nicolaides et al., 1992; Macri et al., 1994; 
Spencer, 1994; Spencer et al., 1994a; Spencer and Marcri, 1994; 
Spencer et al., 1994b; Larose et al., 2003). Deviations of these 
examined parameters from the median of normal pregnancies are 
converted into a risk factor by which the a priori risk is multiplied so 
as to arrive at the final risk for a specific fetal anomaly such as 
trisomies 21, 13 and 18. If the risk of fetal aneuploidy is high 
enough to justify an invasive test (for example, the cut-off value for 
the risk of having a Down syndrome baby is around 1 in 250, that is 
equivalent to the risk in a 35-year old woman at 12 weeks), invasive 
testing such as amniocentesis or chorionic villus sampling is offered 
(Spencer et al., 2003).  
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1.2.1.2 Screening for single gene disorders 
There are 6000 known single gene disorders affecting 1 out of 
every 200 births. Of these, haemoglobinopathies such as sickle cell 
disease and thalassaemias are the most common. As only a single 
gene is involved in each case, most of these monogenic diseases 
have simple inheritance patterns in family pedigrees that can be 
screened based on family history. Screening of autosomal 
recessive conditions such as cystic fibrosis amongst Caucasians 
and Canavan, Tay-Sachs disease within the Ashkenazi (and 
American) Jewish population, Sickle cell disease in individuals of 
African descent and the thalassaemias in Mediterranean, Middle 
East and Asian populations should not be based solely on family 
history. Within these at-risk populations, the couples have to be 
screened using biochemical or genetic analysis to determine their 
carrier status. These tests may investigate the mutations on the 
gene (e.g. ΔF508 deletion in cystic fibrosis), altered protein 
production (e.g. γ4 in alpha thalasaemia) or altered protein function 
(e.g. Hexosaminidase A activity in Tay-Sachs disease). Following 
these genetic tests of both parents, invasive prenatal testing will be 
offered to couples who are both found to carry a mutation as they 
will have a 1 in 4 risk of having an affected fetus due to Mendelian 
trait. 
1.2.2 Prenatal diagnosis 
Current methods of prenatal diagnosis for chromosomal disorders 
and single gene disorders involve invasive procedures such as 
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amniocentesis, chorion villus sampling (CVS) or fetal blood 
sampling (FBS) to obtain fetal genetic material for cytogenetic 
and/or molecular analysis. 
1.2.2.1 Invasive procedures of prenatal diagnosis and their 
risks 
Amniocentesis. Amniocentesis is usually offered to pregnant 
women between 15 to 17 gestational weeks. An area of the 
maternal abdomen is prepared aseptically before a 22-gauge 
needle is inserted into the amniotic cavity to obtain the amniotic 
fluid under continuous ultrasound guidance. Rate of fetal loss is 
between 1 in 400 and 1 in 200 procedures (CDC statement in Morb 
Mortal Wkly, 1995; CEMAT Group, 1998; Caughey et al., 2006) 
while the First- and Second- Trimester Evaluation of Risk (FASTER) 
trial reported a less than 1 in 200 amniocentesis loss rate (Malone 
et al., 2005). Amniocentesis also carries a low risk of uterine 
infection that can cause miscarriage in < 1 in 1000 procedures. 
Early amniocentesis has a higher risk (2.6%) of miscarriage than 
second trimester amniocentesis (0.8%). Talipes, a form of foot 
deformity increased 10-fold after early amniocentesis (1.3%) as 
compared to second trimester amniocentesis (0.1%) (Farrell et al., 
1999). Septicaemia is rare while amnionitis and amniotic fluid 
leakage are serious maternal complications that occur after 
amniocentesis in 0.1% and 3% cases respectively. These studies 
suggest that amniocentesis should be avoided less than 14 
gestational weeks. Early prenatal diagnosis will however, improve 
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clinical management and therefore, chorion villus sampling is 
offered to pregnant women at earlier weeks. 
Chorion villus sampling. CVS has emerged as the only safe 
invasive prenatal diagnostic procedure prior to the 14th week of 
gestation (Wapner, 2005). Therefore, it is usually performed 
between 10-13 gestational weeks by either transcervical or 
transabdominal approach. In transcervical approach, a cannula or 
biopsy forceps is inserted via the cervix into the placental 
substance while a needle is inserted through the maternal abdomen 
into the long axis of the placenta in transabdominal CVS. Tissue 
sample is drawn into a syringe containing heparin and nutrient 
medium in both procedures. Risk of miscarriage in CVS is accepted 
as slightly more than amniocentesis at 15-16 weeks (MRC Working 
Party Report, 1978). Between 1 in 200 and 1 in 100 women 
miscarry after CVS. For a woman with a retroverted uterus and has 
transcervical CVS, this risk increases to 5 in 100 (CDC statement in 
Morb Mortal Wkly, 1995). Transcervical CVS has an excess of 3% 
fetal loss rate compared with mid-trimester amniocentesis (Wald et 
al., 1998). Subchorionic haematomata and vaginal bleeding occur 
in up to 4% of cases after transcervical CVS (Brambati et al., 1987). 
Severe complications such as septicaemia in the mother or limb 
reduction defects in the fetus are rare. When procedure is 
performed under 10 weeks, risk of severe limb defects is high at 2% 
(Jenkins and Wapner, 1999). Limb haemorrhages caused by the 
disruption of fetal utero-placental blood supply have been shown in 
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animal studies (Webster et al., 1987). Facial haemorrhages in the 
human fetus were demonstrated during CVS using real-time 
fetoscopy (Quintero et al., 1992; Quintero et al., 1993). 
Fetomaternal haemorrhage and alloimmune sensitisation after CVS 
could endanger Rh D-negative mothers in future pregnancies 
(Rodeck, 1993). 
Fetal blood sampling. A 22-gauge needle is inserted through an 
aseptic area of the maternal abdomen into the umbilical vein or fetal 
intrahepatic vein to obtain fetal blood under continous ultrasound 
guidance. FBS carries a 2% risk of miscarriage and is usually 
performed after 20 weeks. Increased risk of fetal loss is associated 
with growth restricted or hydropic fetuses or if it is performed under 
18 weeks. FBS is not as common as amniocentesis or CVS. 
1.2.2.2 Laboratory analysis of fetal material 
Amniotic fluid contains cells (amniocytes), enzymes, metabolites 
and cell-free fetal DNA (Bianchi et al., 2001). Amniocytes can be 
cultured to obtain metaphase spreads for karyotyping or direct 
analysis using chromosomal fluorescence in situ hybridisation 
(cFISH) or polymerase chain reaction (PCR) (Caine et al., 2005; 
Moatter et al., 2007; Wauters et al., 2007). However, besides 
requiring 7 to 14 time-consuming days and being labour intensive, 
amniocyte culture risk failure (1%) and chromosomal mosaicism 
(0.5%) (Hsu and Perlis, 1984) and further invasive testing may be 
required. Enzymes and some metabolites from the supernatant and 
cultured or uncultured cells can be used for detecting inborn errors 
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of metabolism (Vamos and Liebaers, 1984; Galjaard, 1987). 
However, this had been replaced largely by molecular testing. DNA 
isolated from the supernatant, cultured or uncultured cells for array 
comparative genomic hybridisation (CGH) and quantitative 
fluorescence PCR analysis (QF-PCR) is useful as results are 
available within two days (Verma et al., 1998; Levett et al., 2001; 
Larrabee et al., 2004; Cirigliano et al., 2005; Cirigliano et al., 2006; 
Ochshorn et al., 2006; Miura et al., 2006; Brown et al., 2006; 
Lapaire et al., 2007a; Lapaire et al., 2007c; Shaffer and Bui, 2007). 
Chorionic villus is a source of fetal DNA that can be obtained in the 
first trimester without cell culture. Uncultured mononuclear 
cytotrophoblast cells contain sufficient number of cells in mitotic 
metaphase to allow rapid karyotyping and banding studies when 
exposed to colchicines (Simoni et al., 1983). For conventional 
karyotyping analysis, the mesenchymal core of the villi can be 
cultured. Similarly to amniotic fluid, chorionic villi is useful for 
biochemical and molecular prenatal diagnoses (Desnick et al., 1992; 
Soler et al., 2007). 
Metaphase spreads for karyotyping can be obtained rapidly with the 
culture of fetal white blood cells (lymphocytes) while DNA can be 
isolated with fetal whole blood obtained from FBS. FBS was initially 
used in the globin chain or red cell analysis for diagnosis of 
haemoglobinopathies. With the increase in the early diagnosis of 
abnormalities by molecular methods however, fetal blood is usually 
not required.  
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1.3 Non-invasive prenatal diagnosis 
Invasive prenatal diagnosis can cause a psychological burden on 
the pregnant woman. The anxiety about the invasive nature of the 
procedure and the attendant risk of fetal loss of a wanted 
pregnancy can cause emotional stress (Weinman and Johnston, 
1988; Beeson and Golbus, 1979; Kowalcek, 2007). Missed 
diagnosis of handicapping congenital diseases occurs in at-risk 
women who reject invasive prenatal diagnosis due to the risk of 
fetal loss or morbidity (Chitty, 1998). Non-invasive and accurate 
prenatal diagnosis that does not carry any risk of procedural-related 
fetal loss is therefore desirable to at-risk pregnant women. The 
presence of intact fetal cells and cell-free fetal DNA circulating in 
the maternal blood forms the basis for non-invasive access to fetal 
genetic material for prenatal diagnosis of chromosomal and 
monogenic disorders. Walknowska et al. found the presence of fetal 
cells in the maternal circulation in 1969 (Walknowska et al., 1969). 
Lo et al. found circulating fetal DNA in both maternal plasma and 
serum (Lo et al., 1990). Since these discoveries, there have been 
studies to isolate and analyse these fetal genetic material for non-
invasive prenatal diagnosis (Jackson, 2003). Recovery of intact 
fetal cells would allow accurate genetic diagnoses of all 
aneuploidies and single gene disorders. However, the rarity of 
these cells in the maternal circulation (1 to 2 fetal cells per ml 
maternal blood) (Bianchi et al., 1997) and evidence that these cells 
may be undergoing apoptosis (van Wijk et al., 2000; Kolialexi et al., 
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2001) are factors that cause technical difficulties limiting clinical 
application. The significant quantity of fetal DNA in the maternal 
plasma and serum (Lo et al., 1998b) contribute to the rapid 
developments of clinical applications for fetal DNA even though it is 
limited to paternally-inherited monogenic diseases.  
1.3.1 Fetal cells in maternal blood 
In 1893, Schmorl found trophoblast sprouts in the lungs of pregnant 
women diagnosed with eclampsia and speculated that feto-
maternal trafficking might occur in normal gestations (Schmorl, 
1893; Lapaire et al., 2007b). Definitive proof that fetal cells circulate 
in maternal blood was reported by Walknowksa et al. who found XY 
metaphases in fetal lymphocytes in the peripheral blood of women 
pregnant with male fetuses (Walknowska et al., 1969). 
Fluorescence-activated cell sorting (FACS) was used in the late 
1970s and early 1980s to detect and isolate fetal cells (Herzenberg 
et al., 1979; Iverson et al., 1981; Bianchi et al., 1990; Wachtel et al., 
1991; Price et al., 1991; Tse et al., 1994; Lewis et al., 1996; Sohda 
et al., 1997). Molecular genetic techniques such as PCR and FISH 
were used to detect unique fetal DNA sequences from the cellular 
components of the blood of pregnant women in the 1990s. The 
scarcity of these cells in maternal blood makes accurate 
quantitation and genetic diagnosis difficult. The true prevalence of 
fetal cells in maternal blood is unknown. The number of fetal cells in 
the maternal circulation was estimated to be 1 to 2 fetal cells per ml 
of maternal blood (Bianchi et al., 1997). The rarity of fetal cells in 
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the maternal blood and the limited types of specific fetal cell 
markers by which it can be distinguished and isolated from the 
maternal cells are drawbacks of using fetal cells for non-invasive 
prenatal diagnosis (Bischoff et al., 2002; Sekizawa et al., 2007). 
Other approaches to recover fetal cells from maternal blood include 
density gradient centrifugation (Sitar et al., 1997; Oosterwijk et al., 
1998; Sekizawa et al., 1999; Kwon et al., 2007), magnetic activated 
cell sorting (MACS) (Busch et al., 1994a; 1994b; Ganshirt-Ahlert et 
al., 1992; 1993), immunomagnetic bead separation (Bianchi et al., 
1996; Wessman et al., 1992), use of magnetic colloid (Steele et al., 
1996; Martin et al., 1997), avidin-conjugated columns with 
biotinylated antibodies (Hall et al., 1994), micromanipulation of 
individual cells (Takabayashi et al., 1995; Sekizawa et al., 1996a; 
Sekizawa et al., 1996b; Sekizawa et al., 1998; Watanabe et al., 
1998), charged flow separation (Wachtel et al., 1996; 1998) and 
micromachined separation device based on size and deformation 
characteristics (Mohamed et al., 2007). Enrichment of fetal cells 
from the maternal blood for noninvasive prenatal diagnosis of 
haemoglobinopathies had been demonstrated. Cheung et al. (1996) 
recovered 7-22 fetal nucleated red blood cells from 16-18 ml 
maternal blood obtained in 10 pregnancies (10-12 gestational 
weeks). Of the 10 pregnancies, one was at risk of sickle cell 
anaemia and another at risk of beta-thalassaemia. Following MACS, 
slides were prepared and stained with anti-ζ (embryonic) and/or 
anti-γ (fetal) antibodies before microdissection of positive fetal 
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erythroblasts for PCR. Reverse dot blot analysis showed normal 
genotypes for both fetuses as confirmed by the molecular diagnosis 
of their respective CVS samples. In another study on 6 couples at 
risk for beta-thalssaemia, 7.5 ml maternal blood was obtained and 
subjected to density gradient centrifugation before slides 
preparation for immunostaining with anti-ζ antibodies.  Three 
different beta-thalassaemia mutations were analysed in 
micromanipulated erythroblasts that were stained strongly positive 
with anti-ζ globin antibodies and all results were concordant with 
results from CVS analysis. In two cases, only weakly stained anti-ζ 
globin erythroblasts were found and they were determined as 
maternal in origin as results were not confirmed by CVS diagnosis 
(Di Naro et al., 2000). Lau et al. (2005) obtained 3 ml maternal 
blood from 8 known Hb Bart’s pregnancies (10-29 weeks’ gestation) 
and 40 at-risk pregnancies (7-14 weeks’ gestation). Blood smears 
using 3 µl whole blood were prepared for immunofluorescence 
staining with anti-α-globin and anti-ζ-globin antibodies. Fetal cells 
that were positive for Hb Bart’s expressed only ζ-globin and lack α-
globin expression. Therefore, fetal nonnucleated red blood cells 
stained with anti-ζ but not with anti-α globin antibodies were 
captured and documented with a fluorescence imaging system. 
Cells that expressed only ζ-globin were found in 15 out of 16 
pregnancies affected by Hb Bart’s but were not detected in 23 out 
of 24 unaffected pregnancies. It was also observed that the majority 
of fetal cells expressing ζ-globin appeared larger than maternal 
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cells expressing α-globin. Although noninvasive prenatal diagnosis 
of haemoglobinopathies using fetal cells from the maternal blood 
had been demonstrated, these methods are laborious and time-
consuming. Large-scale validations and subsequent 
implementation into diagnostic service laboratories can be 
challenging as compared to analysing fetal nucleic acids in 
maternal blood. 
1.3.2 Fetal RNA in maternal blood 
The presence of fetal RNA in maternal plasma was demonstrated 
by Poon et al. (Poon et al., 2000). Studies showed that placental-
derived mRNA species, such as human placental lactogen (hPL), 
beta-subunit of human chorionic gonadotrophin (βhCG), and 
corticotrophin-releasing hormone (CRH), are readily detectable in 
maternal plasma and their expression correlates with the 
corresponding protein product levels (Ng et al., 2003b; Go et al., 
2004; Ge et al., 2005). Using chromosome 21-encoded mRNA as 
the fetal marker, placental-derived transcripts can be detected in 
the maternal plasma (Oudejans et al., 2003). The major advantage 
of using fetal RNA instead of fetal DNA in qualitative non-invasive 
prenatal tests is that it is gender- and polymorphism- independent. 
Studies measuring fetal mRNA levels in maternal plasma in 
preeclamptic pregnancies had been done using CRH as the fetal 
marker (Ng et al., 2003a). The use of plasma mRNA as a non-
invasive prognostic marker to monitor the onset of preeclampsia will 
not be limited by fetal gender (Lo and Chiu, 2004; Tong and Lo, 
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2006). Circulating placental mRNA measurement may also be 
applicable in the non-invasive detection of fetal chromosomal 
aneuploidies (Ng et al., 2004; Lo et al., 2007a). With the use of 
expression microarray technology, new placental-derived mRNA 
markers can be found systematically. Transcripts identified by this 
approach are pregnancy-specific as shown by clearance studies 
(Tsui et al., 2004; Chiu et al., 2006). The rapid clearance after 
delivery and the stability of placenta mRNA species in maternal 
plasma when compared to maternal mRNA (Ng et al., 2002; Tsui et 
al., 2002) suggests that circulating mRNA molecules could be 
practical markers for clinical applications (Wong and Lo, 2003). 
1.3.3 Fetal DNA in maternal blood 
In contrast to fetal cells in maternal blood, fetal DNA can be readily 
detected in maternal plasma and serum (Bianchi and Lo 2001; Lo 
and Poon 2003; Birch et al., 2005; Galbiati et al., 2005). In 1997, Lo 
et al. demonstrated the presence of fetal DNA in the plasma and 
serum from healthy pregnant women (Lo et al., 1997). The amount 
of fetal DNA was estimated to be 3-6% of total DNA in the maternal 
plasma by term using quantitative real-time PCR (QRT-PCR). In 
plasma, fetal DNA reached a mean of 25.4 genome equivalents 
(GE)/ml (range 3.3 – 69.4) in early pregnancy and 292.2 GE/ml 
(range 76.9-769) in late pregnancy. Fetal DNA can also be detected 
in small but substantial amounts (3.4% of total serum DNA) in 
serum (Lo et al., 1997; Lo et al., 1998b). These findings suggested 
that the fetal genetic material could be useful for the non-invasive 
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prenatal diagnosis of the fetus. The detection of fetal DNA 
sequences is dependent on the sensitivity of the assay and the 
amount of target fetal sequences. Using Y-chromosome-specific 
PCR, fetal DNA can be detected in maternal blood in as early as 4 
weeks’ gestation (amenorrhoea, post conception) (Thomas et al., 
1995; Illanes et al., 2007). Fetal DNA has been shown to be 
detectable in the plasma of women who had undergone assisted 
reproduction in as early as 5+2 gestational weeks (Rijnders et al., 
2003). Since the concentration of fetal DNA in the plasma fraction 
was 21-fold greater than in the cellular fraction (Lo and Poon, 2003), 
it is likely that the origin of Y-chromosome-specific sequences came 
from cell-free fetal DNA and not from intact fetal cells. Cell-free fetal 
DNA is more commonly detected in 7 weeks and concentration 
increases as pregnancy advances (Lo et al., 1997; Lo et al., 1998b; 
Birch et al., 2005). Several studies to assess the sensitivity and 
specificity of fetal DNA in maternal plasma during the 1st and 2nd 
trimesters had been reported (Costa et al., 2001; Sekizawa et al., 
2001; Honda et al., 2002; Birch et al., 2005). The overall 87-100% 
sensitivity with 100% specificity was observed using QRT-PCR 
amplification of Y-specific sequences in maternal plasma of 
pregnancies carrying male fetuses (Avent and Chitty, 2006). Ariga 
et al (2001) combined real-time kinetic PCR with liquid oligomer 
hybridisation with 32P-labelled probes to quantify Y-chromosome-
specific sequences throughout pregnancy (Ariga et al., 2001). In 
normal pregnancies, fetal DNA concentrations increased from 10.1 
 19 
to 130.5 copies per 0.5 ml maternal plasma in 20 women carrying a 
male fetus from the 1st to 3rd trimester. During the last 8 weeks of 
gestation, there is a sharp increase of fetal DNA maternal plasma 
(Lo et al., 1998b) that might be related to the gradual breakdown of 
the maternal-fetal interface/placental barrier (Bianchi, 2000). Chan 
et al. (2003) showed a positive correlation with gestational age in 
the 3rd trimester with a mean increase of 29.3% fetal DNA each 
week (Chan et al., 2003). Concentrations of fetal DNA in the 
maternal plasma of normal pregnancies throughout gestation 
provide a comparative set of standard values for monitoring 
mothers in pregnancy-related pathological complications such as 
pre-term labour and preeclampsia by measuring the fetal DNA 
concentrations in the maternal plasma. Farina et al. (2002) showed 
a significant correlation between early pregnancy (10-22 gestational 
weeks) and total fetal DNA concentrations among 63 euploid 
pregnancies that was normally distributed (Farina et al., 2002). Cell-
free fetal DNA was also found in a variety of body fluids for example 
amniotic fluid (Bianchi et al., 2001; Lapaire et al., 2007a; Lapaire et 
al., 2007c), cerebrospinal fluid (Angert et al., 2004) and maternal 
urine (Al-Yatama et al., 2001). The kidney barrier is found to be 
permeable to polymeric cell-free DNA by the detection of male-
specific sequences in the urine of females receiving blood 
transfusion from males or carrying a male fetus (Botezatu et al., 
2000). However, despite using a very sensitive nested-PCR and a 
highly reproducible real-time PCR assay, Zhong et al. (2001a) 
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found no male-specific sequences in urine samples obtained from 8 
women pregnant with male fetuses even though maternal DNA 
sequences can be detected. To determine the source of this cell-
free maternal DNA, urine from female kidney transplant patients 
who had received male kidneys were analysed. Y chromosome-
specific sequences were detected in these samples and urinary 
DNA microchimerism was suggested. Quantitative analysis of Y 
chromosome-specific sequences in serially-obtained samples 
suggests the elevation of transplant-derived sequences during 
periods of graft rejection. These results suggest that the 
measurement of graft-derived urinary DNA may serve as a new 
marker for kidney graft tolerance (Zhong et al., 2001a). Transrenal 
DNA (Tr-DNA) is a class of cell-free urinary DNA that originated 
from apoptotic cells. Tr-DNA containing fetal sequences has been 
isolated from the urine of pregnant women. It was suggested 
recently that potential applications of Tr-DNA-based tests cover a 
broad area of molecular diagnostics and genetic testing, including 
non-invasive prenatal detection of inherited diseases (Umansky and 
Tomei, 2006). Studies reporting the presence of cell-free fetal DNA 
in matermal urine are controversial with some authors reporting 
positive results (Botezatu et al., 2000; Al-Yatama et al., 2001; Koide 
et al., 2005) while some others reporting negative results (Zhong et 
al., 2001a; Li et al., 2003; Illanes et al., 2006). Majer et al. (2007) 
tested urine samples collected in the third trimester of 151 pregnant 
women carrying male and female fetuses for the presence of Y-
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chromosome-specific DNA sequences. They detected male-specific 
DNA in 32.3% maternal urine samples collected from women 
pregnant with male fetuses. However, their data confirmed a study 
by Koide et al. (2005) who reported that the amount of fetal DNA in 
maternal urine is about 10,000 times less than the amount of fetal 
DNA in maternal plasma (Koide et al., 2005). The technical 
challenges in quantifying these low concentrations of cell-free fetal 
DNA in maternal urine seem unsuitable for noninvasive prenatal 
diagnosis (Majer et al., 2007). 
The rapid clearance of fetal DNA from the maternal circulation 
within 2-hour postpartum had been reported (Lo et al., 1999c). This 
means that DNA analysis of the maternal plasma will not be 
complicated by the persistence of fetal DNA from a prior gestation 
(Costa et al., 2001; Bianchi and Lo, 2001; Jackson, 2003; Benachi 
et al., 2003). 
1.3.3.1 Sources of fetal DNA in maternal blood 
The source of fetal DNA in maternal plasma is currently unknown. 
The placenta, fetal haematopoietic cells, and the fetus itself have all 
been considered as sources of fetal DNA (Bianchi, 2004; Maron 
and Bianchi, 2007). Most studies now concur that the placenta is 
the predominant source of fetal DNA in the maternal blood (Guibert 
et al., 2003; Masuzaki et al., 2004; Wataganara et al., 2005). Three 
mechanisms underlying the release of cell-free fetal DNA into the 
maternal circulation: (1) dying fetal and/or placental cells (necrotic 
or apoptotic), (2) active secretion of fetal DNA, (3) terminal 
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differentiation (Bischoff et al., 2005). Of these, apoptosis 
(programmed cell death) is the most likely candidate. Apotosis is 
the most common form of cell death that occurs throughout life from 
early embryogenesis to death. As 1011-1012 cells divide daily and 
the same amount of cells should be lost to maintain tissue 
homeostasis, approximately 1-10 g of DNA is expected to be 
degraded daily in the human (Rudin and Thompson, 1997). Given 
the high turnover, some DNA may escape final 
cleavage/degradation and therefore, appears in the plasma. The 
normal reference range of cell-free DNA concentration of DNA in 
plasma from healthy adults ranges between 103 to 104 GE/ml (Jen 
et al., 2000; Wu et al., 2002). During pregnancy, this DNA could be 
placental in origin. There were however, indications that cell-free 
fetal DNA originates from the breakdown of trophoblast. The 
relatively large volume (as compared to fetal cells) of cell-free fetal 
DNA in maternal plasma and the increase in amounts as pregnancy 
advances especially in the 3rd trimester suggests that the source of 
cell-free fetal DNA comes from the continuous cellular remodelling 
at the maternal-placental-fetal interface instead of apoptotic 
disintegration or immune destruction of fetal cells that enter and 
circulate within maternal blood (Kolialexi et al., 2001; Bischoff et al., 
2005). Intact fetal cells, however, represent a minute fraction of the 
total circulating cell-free fetal DNA. Levels of cell-free fetal DNA had 
been observed to increase in certain aneuploidies such as trisomy 
21 and trisomy 13 (Zhong et al., 2000a; Lo et al., 1999a). Placental 
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abnormalities may allow increased leakage of fetal DNA and cells 
into the maternal circulation (Uitto et al., 2003; Tjoa et al., 2006).  
1.3.3.2 Sensitivity and reproducibility of fetal DNA detection 
in maternal blood 
Studies focusing on the sensitivity and reproducibility of fetal DNA 
detection throughout pregnancy had been established (Sekizawa et 
al., 2001; Chan et al., 2003; Galbiati et al., 2005). Several studies 
monitored quantification of both cell-free fetal and total DNA in the 
maternal plasma across all three trimesters using QRT-PCR where 
the cell-free fetal DNA can be detected in 5 gestational weeks 
(Honda et al., 2002; Birch et al., 2005). Detailed methodology of 
accurate detection and quantification in these studies, however, 
were not described. The standardisation of techniques would allow 
comparison between laboratories and increase confidence in 
analytical results. This is especially important at low concentrations 
such as 1st trimester analyses where sampling effects relating to 
the stochastic distribution of the molecule may affect the accuracy 
of quantification (Stenman and Orpana, 2001). To address the 
accuracy of quantification and variation in DNA concentrations 
throughout gestation, a study in which 201 maternal blood samples 
between 5 and 41 gestational weeks were analysed. Male fetal 
DNA in the maternal plasma can be detected in as early as 5 
gestational weeks. Quantitative real-time PCR was used to assess 
the total and fetal DNA concentrations while weighted quasi-
Newton exponential analysis increases the accuracy of low-level 
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quantification. This increases confidence in the reliability of 
quantitative trace molecular measurements. QF-PCR using the 
ampFLSTR® SGM Plus™ kit to amplify 11 different loci was used to 
detect and identify paternally-inherited fetal alleles in the maternal 
plasma. Paternally-inherited fetal alleles can be detected and 
identified in only one 41-week plasma sample using STR analysis 
(Birch et al., 2005). 
1.3.3.3 Preeclampsia - Disease model for quantitative 
analysis of fetal DNA in maternal blood  
Hypertensive diseases complicate 5% to 8% of pregnancies. These 
are pregnancy-induced hypertension, essential hypertension, and 
hypertension due to chronic renal disease. All of the hypertensive 
states may lead to eclampsia. Preeclampsia (PE) is characterised 
by hypertension and associated proteinuria late in pregnancy of 
previous normotensive women. The underlying pathology is 
suspected to occur early in pregnancy, perhaps even at the time of 
implantation. The aetiology is unknown, but there is increasing 
evidence that the disorder is due to an immunological disturbance 
in which the production of blocking antibody is reduced. This may 
prevent the invasion of maternal spiral arteries by trophoblasts to 
any significant extent, leading to impairment of placental function. 
Widespread damage of the maternal endovasculature and 




Figure 1-1 Normal (A) and abnormal (B) placentation. 
(From Redman CW & Sargent IL. (2005) Latest advances in 
understanding preeclampsia. Science, 308:1592-4. Reprinted with 
permission from AAAS). 
 
Figure 1-2 Two stages of pregnancies leading to 
preeclampsia. 
 
Figure 1-1 shows (A) normal placentation and the effects of poor 
placentation leading to (B) preeclampsia at 15 – 16 gestational 
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weeks. The anchoring villi linked the placenta to the maternal 
deciduas and during normal placentation, cytotrophoblasts (blue) 
cross these placental-maternal bridges. They invade the maternal 
deciduas, adjacent spiral arteries and the arterial walls. The 
maternal endothelium (yellow) is replaced, causing the arterial wall 
to be remodeled. As the artery dilates, the smooth muscle is lost. 
Many NK cells (red) and some macrophages (purple) confront 
these invading cytotrophoblasts in the decidua to aid this deep 
invasion into the myometrial segments (A) for widespread spiral 
artery remodeling. Preeclampsia occurs when invasion is limited (B) 
with impaired arterial remodeling. Figure 1-2 shows the two stages 
of pregnancy in the development of preeclampsia (Redman and 
Sargent, 2005). 
HELLP is characterised by haemolysis, elevated liver enzyme 
levels and a low patelet count. The haemolysis in HELLP syndrome 
is a microangiopathic haemolytic anaemia. As red blood cells pass 
through the small blood vessels with damaged endothelial and fibrin 
deposits, they become fragmented. This is the cause of the 
presence of burr cells, spherocytes, schistocytes and triangular 
cells in the peripheral blood smear. The fibrin deposits in the 
sinusoids obstruct hepatic blood flow, causing periportal necrosis 
and an increase in liver enzyme levels. Subcapsular haematoma 
formation, intrahepatic haemorrhage or hepatic rupture may occur 
in severe cases. The increased consumption and/or platelets 
destruction causes thrombocytopenia. Approximately 90% of 
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patients present with generalised malaise, 65% with epigastric pain, 
30% with nausea and vomiting, and 31% with headache (Wolf, 
1996). The pathogenesis of HELLP syndrome remains unclear. The 
findings of this multisystem disease are attributed to abnormal 
vascular tone, vasospasm and coagulation defects. To date, no 
common precipitating factor has been found. The syndrome seems 
to be the final manifestation of some insult that leads to 
microvascular endothelial damage and intravascular platelet 
activation. With platelet activation, thromboxane A and serotonin 
are released, causing vasospasm, platelet agglutination and 
aggregation, and further endothelial damage (Sibai, 1990). Thus 
begins a cascade that is only terminated with delivery. 
HELLP syndrome occurs in approximately 0.2% to 0.6% of all 
pregnancies. In comparison, preeclampsia occurs in 5% to 7% of 
pregnancies.  Superimposed HELLP syndrome develops in 4% to 
12% of women with preeclampsia or eclampsia (Wolf, 1996). When 
preeclampsia is not present, diagnosis of the syndrome is often 
delayed (Gleeson et al., 1996). Although some investigators 
speculate that disseminated intravascular coagulopathy (DIC) is the 
primary process in HELLP syndrome, most patients show no 
abnormalities on coagulation studies. Patients who develop DIC 
generally do so in the setting of well-developed HELLP syndrome. 
All patients with HELLP syndrome may have an underlying 
coagulopathy that is usually undetectable. The risk factors for 
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HELLP syndrome differ from those associated with preeclampsia 
(Table 1-1).  
Table 1-1 Risk factors of preeclampsia and HELLP 
syndrome. 
Preeclampsia HELLP syndrome 
Nulliparous Multiparous 
Maternal age less than 20 years or 
greater than 45 years 
Maternal age greater than 25 years 
Family history of preeclampsia White race 
Minimal prenatal care                  
Diabetes mellitus; Chronic 
hypertension; Multiple gestation 
History of poor pregnancy outcome 
 
HELLP generally presents in the third trimester of pregnancy, 
although it occurs at less than 27 weeks of gestation in an 
estimated 11% of patients (Sibai et al., 1993). The syndrome 
presents antepartum in 69% of patients and postpartum in 31% of 
patients (Sibai, 1990). With postpartum presentation, the onset is 
typically within the first 48 hours after delivery; however, signs and 
symptoms may not become apparent until as long as seven days 
after delivery. 
Quantitative and qualitative analysis of fetal DNA in the 
maternal plasma.  
Pregnancy-related pathologies. Using quantitative real-time PCR 
strategies in the amplification of Y-chromosome specific SRY 
(Maron et al., 2007), a significant increase in the number of copies 
of fetal DNA (Y-chromosome specific sequences) was observed in 
pre-eclampsia (PE). Studies had shown that fetal DNA in maternal 
plasma was elevated in women with various complications of 
pregnancy, including PE, pre-term labor, invasive placenta, 
 29 
aneuploidies and hyperemesis gravidarum. Fetal DNA had also 
been reported to increase in cases of PE with HELLP syndrome 
(Leung et al., 1998; Lo et al., 1999b; Zhong et al., 2000a; Pertl and 
Bianchi, 2001; Leung et al., 2001; Zhong et al., 2001b; Zhong et al., 
2001d; Zhong et al., 2002; Swinkels et al., 2002; Sekizawa et al., 
2003; Shimada et al., 2004; Tjoa et al., 2004; Farina et al., 2004a; 
Farina et al., 2004b; Levine et al., 2004; Zhong et al., 2005a; Zhong 
et al., 2005b; Bauer et al., 2006).  
As the elevation of fetal DNA in the maternal plasma obtained from 
PE-affected pregnant women was widely reported, I used PE as a 
disease model in the initial stages of my study to demonstrate the 
efficacies in my protocols for the enrichment, detection and 
quantitation of fetal DNA in the maternal plasma. Interestingly, 
when whole blood analysis was performed, fetal DNA 
concentrations do not correlate with the severity of PE (Byrne et al., 
2003). Examples of pregnancy-related pathologies with an 
increased level of fetal DNA in the maternal plasma include preterm 
labor, intra-uterine growth retardation and hyperemesis gravidarum 
(Leung et al., 1998; Lo et al., 1999b; Smid et al., 2001; Sugito et al., 
2003). Pregnancies at risk for trisomy 21 or 18 can be identified 
non-invasively using cell-free fetal DNA. Using QRT-PCR, Lo et al. 
(1999) demonstrated a 2-fold increase in the fetal DNA levels for 
trisomy 21 when compared with euploid cases (Lo et al., 1999a). 
Subsequent studies supported these observations on trisomy 21, 
although increase is not observed in trisomy 18 (Zhong et al., 
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2000a; Wataganara et al., 2003). This suggests that different fetal 
growth and placental pathologies may result in different levels of 
fetal DNA. In 2003, Farina et al. evaluated the use of circulating 
fetal DNA as a 2nd trimester maternal serum marker of Down 
syndrome (DS). The median fetal DNA concentration was 1.7-fold 
greater in DS cases than in controls. When only fetal DNA was 
used as a non-invasive marker for DS, fetal DNA gives a 21% 
detection rate with a set 5% false-positive rate. If combined with the 
quadruple marker screen, non-invasive aneuploidy detection would 
improve to 86% at a fixed 5% false-positive rate (Farina et al., 
2003).  
Single gene disorders. Diagnosis of achondroplasia (Saito et al., 
2000), chromosomal translocations (Chen et al., 2001), 
Huntington’s disease (González-González et al., 2003), myotonic 
dystrophy (Amicucci et al., 2000), cystic fibrosis (Nasis et al., 2004), 
fetal aneuploidies (Lo et al., 1999a; Wataganara et al., 2003; Lo 
and Poon 2003; Tong et al., 2006)  and beta-thalassaemia (Chiu et 
al., 2002b; Ding et al., 2004; Li et al., 2005; Tungwiwat et al., 2007) 
were achieved using cell-free fetal DNA in the maternal plasma. 
Using primers and a probe specific for a deletion in codon 41/42 (-
CTTT) in the beta-globin gene, Chiu et al. (2002) excluded fetal 
inheritance of paternally-inherited codon 41/42 mutation in 2 out of 
8 pregnancies at risk of beta-thalassaemia major noninvasively 
using maternal plasma by real-time PCR. Matrix-assisted laser 
desorption/ionization time of flight mass spectrometry (MALDI-TOF 
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MS) with homogenous MassEXTEND (hME) and single allele base 
extension reaction (SABER) were used to analyse fetal inheritance 
of the four most common Southeast Asian beta-thalassaemia 
mutations (CD 41/41-CTTT, IVS2 654 (C → T), nt - 28 (A → G), 
and CD 17 (A → T) in maternal plasma of 12 pregnancies (7-21 
gestational weeks) at risk of beta-thalassaemia major. Among the 
12 at risk pregnancies, 11 pregnancies involved couples where 
both parents carried different β-thalassaemia mutations. While hME 
gave two false-negatives, the detection of paternal mutation in all 
six maternal plasma samples by SABER was completely 
concordant with the fetal genotype. With a selective enrichment of 
fetal DNA species by size fractionation in addition to PNA-clamp 
PCR before allele-specific real-time PCR, beta-thalassaemia 
mutations from size-fractionated DNA from maternal plasma can be 
detected (Li et al., 2005). Thirty-two maternal plasma DNA samples 
from pregnant women at risk of β-thalassaemia were analysed for 
the presence or absence of 4 common β-thalassaemia mutations 
that were paternally-inherited (IVSI-1, IVSI-6, IVSI-110, codon 39). 
Of the 32 maternal plasma samples that were analysed, 6 (86%) of 
7 cases with the IVSI-1 mutation, 4 (100%) of 4 with the IVSI-6 
mutation, 5 (100%) of 5 with the IVSI-110 mutation, and 13 (81%) 
of 16 with the codon 39 mutation were correctly identified. One 
false-positive test result was scored for the IVSI-1 mutation. Two 
cases with the codon 39 mutation were classified as uncertain and 
1 case was excluded due to lack of a diagnostic test results at the 
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time of analysis. The combined use of size fractionation, PNA 
clamps and fluorescence-based detection in allele-specific real-time 
PCR achieved an overall sensitivity of 100% and specificity of 
93.8%, with classified cases removed. These methods 
demonstrated the potentials of developing technologies and 
combining strategies to achieve non-invasive prenatal diagnosis 
with fetal DNA in maternal plasma.  
Sex-linked disorders and fetal Rhesus status. The strategy of 
analysing fetal loci that is completely absent in the maternal 
genome was implemented into routine clinical practice. The 
identification of male fetuses from the maternal plasma is 
dependent on the detection of male-specific sequences in the 
maternal plasma while the identification of RhD-positive fetus is 
based on the detection of RHD sequences in the maternal plasma 
of RhD-negative mothers. These methods are important clinical 
applications as noninvasive determination of fetal gender is useful 
for pregnancies at risk of sex-linked disorders while determination 
of fetal RhD status access whether the fetus is at risk of HDFN 
(haemolytic disease of the fetus and newborn). Sex-linked 
disorders such as haemophilia (Chi et al., 2006) and Fragile-X 
syndrome (Wald and Morris, 2003) occur only in males and 
therefore, early determination of fetal gender can exclude 
unnecessary invasive testing of female fetuses. Fetal gender 
determination is also useful in the clinical management of 
pregnancies at risk of congenital adrenal hyperplasia (CAH). CAH 
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individuals have high levels of androgens and as a result, female 
fetuses in CAH-affected pregnancies exhibit varying degrees of 
virilisation and can develop ambiguous genitalia from as early as 8 
gestational weeks. Administration of steroid dexamethasone in 
pregnancies with female fetuses suppresses the hypothalamic-
pituitary-adrenal axis and prevents virilisation. The determination of 
fetal gender in pregnancies at risk of CAH enables early cessation 
or avoidance of steroid treatment in all male fetuses (Chiu et al., 
2002; Bianchi, 2002). 
The most widespread clinical application of fetal DNA in maternal 
plasma is fetal Rh D determination (Rhesus D antigen) in rhesus-
negative pregnant women to assess whether the fetus is at risk of 
HDFN (Lo et al. 1998a, Finning et al., 2002; Harper et al., 2004; 
Bianchi et al., 2005; Brojer et al., 2005; Daniels et al., 2006; 
Geifman-Holtzman et al., 2006; Minon et al., 2007). Besides fetal 
Rh D determination, non-invasive prenatal tests using fetal DNA in 
maternal plasma for K, c, C and E were also developed (Finning et 
al., 2007). The International Blood Group Reference Laboratory 
(IBGRL) currently offers molecular tests for Fetal Rh Genotyping. 
The fetus of a sensitized RhD-negative mother and a father who is 
heterozygous for the D antigen has a 50% chance of being RhD 
positive and at risk of alloimmune intrauterine haemolysis, leading 
to fetal anaemia and death (Choolani et al., 2006). Determination of 
fetal RHD status can permit early intervention either by in utero 
transfusion by cordocentesis or administration of prophylactic anti-D 
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during pregnancy. These clinical measures will prevent 
alloimmunization caused by fetomaternal haemorrhage during the 
third trimester of pregnancy. Transfer of IgG1 and IgG3 antibodies 
across the placental barrier from the mother to the fetus causes 
HDFN. These antibodies then facilitate destruction of fetal red blood 
cells or erythroid progenitors throughout pregnancy and after birth. 
The screening of HDFN to identify at risk mothers during pregnancy 
includes monitoring levels of maternal anti-blood group-specific 
antibodies (anti-D and anti-c). The detection of elevated levels of 
anti-D in D-negative mothers leads to fetal Rh genotyping. This will 
avoid unnecessary antenatal prophylaxis of RhD-negative fetuses 
in RhD-negative mothers and allow early antenatal prophylaxis in 
affected mothers. However, invasive procedures such as 
amniocentesis and chorionic villus sampling are required to obtain 
fetal DNA for analysis. Besides a procedural-related risk of 
miscarriage, these invasive procedures might further sensitize the 
mother against fetal Rhesus antigens. Noninvasive detection of 
fetal RhD sequences in maternal plasma using real-time PCR will 
eliminate such procedural-related risks. The diagnostic accuracy of 
large-scale noninvasive fetal RhD determination using real-time 
PCR was more than 99% (Rouillac et al., 2004; Van der Schoot et 
al., 2006; 2008).  
The absence of a positive control demonstrating the presence of 
detectable fetal DNA limits Rh testing.  As such, the development of 
a robust method for discriminating single nucleotide differences in 
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plasma DNA using SABER followed by MALDI-TOF MS has 
opened up the possibilities of using a panel of single nucleotide 
polymorphisms as a positive control. A second approach is the 
recent successful development of fetal epigenetic markers that can 
be developed into universal fetal DNA markers. By using real-time 
quantitative methylation-specific PCR, unmethylated maspin 
sequences were detected in maternal plasma in all three trimesters 
of pregnancy and were cleared within 24 h after delivery, 
suggesting fetal in origin. The maternal plasma concentration of 
unmethylated maspin sequences was elevated by a median of 5.7 
times in preeclamptic pregnancies compared with nonpreeclamptic 
pregnancies. Hypomethylated maspin DNA is the first universal 
marker for fetal DNA in maternal plasma to allow the measurement 
of fetal DNA concentrations in pregnancy-associated disorders, 
irrespective of fetal gender and genetic polymorphisms. Differential 
DNA methylation between the placenta and maternal blood cells 
may be exploited to develop further markers for non-invasive 
prenatal assessment (Poon et al., 2002; Chim et al., 2005; Ding 
and Lo 2006; Li et al., 2006; Chow et al., 2007; Li et al., 2007). 
Other recent studies towards non-invasive prenatal diagnosis 
include the development of a digital RNA SNP strategy and the 
identification of candidate epigenetic biomarkers for non-invasive 
prenatal diagnosis of Down syndrome (Lo et al., 2007b; Old et al., 
2007). All these recent developments will also allow the eventual 
widespread utilization of maternal plasma DNA analysis for the non-
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invasive prenatal diagnosis of paternally-inherited disorders and 
aneuploidies (Lo, 2006; Tong et al., 2006; Bianchi, 2006). Earlier 
attempts to develop a strategy for non-invasive prenatal diagnosis 
of paternally-inherited disorders have been limited in that these 
tests identify cellular or DNA changes in maternal plasma only if the 
fetus is affected (Lau et al., 2005; Chen et al., 2007). Abnormality in 
these cases needs to be confirmed by invasive testing before major 
clinical decisions are made. Normality is assumed by the absence 
of a positive cellular or DNA signal. In these strategies, normality 
cannot be assured unless an invasive test is performed. Molecular 
diagnostics methods such as DNA sequencing, conventional 
polymerase chain reaction (PCR), real-time PCR, quantitative 
fluorescence-PCR (QF-PCR), and fluoresence in situ hybridisation 
(FISH) were used in this study to develop a test that could 
accurately reassure the parents that their fetus is normal, and 
narrow down the at-risk population that would in any case need 
invasive testing for confirmation. 
Current technologies to analyse fetal DNA in maternal plasma. 
Real-time PCR. Real-time PCR was instrumental in the detection 
and quantitation of Y-chromosome-specific DNA sequences (SRY) 
in maternal plasma throughout pregnancy in many studies. The use 
of real-time PCR to detect and quantify fetal SRY sequences in the 
maternal plasma was first demonstrated by Dennis Lo and 
colleagues in 1998 (Lo et al., 1998b). The amount of fetal DNA was 
estimated to be 3.4 - 6.2% of total DNA in the maternal plasma by 
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term. Since then, fetal SRY sequences can be detected and 
quantified in as early as 5 gestational weeks in many studies that 
uses real-time PCR (Birch et al., 2005; Galbiati et al., 2005). The 
overall 87-100% sensitivity with 100% specificity was observed 
when using real-time PCR amplification of Y-specific sequences 
(SRY, DYS14, DYZ3) in maternal plasma of pregnancies carrying 
male fetuses (Avent and Chitty, 2006). The use of multi-copy 
DYS14 sequence instead of single-copy SRY improves the 
sensitivity of real-time PCR (Zimmermann et al., 2005; Purwosunu 
et al., 2008). Targeting multi-copy DYS14 sequences of TSPY allow 
detection of fetal DNA in maternal plasma in as early as 4 weeks’ 
gestation (Illanes et al., 2007). A recent large-scale study to 
compare the efficiencies of predicting fetal gender using real-time 
PCR targeting DYS14 and SRY assays were performed on 145 
plasma samples from healthy pregnant women (11-12 gestational 
weeks). The efficiencies of DYS14 and SRY assays were found to 
be 97.9% and 80% respectively, indicating that the multi-copy 
DYS14 assay is the best approach for early fetal gender 
assessment as it is more sensitive, accurate and efficient than 
using the single-copy SRY assay (Picchiassi et al., 2008). The high 
sensitivities and specificities of real-time PCR to determine fetal 
gender noninvasively result in its implementation into routine clinical 
practice for pregnancies at risk of sex-linked disorders. 
Peptide-nucleic acid (PNA) clamps. PNA is an artificially 
synthesized polymer similar to DNA or RNA. In PNAs, the ribose 
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phosphate backbone is replaced with a polyamide backbone of 
repeating units of N-(2-aminoethyl)-glycine linked by peptide bones. 
The various purine and pyrimidine bases are connected to the 
backbone by methylene carbonyl bonds. There are no charged 
phosphate groups in the backbone of PNA and binding between 
PNA-DNA strands is stronger than between DNA-DNA strands due 
to the lack of electrostatic repulsion. PNA oligomers thus show 
greater specificity in binding to complementary DNAs forming PNA-
DNA strands with much higher thermal stability than corresponding 
DNA-DNA strands. In addition, PNA-DNA strands are more 
susceptible to destablization when single base pair mismatches are 
present. Thus, there is preferential amplification of the PNA-free 
target DNA strand than the wild-type PNA-DNA strand in maternal 
plasma due to the suppression of amplification by PNA. Allele-
specific real-time PCR with prior PNA-clamp PCR can therefore, 
selectively suppress the amplification of normal wild-type 
(background) allele (Li et al., 2008a). 
Size fractionation. The use of size fractionation in the enrichment 
of cell-free fetal DNA from cell-free maternal DNA in the maternal 
plasma was based on observations that the majority (>99%) of 
fetal-derived DNA molecules in the maternal circulation were 
shorter (<313 bp in length) than the maternal-derived DNA 
molecules (Chan et al., 2004). Agarose gel electrophoresis of 
extracted total cell-free DNA followed by excision of the gel slice 
containing approximately 100-300 bp for DNA isolation can enrich 
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cell-free fetal DNA from maternal DNA (Li et al., 2004). Many 
researchers combined different strategies in to improve sensitivity 
and specificity. With a selective enrichment of fetal DNA species by 
size fractionation in addition to PNA-clamp PCR before allele-
specific real-time PCR, paternally-inherited fetal mutant alleles for 
were readily detected (Li et al., 2008a). With this strategy, β-
thalassaemia mutations from size-fractionated DNA from maternal 
plasma can be detected (Li et al., 2005). The usefulness of PNA-
clamps was further demonstrated in a recent study by Galbiati and 
colleagues. PNA-mediated enriched PCR of maternal plasma was 
used in combination with microelectronic microchip analysis, direct 
sequencing and pyrosequencing to detect 7 frequent β-globin gene 
mutations in 41 pregnancies (9-12 gestational weeks) at risk of 
beta-thalassaemia. Results were completely concordant in the 
microchip analysis while >96% accuracy was achieved in direct 
sequencing and pyrosequencing (Galbiati et al., 2008).  
The effect of size fractionation of cell-free DNA on the detection of 
paternally inherited SNPs was examined when using either the 
homogeneous MassEXTEND (hME) or the single allele base 
extension reaction (SABER) assay for the Matrix-assisted laser 
desorption/ionization time of flight mass spectrometry (MALDI-TOF 
MS) analysis. Size fractionation led to increase in the sensitivity of 
hME and not SABER. This improvement in hME is attributable to 
the increased concentration of fetal DNA sequences relative to 
maternal cell-free DNA sequences in the size-fractionated 
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preparation. The use of size fractionation also gave clearer mass 
spectra signals although it did not lead to an increase in the 
sensitivity of detection in SABER (Li et al., 2006a). In a separate 
study, the combination of size fractionation and MALDI-TOF MS 
lead to a more precise detection of the fetal G1138A mutation in the 
maternal plasma of two pregnant women affected with 
achondroplasia (Li et al., 2007). Subsequently, MALDI-TOF MS 
hME was also used to detect paternally inherited SNP alleles in 
size-fractionated maternal plasma DNA. Allele-specific MALDI-TOF 
MS SABER was also used to detect fetal KEL1 gene in maternal 
plasma from KEL1-negative pregnant women with 94% accuracy 
(Li et al., 2008b).  
Mass spectrometry. Matrix-assisted laser desorption/ionization 
time of flight mass spectrometry (MALDI-TOF MS) is a powerful tool 
in SNP genotyping, quantitative DNA analysis, detection of 
insertions and deletions (indels) associated with microsatellite 
repeat instability (MSI) and short tandem repeats, gene expression 
analysis, DNA and RNA sequencing and DNA methylation analysis 
(Tang et al., 1999; Tolson and Nicholson, 1998; Ragoussis et al., 
2006). MALDI-TOF MS with a resolution of approximately 100 times 
higher than capillary sequencing for DNA analysis is effective in 
detecting paternally-inherited SNPs from maternal plasma for 
noninvasive prenatal diagnosis. Sensitivities of MALDI-TOF MS and 
TaqMan real-time PCR in detecting fetal-specific sequences in 
maternal plasma were compared and found to be comparable at 
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95% and 93% respectively (Li et al., 2006b). However, with the low 
quantity of fetal DNA in maternal plasma at approximately 20 
copies per ml of maternal plasma in the first trimester, MALDI-TOF 
MS is a preferred alternative to real-time PCR for the detection and 
analysis of cell-free fetal DNA in maternal plasma (Ding and Lo, 
2006).  
Two amplification steps enhanced the high sensitivity and 
specificity of MALDI-TOF MS. DNA is first amplified by PCR, 
followed by an additional linear amplification step called base 
extension reaction (homogeneous MassEXTEND, hME or single 
allele base extension reaction, SABER). In hME, base extension 
reaction is performed with an extension primer designed to anneal 
to regions immediately upstream of the mutation site. Both mutant 
and wild-type alleles were interrogated by the base extension 
primer which is being extended by adding a mixture of 2’,3’-
dideoxynucleoside triphosphates and deoxynucleotide 
triphosphates (dNTPs) (Tang et al., 1999). In SABER, primer 
extension was restricted to the fetal-specific allele of interest by the 
addition of a single species of dideoxynucleoside triphosphate 
(ddNTP) without any dNTP (Ding et al., 2004). Therefore, 
depending on the specific mutation introduced and the 
ddNTP/dNTP mixtures used, either one or two bases are added to 
the extension primer, producing two extension products from the 
wild-type DNA and the mutant DNA. MALDI-TOF MS was then 
used to discriminate between the single nucleotide differences by 
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the determination of the unique molecular mass of the target 
amplicons containing the interrogated SNP. The protocols of hME 
and SABER are similar, involving PCR amplification of the 
paternally inherited fetal allele and the maternal background alleles 
from maternal plasma, followed by a base extension reaction before 
MS analysis. The primary difference of SABER from hME is that a 
different base extension step that is restricted to the allele of 
interest to improve sensitivity is used. SABER was thus able to 
specifically detect fetal alleles instead of both fetal and maternal 
alleles (Ding et al., 2008). 
 
1.3.3.4 Thalassaemia - Disease model for qualitative analysis 
of fetal DNA in maternal blood  
Thalassaemia derives from the Greek word "thalassemia", meaning 
"anaemia by-the-sea" where the disease geographical association 
with the Mediterranean Sea was responsible for its naming; 
"Thalassa" is Greek for the sea, "Haima" is Greek for blood. William 
Bradford, professor of Paediatrics and Nobel Prize winner, George 
Whipple, coined the name “thalassaemia” at the University of 
Rochester, New York. In addition to the Mediterranean countries in 
which they were first recognised, thalassaemias, especially alpha 
thalassaemias are prevalent in Asia and the Far East. 
Thalassaemia occurs in all populations and ethnic groups. Together 
with worldwide migration, thalassaemia has become a global 
healthcare problem (Figure 1-3). Thalassaemia is caused by 
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mutations in the alpha- and beta- globin gene clusters located on 
chromosomes 16pter-p13.3 and 11p15.5, respectively. These 
genetic mutations result in reduced synthesis of on one or more of 
the globin subunits of haemoglobin, causing imbalanced globin 
synthesis that affects erythropoiesis and shortened red-cell survival. 
The thalassaemias are classified according to which chain of the 
globin molecule is affected; alpha thalassaemia, where alpha-globin 
is deficient, or beta thalassaemia, where beta-globin is deficient. 
Mutations of the alpha- and beta- globin gene clusters result in 
haemoglobinopathy with two main categories; structural 
haemoglobin variants and thalassaemias (Figure 1-4). 












Table 1-2 Pathophysiology of thalassaemia  
(adapted from Weatherall, 2001) 
Pathophysiology Consequences 
  
Effect of primary mutation on globin 
output 
Imbalanced globin synthesis 
Consequences of excess globin on red-
cell metabolism and survival 
Anaemia 




hepatomegaly, hypercoagulable state 
Consequences of profound anaemia Erythropoietin production and marrow 
expansion 
 Skeletal deformity 
 Metabolic abnormalities 
 Adaptivity changes in cardiovascular 
function 
Consequences of abnormal iron 
metabolism 
Iron loading 
 Damage to liver, endocrine organs 
and myocardium 
 Susceptibility to specific infections 
Effects of cell selection Raised levels of HbF 
 Heterogeneity of red-cell populations 
Effects of secondary genetic modifiers Variation in phenotype, particularly 
through HbF response 
 Variation in bilirubin, iron and bone 
metabolism 
Effects of therapy Iron overload, bone disease, blood-
borne infection, drug toxicity 
Effects of evolutionary history 
 
Variation in genetic background, 
response to infection 




Figure 1-4 Characteristics of haemoglobin in alpha and beta 
thalassaemias where red symbols indicate deficient globin 
synthesis.  
 
Haemoglobin (Hb) is the concatenation of haem and globin, where 
each subunit of haemoglobin is a globular protein (globin) 
embedded with a haem group. Each haem group contains an iron 
atom that binds oxygen and therefore, allows the transport of 
oxygen from the lungs to the rest of the body in vertebrates. The 
globular protein of normal haemoglobin is made up of two pairs of 
different globin chains that vary during embryonic, fetal and adult 
life (Figure 1-5).  During embryonic stage, the synthesis of these 









Selective survival of F-cells 
increased level in blood 
Precipitate in marrow 
ineffective erythropoiesis 
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Physiologically useless Physiologically useless 











sac erythroblasts is controlled by structural genes located on 
chromosomes 16 and 11 (Figure 1-6). These synthesized globin 
chains combine to form the embryonic haemoglobins Gower I 
(Huehns and Faroqui, 1975), Gower II (Gale et al., 1979), Portland I 
(Capp et al., 1967) and Portland II (Randhawa et al., 1984) (Table 
1-3). At 6-8 gestation weeks, the primary site of erythropoiesis 
shifts from the yolk sac to the liver and the three embryonic 
haemoglobins are replaced by fetal haemoglobins (HbF) as the 
predominant oxygen transport system. Epsilon- and zeta- globin 
production gives way to gamma-, alpha- and beta- globin 
production within definitive erythrocytes (Peschle et al., 1985a; 
Peschle et al., 1985b). HbF remains the principle haemoglobin until 
birth. After birth, a second globin switch occurs and beta-globin 
chain production accelerates, making HbA the predominant 
haemoglobin in adult life (Figure 1-7). 
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Figure 1-5 Schematic representation of the haemoglobin 
molecule. 
The haemoglobin molecule comprise of two α (yellow) and two β 
(grey) polypeptides. Each chain incorporates a haem group (red). 
Key amino acids, histidines (turquoise) within the heam pocket, 
coordinate with the haem group. [Adapted by permission from 
Macmillan Publishers Ltd: Nat Rev Drug Discov (Alayash, 2004)]. 
 
 




Table 1-3 Human haemoglobins and their synonyms. 
Hb name Synonym Structure 
A (HbA) Adult Hb α2β2 
A2 (HbA2) - α2δ2 
F (HbF) Fetal Hb α2γ2 
H - β4 
Barts - γ4 
Gower I Embryonic Hb ζ2ε2 
Gower II Embryonic Hb α2ε2 
Portland I Embryonic Hb ζ2γ2 
Portland II Embryonic Hb ζ2β2 
 
Figure 1-7 Ontogeny of globin chain synthesis in humans.  
 
Normal alpha chains contain 141 amino acids while normal beta 
chains contain 146 amino acids. Single amino acid substitutions in 
the alpha- or beta- chains of structural haemoglobin variants may 
alter the stability and functional properties of haemoglobin resulting 
in a clinical disorder e.g. HbS, HbC, and HbE. In haemoglobin S 
(HbS), a missense mutation in a single base pair (A→T) in codon 6 
of the beta-globin gene replaces glutamine (GAG; glu) with valine 
(GTG; val). The association of two normal alpha-globin subunits 
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with two mutant beta-globin subunits forms HbS that polymerise 
and precipitate in its deoxygenated form. This distorts the red blood 
cell into a sickled conformation resulting in sickle cell anaemia. 
Vaso-occlusion and shortened red-cell survival cause blood 
sequestration into the lung, liver or spleen, or the occlusion of 
cerebral vessels resulting in stroke in patients with sickle cell 
anaemia. They are also prone to infection throughout life (Serjeant, 
1993; Bunn; 1997; Balgir, 2005a; Balgir, 2005b; Al-Salem, 2006; 
Qureshi et al., 2006). In haemoglobin C (HbC), glutamine (GAG; glu) 
is replaced with lysine (AAG; lys) in codon 6 of beta-globin gene 
with a missense mutation of a single base pair (G→A). The 
compound heterozygous state for sickle cell and Hb C genes 
results in HbSC. Patients with HbSC experience a high frequency 
of aseptic necrosis of the femoral or humoral heads, haematuria, 
proliferative retinopathy, and a thrombotic tendency that may lead 
to massive pulmonary thrombo-embolic disease and death, 
espcially during pregnancy (Serjeant, 1992). Haemoglobin E (HbE) 
results from a mutation (G→A) in codon 26 of the beta-E-globin 
gene, replacing glutamine (GAG; glu) with lysine (AAG; lys). 
Patients with homozygous HbE (HbE/E) have no significant health 
problems and are characterised by mild, hypochromic, microcytic 
anaemia with reduced red blood cell survival. However, the 
compound heterozygous state for HbE and beta thalassaemia is 
HbE/beta-thalassaemia that falls within the category of 
thalassaemia intermedia. Patients with HbE/beta-thalassaemia 
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suffer from splenomegaly, skeletal deformities, poor growth, 
hepatomegaly and are transfusion-dependent. Its high prevalance 
in Southeast Asia poses a significant health problem (Fucharoen 
and Winichagoon, 1997; Rees et al., 1998b; Rees et al., 1998a; 
Vichinsky, 2005).  
Beta thalassaemia. Beta thalassaemias result from reduced 
synthesis of beta-globin chains of adult haemoglobin and are 
classified mainly into beta thalassaemia major (or Cooley's 
anaemia), beta thalassaemia minor (or beta thalassaemia trait), and 
thalassaemia intermedia (Table 1-4). The two genetic defects that 
produce beta thalassaemias are (1) nondeletional, where single 
base substitution or small deletion or inserts occur near or 
upstream of the beta-gloin gene, usually in the promoter regions; (2) 
deletional, where larger deletions occur involving the beta-globin 
gene. 
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Table 1-4 The different forms of beta thalassaemia.  
β thalassaemia Forms 
β thalassaemia major β0 thalassaemia 
 β+ thalassaemia 
 (β++ thalassaemia)* 
β thalassaemia intermedia  
β thalassaemia minor (trait)  
- With raised level of HbA2 Normal or slightly elevated levels of 
HbF 
 Unusually high levels of HbF 
 Unusually high levels of HbA2 
- Normal levels of HbA2 β thalassaemia and δ thalassaemia 
 Mild β thalassaemia (HbA2 may be 
slightly elevated) 
 Silent β thalassaemia 
Dominant β thalassaemia  
β thalassaemia with genetic determinant unlinked to β-globin-gene locus 
*Term to describe very mild allele; not in common usage. (Adapted 
from Weatherall., 2001). 
 
The severity of clinical phenotypes for homozygous or compound 
heterozygous beta thalassaemia varies. Beta thalassaemia is 
inherited as haploinsufficient Mendelian recessives. Patients with 
beta thalassaemia major, inherit two β°-thalassaemia alleles 
(homozygous or compound heterozygous states) which result in 
complete absence of HbA (α2β2), leading to severe microcytic, 
hypochromic anaemia which if left untreated, is fatal. Treatment 
consists of splenectomy if splenomegaly is present, blood 
transfusion, and treatment of iron overload caused by the blood 
transfusion. To date, bone marrow tranplantation is the only cure for 
patients with beta thalassaemia major. In beta thalassaemia minor, 
individuals inherit a single beta thalassaemia allele, whether β° or 
β+. As only one beta-globin allele is affected with the mutation, most 
patients with β thalassaemia minor are phenotypically ‘silent', being 
clinically asymptomatic with no or mild anaemia with characteristic 
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hypochromic microcytic red blood cells, elevated levels of HbA2 
(α2δ2) and variable increases of HbF (α2γ2) (Maragoudaki et al., 
1999; Moi et al., 2004). Patients with beta thalassaemia intermedia 
inherit two beta thalassaemia alleles. Their condition ranges from 
slightly less severe than transfusion-dependence to asymptomatic. 
Occasional blood transfusion may be required depending on the 
severity of the condition (Table 1-4). 
Pathophysiology of beta thalassaemia.  Beta-globin chain 
synthesis is fully activated after birth and thus, unborn fetuses with 
beta thalassaemia are unaffected. Clinical effects of reduced beta-
chain synthesis are more significant during the first year after birth 
as gamma-chain synthesis declines. This is characterised by 
persistent gamma-chain and delta-chain synthesis resulting in 
elevated HbF (α2γ2) and HbA2 (α2δ2) levels in heterozygotes. In 
more severe forms of beta thalassaemia, the persistent synthesis of 
gamma-chain does not compensate the deficit of beta-globin chains. 
As a result of this imbalance, an excess of alpha-globin chains 
aggregates within the erythroid precursors. These alpha-globin 
chains are unable to form viable tetramers and they precipitate, 
forming inclusion bodies in the erythroid precursors in the bone 
marrow. Erythropoiesis is therefore affected as developing red-cell 
precursors and mature red cells are damaged. This excess alpha-
globin chain is the underlying cause of the pathophysiological 
manifestation of beta thalassaemia and the damage is caused at 
every stage of erythropoiesis. The combination of Ineffective 
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erythropoiesis, peripheral haemolysis, and an overall reduction in 
haemoglobin synthesis in turn, causes anaemia (Figure 1-8).  
Alpha thalassaemia. Alpha thalassaemia (OMIM 141850 and 
141800) is one of the commonest single gene disorders in 
Southeast Asia (SEA). This inherited anaemia syndrome is 
characterised by decreased or complete lack of synthesis of alpha-
globin chains (Higgs et al., 1986). It is caused by deletion or 
mutation (non-deletion) in the alpha-globin genes (Higgs et al., 
1986; Higgs et al., 1989). If all four loci are affected such as in the 
common Southeast Asian (--SEA) type deletion, the fetus cannot 
live once outside the uterus: most such infants are dead at birth 
with hydrops fetalis, and those who are born alive die shortly after 
birth. They are edematous and have little circulating haemoglobin, 
and the haemoglobin that is present is all tetrameric gamma chains 
(haemoglobin Barts). Usually, this involves homozygous inheritance 
of an alpha thalassaemia trait, type 1. Haemoglobin H disease 
results if three loci are affected. Two unstable haemoglobins are 
present in the blood, both haemoglobin Barts (tetrameric gamma 
chains) and haemoglobin H (tetrameric beta chains). There is 
microcytic hypochromic anaemia with target cells and Heinz bodies 
(precipitated HbH) on the peripheral blood smear. The disease may 
first be noticed in childhood or in early adult life, when the anaemia 
and splenomegaly are noted. This is usually due to compound 
heterozygous inheritance of alpha thalassaemia type 1 and type 2 
traits. If two of the four alpha loci are affected, alpha thalassaemia 
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trait, type 1 result. Two alpha loci permit nearly normal 
erythropoiesis, though there is mild microcytic hypochromic 
anaemia. There is a high prevalence (about 30%) of deletion of one 
of the two alpha loci on chromosomes of people of recent African 
origin, and so the inheritance of two such chromosomes is not 
uncommon. The disease in this form can be mistaken for iron 
deficiency anaemia and treated inappropriately with iron. Two 
modes of alpha thalassaemia trait, type 1 have been noted. One 
involves cis deletion of two alpha loci on the same chromosome; 
another involves trans-deletion of allelelic genes on homologous 
chromosomes (chromosome 16). If one of the four alpha loci is 
affected, alpha minor or alpha+ thalassaemia trait or alpha 
thalassaemia trait, type 2 results and there is minimal effect. Three 
alpha-globin loci are enough to permit normal haemoglobin 
production, and there is no anaemia or hypochromia in these 
people. They are called alpha thalassaemia carriers (Kan et al., 
1976; Kan et al., 1992). Of the numerous mutations that have been 
described, deletions at the alpha-globin gene locus account for the 
vast majority of alpha thalassaemia alleles. The most widely 
occurring of these are the -α3.7 and -α4.2 single alpha-globin gene 
deletions, while double alpha-globin gene deletions in cis, such as 
the --SEA, --FIL, and --THAI alleles are very common within Southeast 
Asia, and the --MED and -(α)20.5 double-gene deletions occur more 
frequently in the Mediterranean area. Single alpha-globin gene 
deletions are termed ‘alpha-thal 2’ while double alpha-globin gene 
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deletions that remove both α2 and α1 globin genes are termed 
‘alpha-thal 1’ (Figure 1-9). 
 
Figure 1-8 Mechanisms in the pathophysiology of beta 
thalassaemia. 
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Figure 1-9 Alpha thalassaemia deletions throughout the 
alpha globin gene cluster. 
 
 
Since these deletions are regionally specific with the geographical 
and ethnic distributions determined (Bernini et al., 2001), a program 
of control through screening, genetic counselling, and prenatal 
diagnosis can be developed (Cao et al., 2002). In Singapore, 5.6% 
of the population carries α-thalassaemia mutations. Of these, 27% 
carry the Southeast Asian (--SEA) deletion (Kham et al., 2004). For 
at-risk couples where both parents are alpha-1 thalassaemia 
heterozygotes of the --SEA type deletion, there is a 1 in 4 chance 
that the fetus will have Hb Bart’s if it inherited both the parents’ 
deleted alleles. In these cases, prenatal diagnosis of Hb Bart’s will 
be required.  
Pathophysiology of alpha thalassaemia.  Since alpha-chains are 
shared by both fetal and adult haemoglobin, alpha thalassaemias 
manifest in both fetal and adult life. Excess gamma- and beta- 
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chains that result from defective alpha-chain production form 
soluble homotetramers, γ4 (HbBart’s) and β4 (HbH). These 
molecules are physiologically useless due to high oxygen affinity 
and instability (HbH). The clinical features of the more severe forms 
of alpha thalassaemia reflect the properties of Hb Bart’s and Hb H 
and their effects on erythropoiesis (red-cell survival). The critical 
level of beta-chain excess is required before viable β4 molecules 
are formed.  
Diagnosis of haemoglobinopathies. The laboratory diagnosis of 
a haemoglobinopathy usually requires a combination of different 
tests, with results being assessed in relation to clinical features, 
ethnic origin of the patient, blood count and film. Beta thalassaemia, 
being asymptomatic with the compensation of HbF (α2γ2) for 
ineffective erythropoiesis is often missed in neonates. Biochemical 
diagnostic tests of neonatal blood used in identifying thalassaemia 
major are inconclusive at this early stage while thalassaemia 
intermedia may remain undiagnosed with the absence of a variant 
such as HbE or HbS. Genetic analysis to determine the types of 
mutations in the beta-globin gene cluster is therefore, necessary. 
Methods of thalassaemia diagnosis consist of haematological 
indices measurement, microscopic analysis of red blood cells 
morphology, haemoglobin electrophoresis and molecular genetic 
analysis (Gill et al., 2007). 
A red cell counter measures haematological indices by assessing 
the size and volume of red blood cells, as well as the amount of 
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contained haemoglobin.  Thalassaemia is diagnosed where the size, 
volume of red blood cells and the concentration of haemoglobin are 
significantly reduced. Microcytosis (mean corpuscular volume, MCV 
<80 fL) or hypochromia (mean corpuscular haemoglobin or MCH < 
27 pg), normal Hb A2 level (<3.5%), and normal iron store are 
indicative of alpha thalassaemia (Table 1-5). 
Table 1-5 Haematological indices of patients with 
thalassaemia.  
Indices Mean Range Normal Range 
Hb (haemoglobin, g/dL) 6.8 3.9 – 9.3 11.1 – 15.0 
MCH (Mean corpuscular haemoglobin, pg) 20.9 15 – 26 26 - 35 
MCV (Mean corpuscular volume, FL) 65.8 57 – 75 77 - 99 
MCHC (Mean corpuscular haemoglobin 
concentration, g/dL) 30.9 26 - 34 34 - 36 
 
The morphology of red blood cells is also investigated with a blood-
smeared slide under a microscope. Red blood cells of beta 
thalassaemia patients appear paler (hypochronic), smaller 
(microcytic) and have abnormal shapes (anisocytosis – variation in 
cell sizes, poikilocytosis – variation in cell shapes). In alpha 
thalassaemia where there is a reduction in alpha chain synthesis, 
excess beta chains will link up forming tetramers also known as 
HbH (β4). These unstable β4 tetramers can be induced to precipitate 
to form red cell HbH inclusions (Heinz bodies) with a characteristic 
appearance, which can be easily detected. In brief, fresh EDTA-
anticoagulated whole blood was mixed with methylene blue solution 
and incubated at 37°C for 2 hours. The stained blood smears were 
then examined under oil immersion at 100X magnification. The 
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detection of more than one cell containing unequivocal Hb H 
inclusion bodies establishes a diagnosis of alpha thalassaemia trait 
(TWP, 1994; Dacie et al., 1984). However, if there is simultaneous 
HbE, there would be fewer or even absent of HbH inclusion bodies, 
which might confound the correct diagnosis of the underlying HbH 
disease (Chui and Waye, 1998). In general, there is no need for 
prenatal diagnosis of a pregnancy at risk for HbH disease, unless 
the fetus is at risk for the HbH hydrops fetalis syndrome.  
Haemoglobin electrophoresis is used to detect structural 
haemoglobin variants and quantify the main haemoglobins present. 
It is performed at an alkaline pH where haemoglobin becomes a 
negatively charged protein and migrates to the anode. Normal 
haemoglobin A, A2, and F separate from each other as distinct 
bands on the basis of different charge and abnormal haemoglobins 
with different surface charges (eg. HbBart’s, γ4) will separate from 
these normal haemoglobins as distinct abnormal bands. The 
normal adult ranges are HbA > 95%, HbA2 < 3.5% and HbF < 
1.5%. The detection of HbBart’s (γ4) indicates HbBart's hydrops 
fetalis while beta thalassaemia is diagnosed when levels of HbF 
(α2γ2) are higher than normal, varying between 20-90%. HbA2 
(α2δ2), which usually accounts for up to 3% of normal adult 
haemoglobin may be non-existent, reduced, normal or slightly 
elevated in blood samples of beta thalassaemia patients. However, 
HbA2 and HbF levels are normal in other forms of alpha 
thalassaemia (except Hb Bart’s) and therefore, DNA analysis may 
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be required for definitive diagnosis of alpha thalassaemia. Although 
the diagnosis of beta thalassaemia major is usually fairly 
straightforward, difficulties may arise, particularly in developing 
countries where the prevalence of diseases such as malaria can 
complicate diagnosis. For example, malaria can cause anaemia 
and splenomegaly, and although the haematological laboratory 
findings are quite different, it may be necessary to treat the patient 
with anti-malarial drugs before reassessing the patient's condition 
and diagnosis. Other conditions may also cause anaemia, 
splenomegaly and raised HbF levels. A differential diagnosis is 
necessary with additional clinical and laboratory tests. Therefore, 
an investigation of haematological parameters as well as genetic 
mutations to the alpha, beta, and gamma genes are necessary to 
confirm diagnosis of thalassaemia and in deciding treatment. 
Molecular identification of alpha thalassaemia deletions are carried 
out by specific PCR amplification of the alpha-2 or alpha-1 gene, 
followed by technically demanding methods such as single-strand 
conformation polymorphism (SSCP) analysis, denaturing gradient 
gel electrophoresis (Foglietta et al., 1996; Harteveld et al., 1996; 
Jorge et al., 2003), direct sequencing and reverse dot-blot analysis 
with a limited rate of detection (60-80%). These techniques are 
labour intensive, costly and time-consuming (Foglietta et al., 1996). 
Various PCR methods had been developed by several investigators 
to improve the sensitivity and reliability of molecular diagnosis of 
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alpha thalassaemia (Chong et al., 2000a; Chong et al., 2000b; Tan 
et al., 2001; Ho et al., 2007).  
Invasive procedures such as amniocentesis, chorionic villus 
sampling or fetal blood sampling to obtain fetal samples for genetic 
analysis carry a risk of miscarriage. Ultrasonography is a non-
invasive method that can be used to measure the cardiothoracic 
ratio or placental thickness for the detection of Hb Bart's (Lam et al., 
1999; Tongsong et al., 1999; Tongsong et al., 2004). However, the 
accuracy of ultrasonography is dependent on trained expertise. 
Leung et al. reported a 2.9% false-positive rate in ultrasonography 
(Leung et al., 2004). This is undesirable as false-positives will lead 
to invasive procedures that can cause miscarriages of unaffected 
fetuses (Leung et al., 2004). 
Clinical management. Clinical treatment of thalassaemia involves 
periodic blood transfusion to control anaemia. Although blood 
transfusion treatment increases life expectancy, it leads to 
progressive iron deposition in the tissues and poses risk of cardiac, 
endocrinological, and hepatic complications that can be fatal. Iron 
overloading is the most important complication in beta thalassaemia 
and is the main focus of clinical management. In the past 20 years, 
treatment of thalassaemia major has improved tremendously in 
countries with access to adequate and safe blood and iron 
chelation therapy with desferrioxamine (DFO). Despite wide 
availability of DFO in Western countries, many patients develop 
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complications due to iron overload with deaths occurring most 
frequently with cardiac disease (Borgna-Pignatti et al., 2006).  
Almost all fetuses with Hb Bart’s are stillbirths or die shortly after 
birth. The adverse psychological impact on couples who carry a 
fetus with Hb Bart’s to term only to result in a stillbirth can be 
avoided with proper genetic counselling. Therefore, efforts should 
be directed to identify couples at risk and provide them with 
prenatal diagnosis so that they can make an informed choice. 
Maternal morbidities such as pre-eclampsia and haemorrhage can 
also be avoided. In utero transfusions followed by lifelong 
transfusions have been touted as a possible treatment for Hb Bart’s 
in recent years. Until now, only anecdotal reports have been 
published, which tend to be biased towards those with good 
outcomes. These newborns often had serious neonatal 
complications, and congenital anomalies. In addition, the high costs 
of such a treatment plan in countries with limited resources deserve 
to be thoughtfully debated before their implementation. For HbH 
disease, the treatment plan ought to be anticipatory prevention and 
supportive therapy. Care should be taken to avoid oxidant drugs or 
herbal medicines, and with prompt treatment of febrile and 
infectious diseases. Other late complications such as 
hypersplenism, cholelithiasis, iron-overload, and osteopoenia need 
to be observed and treated. 
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1.4 DNA molecular technologies 
1.4.1 DNA sequencing 
DNA sequencing is the process used to determine the nucleotide 
order of a given DNA fragment, known as the DNA sequence. The 
target DNA is denatured and annealed to an oligonucleotide primer, 
which is then extended by DNA polymerase using a mixture of 
deoxynucleotide triphosphates (normal dNTPs) and chain-
terminating dideoxynucleotide triphosphates (ddNTPs). ddNTPs 
lack the 3'-OH group to which the next dNTP of the growing DNA 
chain is added. Without the 3'-OH group, nucleotides can no longer 
be added and the DNA polymerase dissociates and falls off. The 
resulting newly synthesised DNA chains will be a mixture of 
different lengths. In this project, dye terminator sequencing 
technique, which is a cheaper and faster alternative to the chain 
termination method (Sanger sequencing), is used. In dye terminator 
sequencing, each ddNTP (ddG, ddA, ddT or ddC) is labeled with a 
different fluorescent dye, which fluoresces at a different wavelength 
that is activated and captured by an automated genetic analyzer. 
This labeling of each dideoxynucleotide chain-terminators with a 
separate fluorescent dye enables visualisation of the DNA 
sequence by the genetic analyser. 
1.4.2 Conventional PCR 
Polymerase chain reaction (PCR) was invented in 1983 by Nobel 
laureate, Kary Mullis to amplify specific regions of a DNA strand. 
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PCR requires several components such as DNA template 
containing the region of DNA strand to be amplified, one or more 
primers that are complementary to the DNA regions at the 5’ and 3’ 
ends of the DNA region to be amplified, a DNA polymerase (more 
commonly, Taq polymerase) to synthesise a DNA copy of the 
region to be amplified, deoxynucleotide triphosphates (dNTPs) from 
which the DNA polymerase builds the new DNA, buffer solution 
containing divalent and monovalent cations for optimal activity and 
stability of the enzyme DNA polymerase. The PCR is carried out in 
small reaction tubes containing all the above components. It 
consists of a series of 20 to 35 cycles of denaturation, annealing 
and elongation. Before PCR cycling, initiation is required whereby 
the PCR reaction is heated to a temperature of 94 – 96°C and held 
for 1-9 minutes to ensure that most of the DNA template and 
primers are denatured. The double-stranded DNA is denatured into 
single-strand by disrupting the hydrogen bonds between the 
complementary bases of the DNA strands. Following this hold, PCR 
cycling begins with a denaturation step at 94-98°C for 20-30 
seconds followed by annealing step of 50-64°C for 20-30 seconds 
where primers attach to the single-strand DNA template. Stable 
bonds are formed when the primer sequence matches the DNA 
template sequence, forming a double-stranded primer-template for 
the attachment of DNA polymerase to initiate DNA synthesis.  
During this extension step, the DNA polymerase condenses the 5’-
phosphate group of the dNTPs with the 3’-hydroxyl group at the end 
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of the nascent DNA stand. 
1.4.3 Quantitative real-time PCR (QRT-PCR) 
QRT-PCR is a technique that uses double-stranded DNA dyes and 
fluorescence-labeled probes as reporters to reflect the amount of 
generated amplicons ‘live’ during PCR. Fluorescence-labeled 
probes are used during quantitative real-time PCR using Applied 
Biosystems Prism 7000 Sequence Detection System (Applied 
Biosystems, Foster City, CA), which is essentially a combined 
thermal cycler/fluorescence detector with the ability to monitor the 
progress of individual PCR reactions. The amplification and 
product-reporting system used was based on the 5’ nuclease assay 
(Taqman assay, Perkin-Elmer). In this system, a dual-labeled 
fluorogenic hybridisation probe was included in addition to the two 
amplification primers normally used in conventional PCR. The 
probe consists of two types of fluorophores, the quencher and the 
reporter. The reporter dye is found on the 5’ end of the probe and 
the quencher at the 3’ end. The quencher, by the Fluorescence 
Resonance Energy Transfer (FRET), quenched the emission 
spectrum of the reporter dye. During the extension phase of PCR, 
the 5’ to 3’ exonuclease activity of the Taq DNA polymerase 
cleaves the reporter dye from the probe, releasing it from the 
quencher. This release result in an increase in fluorescent emission 
from the reporter dye which the charge coupled device (CCD) 
camera captures (Figure 1-10). The list of commonly-used probes 
in QRT-PCR and QF-PCR are as shown (Table 1-6). 
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Figure 1-10 QRT-PCR chemistry. 
 
 
Table 1-6 Spectral properties of fluorescent probes. 
Dye Excitation Wavelength (nM) Emission Wavelength (nM) 
FAM 488 518 
VIC 488 552 
TET 488 538 
JOE 488 554 
TAMRA 488 582 
SYBR 488 520 
ROX 488 610 
 
Usefulness of QRT-PCR. In prenatal diagnosis, amniocentesis is 
the most common procedure for obtaining amniocytes for 
chromosomal analysis. Though reliable and accurate, 7 - 21 days of 
culture for metaphase analysis are required before results are 
released. This extended period of waiting causes parental anxiety. 
Abnormal results are important in clinical decision-making, but 
normal results allay the anxiety associated with the longer wait for 
the full karyotype. Alternative methods include FISH (Pertl et al., 
1994; Pergament et al., 2000; Witters et al., 2002; Choolani et al., 
R Q 
Q R 
Double strand DNA (light blue)
Denaturation; 94-96ºC
Annealing of primers (pink) and probe (green); 
40-65ºC 
Extension of complementary strand (blue) by 
DNA polymerase (orange); probe breaks; 
reporter (R) dye released from quencher (Q) 
and emits fluorescence captured by detector 
in machine; 72ºC 
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2007) or by genomic DNA amplification and quantification 
(Mansfield, 1993; Pertl et al., 1994; Mann et al., 2004). In these 
tests, only common aneuploidies involving chromosomes 13, 18, 
21, X and Y are analysed. FISH relies on visual counting of 
fluorescence signals within target fetal cells and is therefore, 
labour-intensive, time-consuming and costly. Although the use of 
QF-PCR to amplify and quantitate short tandem repeats (STR) 
reduces cost and time (Mansfield, 1993; Pertl et al., 1994; Mann et 
al., 2004), a minimum of 6 hours is still required for QF-PCR. By 
making use of a multiplex QRT-PCR assay that combines 
amplification and quantitation steps in one step, reporting time can 
be reduced (Zimmermann et al., 2002; Tanzi et al., 1987; Cornel et 
al., 1993; Ho et al., 2004; Caine et al., 2005) as data are collected 
throughout the QRT-PCR process during cycling rather than by the 
amount of target accumulated at the end of PCR (Saiki et al., 
1985). I investigated the usefulness of QRT-PCR in gene dosage 
quantitation by the simultaneous multiplex amplification of APP and 
HBB loci. The APP gene, located on chromosome 21q21.3, 
encodes for the amyloid beta A4 precursor protein. The triplication 
of the amyloid precursor protein gene in trisomy 21 (Down 
syndrome, DS) was known to cause the early-onset of Alzheimer 
disease in patients with DS (Wisniewski et al., 1985) and other 
physiological lesions associated with DS (Tanzi et al., 1987). HBB 
is located on chromosome 11p15.5 and codes for the haemoglobin 
beta chain. It is used as the endogenous control as an active 
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reference for normalization due to its consistent expression levels 
regardless of DS or normal samples (Figure 1-11). 
Figure 1-11 Locations (in red) of APP and HBB on 




RQ uses comparative threshold cycle (CT) to determine the 
differences in the expression levels of a target (APP) and the 
endogenous control (HBB). CT is the fractional cycle number at 
which the fluorescence passes the threshold. The threshold is a 
level of ΔRn that is automatically or manually set for CT 
determination. The level is set to be above the baseline and 
sufficiently low to be within the exponential growth region of the 
amplification curve. The threshold is the line whose intersection 
with the amplification plot defines the CT. The baseline intersects 
with the initial cycles of PCR in which there is little change in 










Figure 1-12 Amplification curves of real-time PCR. 
 
PCR amplification efficiency is the rate at which a PCR amplicon is 
generated. It is commonly expressed as a percentage value. If a 
particular PCR amplicon doubles in quantity during the geometric 
phase of its PCR amplification, then the PCR assay has 100% 
efficiency. The slope of a standard curve is commonly used to 
estimate the PCR amplification efficiency of a QRT-PCR reaction. A 
real-time PCR standard curve is graphically represented as a semi-
log regression line plot of CT value vs. log of input nucleic acid. A 
standard curve slope of -3.32 indicates a PCR reaction with 100% 
efficiency. Slopes more negative than -3.32 (eg. -3.9) indicate 
reactions that are less than 100% efficient. Slopes that are more 
positive than -3.32 (for example, -2.5) may indicate sample quality 





Figure 1-13 Standard curve of a QRT-PCR reaction. 
Figure 1-13 shows a highly efficient PCR reaction which will yield a 
10-fold increase in PCR amplicon every 3.32 cycles during the 
exponential phase of amplification (log210 = 3.3219).  
1.4.4 Quantitative fluorescence PCR (QF-PCR) 
The difference between a conventional PCR and QF-PCR is that a 
primer (either forward or reverse), is labeled with a fluorophore in 
QF-PCR. This results in the synthesis of PCR products that are 
labeled with fluorophores during PCR amplification (Figure 1-14). 
The fluorescent-labeled PCR products are then resolved using 
capillary electrophoresis in a Genetic Analyzer. In detail, the 
separation of fluorophore-labeled PCR products by capillary 
electrophoresis is dependent on the differential migration of 
analytes in an applied electric field. PCR products are 
Y = -3.33x + 20 
R2 = 1 
Predicted Y 








electrophoretically injected into capillaries filled with polymer 
followed by 1 kv voltage across the capillaries. This results in 
slower movment of longer PCR products than shorter PCR 
products. These PCR products pass through an excitation laser 
beam that caused the attached fluorophores to fluoresce. The 
emitted fluorescence is captured by an optical detection device. 
The attached softwares running the Genetic Analyzer will enable us 
to analyse the exact size of the PCR product. 
Figure 1-14 QF-PCR chemistry. 
  
Microsatellite markers. The DNA sequences that are amplified in 
QF-PCR are known as microsatellite markers or STRs. A STR is a 
class of polymorphisms that occurs when a pattern of 2 or more 
nucleotides are repeated and the repeated sequences are directly 
adjacent to each other. The pattern can range in length from 2-6 
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base pairs and is typically located in the non-coding intron region. 
The repeated sequences are directly adjacent to each other (Figure 
1-15). Different individuals carry different number of repeat units. By 
examining several STR loci and counting the number of repeats at 
a given locus, a unique genetic profile of an individual can be 
created.  
Figure 1-15 Short tandem repeats. 
 
In addition to genetic profiling, the amplification and analysis of 
STRs on a given chromosome can be used in gene dosage study 
or diagnosis of aneuploidies. The identification of an additional 
allele denotes trisomy (from the third copy of the chromosome) 
while the absence of an allele denotes monosomy. Quantitative 
assessment of copy number can also be performed by measuring 
the area under the curve of the specific peak on the generated QF-








Figure 1-16 Electropherograms of STRs (D21S1411, D21S11) 
in trisomy 21 (A) and normal (B) DNA samples isolated from 
amniocytes.  
 
1.4.5 Fluorescence in situ hybridisation (FISH) 
As shown in the Figure 1-17, FISH uses probes, which are short 
sequences of double-stranded DNA labeled with fluorescent 
molecules. Under high temperature, these probes denature into 
single-stranded DNA sequences and hybridise to the 
complementary DNA within the nucleus of a cell. Under an 
epifluorescence microscope, the target DNA that is labeled with the 
fluorescent probes can be visualised.  The copy number of the 
target DNA loci can be enumerated based on the number of 
fluorescent signals in each nucleus (Figure 1-18). 
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Double strand DNA probe (light 
blue) 
Labeling with fluorescent dye 
(green) 
Denaturation and hybridisation to 
target DNA sequences (light purple) 
Visualisation of fluorescent signals in the 
nucleus (grey) under epifluorescent 
microscope 
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Figure 1-18 FISH of fetal cells. 






Figure 1-18 showing interphase FISH of CEP and LSI probes on 
different cell types. Colours have been enhanced for ready 
recognition: CEP X (Red); CEP Y (Green); LSI 21 (Yellow); CEP 18 
(Aqua); LSI 13 (Purple); LSI TUPLE1 (HIRA) (3' noncoding region 
of TUPLE1, D22S553, D22S609, and D22S942) (Red); LSI ARSA 
(Arylsulfatase A gene) (Green). A - E: Uncultured amniocytes (A-XY; 
B-XX); C-Normal diploid 21; D-Trisomy 18; E-Trisomy 13; F: 
Trophoblast cells (Normal diploid 13 and 21). G-H: Mononuclear 
cells from fetal blood (G-XY; H-Normal diploid 13 and 21). I: 
Cultured neonate peripheral blood cells in the metaphase and 
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interphase of a DiGeorge patient showing deletion of TUPLE 1 
locus on chromosome 22q11.2. J: Mononuclear cell from fetal cord 
blood (Trisomy 18). K: Mononuclear cell from neonatal blood 
(Trisomy 21). L: Mononuclear cell of a Turner syndrome patient (45, 
XO). M: Uncultured amniocyte (Trisomy 21). N: Uncultured 
amniocyte; Klinefelter syndrome (47, XXY). 
Fluorescence microscope. The most common light source for 
fluorescence microscopy is the mercury arc lamp. It emits light 
energy in several narrow bands, approximately 10 nm wide and 
located in UV (360 nm), in violet (405, 436 nm) green (546 nm) and 
yellow (578 nm). Use of an oil-immersion objective and low 
fluorescence oil ensures that only a tiny fraction of the incident light 
scatters back towards the visual sensor. A filter angled at 45 
degrees to the incident light has the unique ability to reflect one 
colour (excitation light) but transmit another colour (emitted 
fluorescence), which effectively subtracts all light reaching the 
specimen to allow the inspection of only emitted fluorescence in a 
dark background (Figure 1-19). Figure 1-20 shows fluorescence 
emission separation using selected, high quality dichroic 
beamsplitters with a threshold wavelength. The beamsplitter 
reflects and transmits all wavelengths that are shorter and longer 
than the threshold respectively. The characteristic emission of 
intense, highly saturated colours within a narrow bandwidth gives 
the fluorescent object (or probe) the appearance of a pure colour. 
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Figure 1-19 Basics of a fluorescence microscope. 
 
 
Figure 1-20 Separation of fluorescence emission. 
 
 
Our Olympus BX61 (Olympus, Tokyo, Japan) is a fluorescence 
automated microscope fitted with a Xenon light source lamp for 
fluorescence and the following filter sets: single bandpass spectrum 
orange, single bandpass spectrum green, single bandpass aqua 
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(Vysis Inc, Downer’s Grove, Illinois, USA), SKY and DAPI filter 
cubes (ASI GmbH, Mannheim, Germany). A Dell workstation 
installed with FISHView v EXPO 2.0 software operating under MS 
Windows XP was connected to the microscope for image capture 
using a CCD camera (Media Cybernetics Inc, MD, USA). 
1.5 Experimental aims and hypotheses 
This thesis explores the use of polymorphic microsatellite markers 
within the common alpha thalassaemia double gene deletions to 
differentiate between paternally- and maternally- inherited fetal 
alleles in maternal plasma. The detection of these unaffected 
paternally-inherited fetal microsatellite markers will exclude Hb 
Bart’s non-invasively. This study was planned in four stages: (a) to 
determine if QRT-PCR is a reliable technique to detect and quantify 
limiting amounts of target DNA, (b) to determine if Y-chromosome 
specific sequences in maternal plasma samples can be detected 
using QRT-PCR, (c) to determine if polymorphic microsatellite 
markers located within the common alpha thalassaemia double 
gene deletions are useful for the discrimination between maternally- 
and paternally- inherited fetal alleles, (d) to determine if these 
polymorphic microsatellite markers will be useful to exclude Hb 
Bart’s non-invasively using fetal DNA from maternal plasma.   
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1.5.1 Hypotheses 
1.  QRT-PCR can detect and quantify fetal DNA from the maternal 
plasma. 
2. Hb Bart’s can be identified simultaneously with maternal 
contamination exclusion using microsatellite markers within 
deleted regions.  
3.  QF-PCR of these microsatellite markers will exclude Hb Bart’s 
non-invasively using fetal DNA from the maternal plasma. 
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2  MATERIALS AND METHODS 
2.1 Samples 
2.1.1 Research ethics board approval 
Sample collection for this study was approved by the Domain-
Specific Review Board (DSRB) of National Healthcare Group 
(NHG). All pregnant women who were undergoing amniocentesis, 
chorionic villus biopsy, fetal blood sampling, at delivery or 
termination of pregnancy (TOP) gave written informed consent that 
was approved by DSRB for collection of surplus amniotic fluid (AF), 
trophoblast tissue, fetal blood (FB) and umbilical cord blood (UCB). 
All adult peripheral blood samples were collected from healthy 
volunteers, pregnant women and their spouses with written 
informed consent.  
2.1.2 Amniotic fluid 
Amniocentesis was offered at ≥ 15 gestational weeks to pregnant 
women who were at-risk of chromosomal aneuploidies. An area of 
the maternal abdomen was prepared aseptically before a 22-gauge 
needle was inserted into the amniotic cavity to obtain the AF under 
continuous ultrasound guidance. AF surpluses (2 – 4 ml) to 
required amount for culture were collected for research purposes of 
this study. 
2.1.3 Trophoblast  
CVS was performed at 10 to 13 gestational weeks by 
transabdominal approach where a needle was inserted through the 
maternal abdomen into the long axis of the placenta in 
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transabdominal CVS. Tissue sample was drawn into a syringe 
containing heparin and nutrient medium in both procedures. 
Surplus chorionic villi (3 - 5 villi) were collected for research 
purposes of this study. First trimester fetal trophoblast tissue was 
collected immediately after TOP from within the products of 
conception (POC).  
2.1.4 Fetal blood 
FB samples were collected from pregnant women undergoing 
prenatal diagnosis in the second trimster by trans-abdominal 
cordocentesis. A 22-gauge needle was inserted through an aseptic 
area of the maternal abdomen into the fetal intrahepatic vein under 
continous ultrasound guidance. 
2.1.5 Umbilical cord blood 
Umbilical cord blood samples (10–20 ml) were collected in 
ethylenediaminetetraacetate (EDTA) vacutainer tubes at delivery. 
2.1.6 Adult peripheral blood 
Peripheral blood was collected by venesection from healthy non-
pregnant volunteers, and both parents whose fetal sample was 
collected for this project. 
2.1.7 Cell lines 
Three cell lines were obtained from the Coriell Cell Repositories 
(GM10799, GM03037, GM03433). GM10799 was initiated from B-
lymphocytes of a 26-year-old male alpha thalassaemia carrier (αα/--
SEA) while both GM03037 and GM03433 were initiated from 
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fibroblasts of a 23 fetal weeks (FW) male and 29 FW female 
respectively with Hb Bart’s (--SEA/--SEA). 
2.2 Deoxyribonucleic acid (DNA) analysis 
2.2.1 DNA isolation 
2.2.1.1 Amniotic fluid samples 
Amniotic fluid samples (2 – 4 ml) were centrifuged at 800 g for 5 
minutes in 15 ml conical-bottom polypropylene tubes (BD 
Biosciences, Oxford, UK) to pellet the amniocytes and amniotic fluid 
supernatant was discarded. The amniocyte pellet was resuspended 
with equal volumes of 1X phosphate-buffered saline (PBS) (0.1 
molar (M), pH 7.4) before centrifugation at 800 g for 5 minutes. The 
supernatant was carefully removed and the washed amniocyte 
pellet was again resuspended with equal volumes of 1X PBS for 
DNA isolation and/or FISH. DNA was isolated from 800 μL of the 
resuspended amniocytes using the QIAamp DNA Mini Kit (Qiagen 
GmbH, Hilden, Germany), according to the manufacturer’s 
recommendations. 
2.2.1.2 Trophoblast samples 
Trophoblast tissue was washed with 1X PBS before dissecting 3 – 
5 villi under inverted light microscope (Olympus, Hamburg, 
Germany) for DNA isolation and/or FISH. DNA was isolated from 
the washed villi using the High Pure PCR Template Preparation Kit 
(Roche GmbH, Mannheim, Germany) according to the 
manufacturer’s recommendations.  
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2.2.1.3 Blood samples - buffy coats and plasma 
All blood samples were centrifuged at 1600 g for 10 min to obtain 
the buffy layer which was diluted 1-fold with 1X PBS (0.1 molar (M), 
pH 7.4). The plasma fraction was centrifuged at 16 000 g for 10 min 
to remove any remaining cellular components. DNA was isolated 
from 200 μl of the diluted buffy layer and 1 ml of maternal plasma, 
together with 1 mL deionised distilled water as internal negative 
control, using the High Pure Template DNA Purification Kit 
according to the manufacturer’s recommendations (Roche).  
2.2.1.4 Cell lines 
DNA was isolated from the three cell lines obtained from the Coriell 
Cell Repositories (GM10799, GM03037, GM03433), using the 
PUREGENE DNA Purification Kit according to the manufacturer’s 
recommendations (Gentra Systems Inc., Minneapolis, USA). 
2.2.2 Conventional PCR 
Conventional PCR was performed using 15-20 ng genomic DNA in 
a volume of 25 μl, with 1X PCR buffer, 2.0 mM MgCl2, 0.8 mM each 
of deoxynucleotide triphosphates (dNTPs, PE Biosystems, 
Warrington, England) and 1 U of AmpliTaq Gold polymerase 
(Roche, Mannheim, Germany). I used 0.6 μM and 0.1 μM of each 
specific primer (Proligo-Sigma-Aldrich Company Ltd, Singapore) for 
singleplex and multiplex PCR respectively. Thermal cycling was 
performed in a Peltier Thermal Cycler (PTC)-200 (MJ Research Inc., 
Waltham, USA) with an initial 5-min denaturation at 95°C, followed 
by 35 cycles of 95°C for 30 s, *TA°C (respective annealing 
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temperatures) for 30 s, and 72°C for 30 s, with a final extension of 
72°C for 5 min. (*Annealing temperature differs between individual 
pairs of primers). PCR products were electrophoresed in 2% 
agarose gels in Tris-borate-EDTA electrophoresis buffer, stained 
with ethidium bromide (EtBr) and photographed under a UV 
transilluminator (Alpha Innotech Corp, CA, USA). Product size was 
defined using a 1 kb DNA ladder (Promega, Madison, USA). 
2.2.3 Real-time PCR 
For the detection of Down syndrome (DS), amyloid gene (APP) was 
used as the target gene as it is located specifically on chromosome 
21. The endogenous housekeeping reference gene used was beta-
globin (HBB), a chromosome 11 locus. To examine the 
coamplification of both target and endogenous reference genes, it 
is essential that the probe of each gene be labeled with a different 
fluorescence reporter dye to enable differentiation. The following 
APP and HBB primers and probes (Applied Biosystems, Foster City, 
CA) were used for gene dosage quantitation: APP-forward, 5’-GGG 
AGC TGG TAC AGA AAT GAC TTC-3’, APP-reverse, 5’-TTG CTC 
ATT GCG CTG ACA A-3’, APP-probe, 5’-(FAM) AGC CAT CCT 
TCC CGG GCC TAG G (TAMRA); HBB-forward, 5’-GTG CAC CTG 
ACT CCT GAG GAG A-3’; HBB-reverse, 5’-CCT TGA TAC CAA 
CCT GCC CAG-3’; HBB-probe, 5’-(VIC) AAG GTG AAC GTG GAT 
GAA GTT GGT GG (TAMRA)-3’. Commercial male and female 
genomic DNA samples were used as endogenous controls for the 
coamplification of APP and HBB in all runs. Reactions were set up 
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in a reaction volume of 25 µl using the TaqMan Universal PCR 
Master Mix (Applied Biosystems). We used 15 ng of DNA template 
for amplification. All primers were added to a final concentration of 
300 nM, while probes were added to a final concentration of 150 
nM. Thermal cycling was initiated with a 2 min incubation at 50˚C, 
to allow the uracil N-glycosylase (UNG) to act, followed by a first 
denaturation step of 10 min at 95˚C and then 30 cycles of 95˚C for 
15 s and 60˚C for 1 min. 
In the detection of fetal DNA from the maternal plasma, SRY (sex 
determining region Y) was used for fetal DNA quantitation and 
determination of male fetal gender, together with HBB as the 
endogenous housekeeping reference gene total DNA quantitation. 
The following SRY and HBB primers and probes (Applied 
Biosystems) were used: SRY-forward, 5’-TGG CGA TTA AGT CAA 
ATT CGC-3’; SRY-reverse, 5’-CCC CCT AGT ACC CTG ACA ATG 
TAT T-3’; SRY-probe, 5’-(FAM) AGC AGT AGA GCA GTC AGG 
GAG GCA GA (TAMRA); HBB-forward, 5’-GTG CAC CTG ACT 
CCT GAG GAG A-3’; HBB-reverse, 5’-CCT TGA TAC CAA CCT 
GCC CAG-3’; HBB-probe, 5’-(VIC) AAG GTG AAC GTG GAT GAA 
GTT GGT GG (TAMRA)-3’. Commercial male and female genomic 
DNA (Promega, Madison, USA) were used as positive and negative 
controls respectively. Commercial male genomic DNA was serially 
diluted 5-fold to generate standard curves for absolute quantitation. 
Each sample and standard was run in triplicates with both sample 
and standards running in parallel. Water used in preparing the PCR 
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master mix and water that had undergone DNA isolation process in 
parallel with DNA isolation of maternal plasma samples were 
included in triplicates as external and internal negative controls 
respectively. Reactions were set up in a reaction volume of 25 µl 
using the TaqMan Universal PCR Master Mix (Applied Biosystems). 
SRY primers and probe were used in a final concentration of 450 
nM each primer and 225 nM respectively while HBB primers and 
probe at a final concentration of 240 nM each primer and 100 nM 
respectively. Five microliters of extracted plasma DNA were used 
for amplification. Thermal cycling for both SRY and HBB was 
initiated with 2 min incubation at 50˚C, to allow the UNG to act, 
followed by a first denaturation step of 10 min at 95˚C and then 55 
cycles of 95˚C for 15 s and 60˚C for 1 min. 
For all QRT-PCR experiments, commercial genomic DNA 
(Promega, Madison, USA) of pooled male and female DNA were 
used to generate the standard curves for the calibration and 
normalization of each run. The standard curve is required to 
measure the efficiencies of APP/HBB coamplification as well as to 
quantitate the amounts of fetal and total DNA from the maternal 
plasma. In brief, the commercial genomic DNA was serially diluted 
5-fold from the stock concentration of 213.1 μg/ml for standard 
curve calibration (Table 2-1). 
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#1 31.25 (31250 pg/µl) 23674 47348 
#2 6.25 (6250 pg/µl) 4735 9470 
#3 1.25 (1250 pg/µl) 947 1894 
#4 0.25 (250 pg/µl) 189 379 
#5 0.05 (50 pg/µl) 38 76 
#6 0.01 (10 pg/µl) 7.6 15 
#7 0.002 (2 pg/µl) 1.5 3 
There were seven dilution series for the generation of the standard 
curve. Each human cell contains approximately 6.6 pg of DNA 
which is defined as the genome equivalent (GE). 1GE defines the 
GE of a single copy gene (ie. SRY), while 2GE defines the GE of a 
double copy gene (ie. HBB and APP) present in each PCR reaction. 
Each sample and standard was run in triplicates with both sample 
and standards running in parallel together with negative controls. 
2.2.4 Quantitative fluorescent (QF)-PCR (singleplex and 
multiplex) 
In QF-PCR, the forward primer is labelled with a fluorophore to tag 
the amplicon during amplification. The resulting fluorescent-tagged 
amplicon can therefore be detected and visualised using the CCD 
camera after capillary electrophoresis. PCR was performed as 
described earlier except that 30 cycles was used instead of 35 for 
QF-PCR. In singleplex QF-PCR, I used 0.6 µM of each specific 
primer (Sigma-Aldrich, Proligo Primers and Probes Pty, Singapore) 
(Table 2-2). For multiplex QF-PCR, I used 0.2 µM D16S539-F/R, 
0.5 µM 16PTEL05-F/R and 1.5 µM 16PTEL06-F/R. Thermal cycling 
was performed in a PTC-200 Thermal Cycler (MJ Research Inc., 
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Waltham, USA) with an initial 5-min denaturation at 95°C, followed 
by 30 cycles of 95°C for 30 s, 66°C for 30 s, and 60°C for 30 s, with 
a final extension of 60°C for 5 min, followed by a 1 hour incubation 
at 60°C. The high enzyme annealing temperature of 66°C and low 
extension temperature of 60°C (instead of 72°C) were optimised in 
previous experiments to minimise polymerase slippage mispairing 
which result in stutter peaks (n-1 peaks) (Data not shown). 
Following PCR, two microliters of the amplified PCR products were 
mixed with 9.5 μl of deionized formamide and 0.5 μl of GS-500 
ROX standard (Applied Biosystems, Foster City, CA, USA). The 
mix was heated at 90°C for 2 min, followed by 4°C for 5 min before 
resolving on the ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems). The resulting peaks were analysed using the 
GeneScan analysis software (Applied Biosystems).  
2.2.4.1 Microsatellite markers 
 
Figure 2-1 Microsatellite markers (16PTEL05, 16PTEL06) are 
located within the breakpoint region of –SEA while control 
microsatellite marker (D16S539) is located outside the alpha-
globin gene cluster. 
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The breakpoints of --SEA were described by Kutlar et al. (GenBank 
Accession AY207443). These breakpoint sequences correspond to 
nucleotide (nt) 155395 - 174700 of AE006462. Two microsatellite 
markers (16PTEL05 and 16PTEL06) within this deleted region were 
found using the Marshfield Genetic Map Database 
(http://research.marshfieldclinic.org/genetics/home/index.asp). 
16PTEL05 is located within nt 160725 – 160915 while 16PTEL06 is 
located within nt 171931 – 172078 (with reference to AE006462.1). 
16PTEL05 contains 2 STRs: a (AATA)n tetranucleotide repeat and 
a (CA)n dinucleotide repeat while 16PTEL06 consists of only (CA)n 
dinucleotide repeats. The polymorphic nature of the 16PTEL05 
microsatellite marker is derived from (CA)n repeats and not 
(AATA)n repeats (sequencing data not shown). Therefore, I 
intended the primer pair sequences named “16PTEL05-F/R” to 
flank only the (CA)n repeats so that the resulting size of the 
amplicon will be small. This will improve the sensitivity of QF-PCR 
in order to detect the low amounts of fetal DNA from the maternal 
plasma. The other primer pair, 16PTEL06-F/R, was designed to 
flank the (CA)n repeats of 16PTEL06 microsatellite marker. All 
primer sequences were designed using the Primer Express 
Software v2.0 (Applied Biosystems, Foster City, CA) with the 
downloaded DNA sequence from GenBank (Accession AE006462). 
As a control, polymorphic microsatellite marker D16S539 was used. 
D16S539 is located on 16q24-qter which lies outside the alpha-
globin gene cluster (Figure 2-1). Therefore, deletions and mutations 
 90 
of the alpha-globin gene cluster will not affect the integrity of 
D16S539. The D16S539 primer sequences (D16S539-F/R) were 
obtained from the STRBase website 
(http://www.cstl.nist.gov/div831/strbase/). All forward (F) primers 
were fluorescent-tagged for the detection of the amplified PCR 
products during capillary electrophoresis (Table 2-2). 
Table 2-2 Primer sequences for QF-PCR. 
Primers Expected Size (bp) *Dye 
F Primer (5’Æ 
3’) R Primer (5’Æ 3’) 






















*fluorescent dye is labeled on the respective forward primer at 5’ 
end 
F = forward; R = reverse 
 
Figure 2-2 Locations of microsatellite markers, 16PTEL05 
and 16PTEL06, and the breakpoint regions of alpha 
thalassaemia deletions. 
 
Both microsatellite markers are located within the breakpoints of –
SEA, -MED, -FIL, and –THAI. Of these 4 double gene deletions, -SEA, -FIL 
and –THAI are the most common in Southeast Asia. However, the 
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inheritance of both alleles with –SEA deletion is the most clinically 
significant as the fetus may survive to term with Hb Bart’s hydrops 
fetalis. Fetuses which inherit the homozygous –FIL or –THAI will be 
unable to survive beyond 8 gestational weeks due to the lack of 
zeta-globin chain synthesis.  
2.2.5 DNA sequencing 
A 5 µl aliquot of each PCR product was analysed by 
electrophoresis through a 2% agarose gel in 0.5 x Tris-Borate-
EDTA buffer at 15 volts/cm for 90 min to confirm successful DNA 
amplification. The remaining PCR product was purified using the 
QIAquick™ PCR Purification Kit (Qiagen GmbH, Hilden, Germany) 
and sequenced using the same primers described for PCR. The 
cycle sequencing Cycle sequencing was performed using the 
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), 
conditions were as follows: an initial 1 min denaturation at 96°C, 
followed by 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds, 
and 60°C for 4 min. Sequencing products were precipitated with 
ethanol and resuspended in Hi-DiTM formamide (Applied 
Biosystems), and analyzed by automated capillary electrophoresis 
on an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems). 
All primer sequences and their respective amplicons used in this 
project were sequenced. Nucleotide-nucleotide BLAST (blastn, 
http://www.ncbi.nlm.nih.gov/BLAST/) was used to ensure that all 
the target sequences of the primers were correctly amplified.  
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2.3 Fluorescence in situ hybridisation (FISH) 
FISH allows the direct visualisation of DNA sequences on 
chromosomes, in cells and in tissue. This technology is based on 
the hybridisation between target sequences of the single-strand 
DNA of chromosomes or cell nuclei with labelled complementary 
sequences. The signal is intensified by means of specific 
fluorochrome-labelled antibodies and visualised in the microscope. 
2.3.1 FlashFISH  
Current conventional FISH protocols recommended by the 
manufacturer (Vysis Inc, Downers Grove, Illinois, USA) were 
modified to develop a rapid FISH method, ‘FlashFISH’. FlashFISH 
enables the release of prenatal diagnostic results within the same 
day of fetal sampling without compromisation of accuracy.  
Pretreatment of cells. For slide preparation and FISH on 
uncultured amniotic fluid cells, I modified current protocols 
recommended by the manufacturer (Vysis Inc, Downers Grove, 
Illinois, USA) to be used in FlashFish.  Briefly, after centrifuging 2 – 
4 ml of amniotic fluid at 800 g for 5 min, the amniocyte pellet was 
resuspended and incubated in 3 ml prewarmed 0.075 M KCl for 15 
min at 37°C. Two mililitres of Carnoy’s Fixative (3:1 of Methanol: 
Glacial Acetic Acid) was added drop wise, the cell suspension 
centrifuged at 800 g for 5 min and the pellet resuspended in 
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Carnoy’s.  The cell suspension was dropped onto two cold slides 
and placed on a 60ºC hot plate before hybridisation. 
Pretreatment of tissues. Fetal trophoblast tissues were obtained 
either from the products of conception (POC) following TOP or from 
CVS samples. The trophoblast tissues were carefully dissected off 
adjacent deciduas and washed twice with 1X PBS to remove 
maternal blood contamination. For trophoblast tissues obtained 
from POC sample, the cleaned villi were incubated in trophoblast 
digestion buffer at 37°C for 30 minutes in a water bath. Trophoblast 
digestion buffer was prepared with 0.182 g trypsin (Difco, BD 
Biosciences, Oxford, UK) dissolved in 146.25 ml HBSS (Hank’s 
Balanced Salt Solution, Invitrogen Ltd, Paisley, UK) with 3.75 ml 1M 
Hepes (GE Healthcare Ltd, England, UK) at 37°C. The resulting cell 
suspension was transferred into a clean 50 ml polypropylene tube 
(BD Biosciences, Oxford, UK) where enzyme activity was stopped 
with 5 ml of FCS (fetal calf serum, ICN Pharmaceuticals, 
Hampshire, UK). The cell suspension was strained through through 
a 70 μm filter (Falcon, VWR International Ltd.) to obtain a single cell 
suspension and centrifuged at 3000 rpm (2060 g) (Beckman GS-
06R, CA, USA) with brakes off at room temperature for 10 minutes. 
The cell pellet was resuspended in 5 ml PBS and layered over 
Percoll 1083 (GE Healthcare Ltd, England, UK) before 
centrifugation at 3000 rpm (2060 g) (Beckman GS-6R, CA, USA) 
with brakes off for 20 minutes. A gradient interface layer was 
obtained and the red cells were pelleted at the bottom. The cells in 
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the interface layer containing the trophoblast cells were collected 
separately and suspended in 0.5% BSA/PBS. Up to 3 x 104 cells 
were re-suspended into 300 μl 0.5% BSA/PBS (w/v) for 
cytocentrifugation (Cytospin 3, Shandon, Manchester, UK) at 500 
rpm for 5 minutes onto glass slides for FISH. In trophoblast 
samples obtained from CVS, the cleaned villi was minced into fine 
pieces with a clean scalpel before pipetting into a clean 15 ml 
polypropylene tube (BD Biosciences, Oxford, UK) containing 1 ml of 
1x PBS. Collagenase type IV (Sigma-Aldrich Company Ltd, Dorset, 
UK), which is supplied as lyophilized powder in 223 U/mg, was 
dissolved in distilled water before filter-sterilize using 0.20 μm filter 
(Falcon, VWR International Ltd.). The villi were incubated at 37°C 
for 45 minutes with 200 μl of the prepared collagenase type IV 
mixed with the PBS in the 15 ml polypropylene tube. The digested 
villi were centrifuged at 800 g for 3 minutes before supernatant is 
removed. The cell pellet was resuspended in 2 ml of 1:1 (1% NaCit: 
0.075M KCl) for further incubation at 37°C for 20 minutes. After 
centrifugation to obtain the cell pellet, Carnoy’s Fixative (3:1 of 
Methanol: Glacial Acetic Acid) 2 ml was added drop wise to the cell 
suspension. The cell suspension was centrifuged at 800 g for 5 min 
and the pellet resuspended in Carnoy’s.  The cell suspension was 
dropped onto two cold slides and placed on a 60ºC hot plate before 
hybridisation. 
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Hybridisation. Preparation of probe mixtures for FlashFISH differs 
between CEP® and LSI® probes. For the preparation of CEP® 
probes, 2 μl CEP® probe (Vysis Inc, Downers Grove, Illinois, USA) 
was mixed with 3 μl hybridisation buffer (50% formamide and 10% 
dextran sulphate in 2 x salted sodium citrate (SSC), pH7.0). SSC 
was prepared from a stock of 20X SSC (3M NaCl, 0.3 M tri-sodium 
citrate). For the preparation of LSI® probes, 1 μl LSI® probe (Vysis 
Inc, Downers Grove, Illinois, USA) was mixed with 7 μl hybridisation 
buffer (50% formamide and 10% dextran sulphate in 2 x SSC, 
pH7.0) and 2μl deionised distilled water. For each slide, 5 μl of the 
probe mixture was added to the cell spot under a coverglass sealed 
with ParafilmTM (American National Can Company, Chicago, 
Illinois). Target DNA was denatured on an in situ hybridisation block 
(PTC-200, MJ Research Inc., Waltham, USA) at 80°C for 90 s 
followed by 15 min hybridisation at 42°C.  Post-hybridisation 
washes included once in 0.4 x SSC/0.3% NP-40 at 75°C for 2 min 
and once in 2 x SSC/0.1% NP-40 at room temperature for 2 min.  
Slides with LSI® probes gave better signals when washes were 
only 1 min each with less agitation.  Air-dried slides were mounted 
in fluorescence antifade medium containing DAPI (Vector 
Laboratories, Burlingame, CA) and analysed by epifluorescence 
microscopy.  Fifty nuclei were scored for each probe, and the 
sample considered informative if ≥ 80% of the nuclei displayed 
respectively the same normal/abnormal hybridisation pattern for 
any specific probe.    
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Figure 2-3 Locations of probes used in AneuVysion® 
Prenatal Test kit on the respective chromosomes. 
 
Figure 2-4 Sizes and locations of LSI 21, 13 and TUPLE 1 
probes on the respective chromosomes. 
 
Probes. Centromeric repeat probes DXZ1, labelled with 
SpectrumOrange™, and DYZ3, labelled with SpectrumGreen™ 
(Vysis, Downers Grove, Illinois, USA) were used as standard 
vysis.com 
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probes. This X/Y probe has been optimised for identifying 
chromosomes in interphase nuclei and hybridisation to its target 
chromosomes is marked by red/orange and green, while the 
remaining DNA fluoresces blue with the DAPI stain. Therefore, 
nuclei with two red signals were classified as female (XX) and those 
with one red signal and one green signal as male (XY). LSI® 21 
probe was used in the labelling of chromosome 21. This DNA probe, 
which is labelled with SpectrumOrange™, is approximately 200 kb 
and targets loci D21S59, D21S341 and D21S342 (21q22.13 – 
q22.2). Nuclei with three red signals were classified as trisomy 21 
and those with two red signals were classified disomy 21. In the 
identification of DiGeorge syndrome (DGS), LSI® 
DiGeorge/Velocardiofacial syndromes (VCFS) Dual Colour Probes 
(Vysis) were used. This probe mixture contains the 
SpectrumOrange LSI TUPLE1 (HIRA) probe (3' noncoding region 
of TUPLE1, D22S553, D22S609, and D22S942) and the 
SpectrumGreen LSI ARSA (Arylsulfatase A gene) control probe that 
maps to 22q13.3. In nuclei with two green signals and one red 
signal, the cell is classified as having the microdeletion at 22q11.2 
causing DGS. Normal nuclei displayed two green with two red 
signals. In the identification of trisomies 13 and 18, the 
AneuVysion® Prenatal Test kit is used. This kit consists of two 
probe mixtures to label chromosomes 13, 21, 18, X and Y. LSI 13 
(13q14) consists of a set of overlapping clones that contain the RB1 
gene and flanking regions. The RB1 gene is 180 kb. The probe 
 98 
extends beyond the gene for 110-170 kb in the 5' direction and 
approximately 120 kb in the 3' direction. The entire probe is 
approximately 440 kb in size. CEP® 18 (alpha satellite D18Z1) 
hybridises to the centromere region of chromosome 18 (18p11.1-
q11.1). CEP X (alpha satellite DXZ1) hybridises to the centromere 
region of chromosome X (Xp11.1-q11.1) and CEP Y (alpha satellite 
DYZ3) hybridises to the centromere region of chromosome Y 
(Yp11.1-q11.1) (Figure 2-3, Figure 2-4). 
2.4 Statistical analysis 
2.4.1 PowerStats V12 
To analyse the polymorphism of the microsatellite markers, 
Promega PowerStats v12 freeware downloaded from 
http://www.promega.com/geneticidtools/powerstats was used. 
PowerStats is a Microsoft® Excel workbook developed by Promega 
for the analysis of population statistics. When data is entered, the 
template automatically determines the unique alleles observed, 
calculates population statistics for each race or subgroup and 
charts the results in a way that allows for easy identification of 
heterozygosity and racial comparisons. The polymorphism 
information content (PIC), which is an estimated at each locus as a 
measure of genetic variation; PIC = 1 - ∑p2i, where pi is the 




For all other statistical analysis, software SPSS v14.0 (SPSS Inc., 
Chicago, IL) was used. 
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3 SENSITIVITY AND SPECIFICITY OF REAL-
TIME PCR  
3.1 Introduction 
The sensitivity and reliability of relative quantitation (RQ) in QRT-
PCR were tested on DNA obtained from patients with Down 
syndrome (DS). DS patients carry three copies of APP located on 
chromosome 21q21.3 instead of the normal two copies. RQ 
between the APP and HBB loci will allow the identification of DS 
samples with this difference in gene dosage ratio, i.e. APP:HBB, 
3:2 (Zimmermann et al., 2002). The identification of DS samples 
using multiplex QRT-PCR that co-amplify both APP and HBB loci 
will determine the high sensitivity and reliability of RQ in QRT-PCR, 
which is critical in the amplification, detection and quantitation of 
limiting amounts of fetal DNA in maternal plasma samples. 
 
3.2 Materials and methods 
Sample collection and DNA isolation were as described in Chapter 
2. In brief, DNA was isolated from 200 µl of resuspended 
amniocytes obtained from 85 mothers undergoing amniocentesis 
between 14+4 to 35+2 gestational weeks. Multiplex QRT-PCR of 
APP and HBB was performed on 15 ng isolated DNA together with 
serially-diluted commericial genomic DNA to measure the 
efficiencies of APP/HBB coamplification (Table 2-1). DNA 
sequencing of primers and probes that target HBB and APP were 
aligned with nucleotide-nucleotide BLAST (blastn, 
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http://www.ncbi.nlm.nih.gov/BLAST/). Each sample and standard 
was amplified in triplicates with both samples and standards 
running in parallel. Water blanks were included in triplicates for 
each PCR reaction as negative controls.  
3.3 Results 
3.3.1 Qualitative analysis and relative quantitation of APP 
gene expression 
In all cases (100%), DS diagnostic results in this blinded study were 
concordant with their respective karyotypes. Both APP and HBB 
amplified in all endogenous controls (100%). To calculate the mean 
ΔCT (HBB-APP) values, the difference between CT of HBB and 
APP in each well of the triplicate was averaged. This gives the 
mean ΔCT (HBB-APP) for relative quantitation of APP gene 
expression against HBB. The ΔCT (HBB-APP) values were low 
(mean ± SD = -1.41 ± 0.17) in 82 pregnancies and high (mean ± 
SD = -0.75 ± 0.08) in three pregnancies (Table 3-1). 
Table 3-1 Mean and median of delta cycle threshold, ΔCT, 
between HBB and APP amplifications (HBB-APP) in normal 
and DS samples.  
 
 ΔCT (HBB-APP) 
 Normal DS 
Mean -1.406 -0.753 
Median -1.40 -0.75 
SD ±0.17 ±0.08 
With conventional karyotypes, these 3 cases with high ΔCT (HBB-
APP) were confirmed to be DS while the remaining 82 were 
excluded of DS. The difference in the ΔCT (HBB-APP) values 
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between normal and DS cases is significant (P = 0.003, Mann-
Whitney rank-sum test) (Figure 3-1, Figure 3-2).  
Figure 3-1 QRT-PCR amplification curves showing the 
difference between HBB and APP of normal (A) and DS (B) 
amniotic fluid samples. 
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Figure 3-2 Differences in delta cycle threshold values 
between normal and DS samples. 
 
Figure 3-2 shows the distinct differences in ΔCT (HBB-APP) 
between normal and DS amniotic fluid samples. Blue dots 
represent ΔCT of normal samples while red dots represent ΔCT of 
DS samples. 
3.3.2 Sensitivities of HBB/APP multiplex QRT-PCR 
assays 
Sensitivities of both HBB and APP amplifications in all HBB/APP 
multiplex QRT-PCR assays are high. All standards including the 
lowest dilution of 3 GE per PCR reaction amplified in both HBB and 
APP coamplifications (Figure 3-3).  
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3.3.3 Standard curves 
Regression coefficients for all runs were at -0.99 (ideal -1.00). For 
APP standard curves, the mean ± SD slope was -3.68 ± 0.14 with 
the mean ± SD intercept of 39.95 ± 0.77. For HBB standard curves, 
the mean ± SD slope was -3.46 ± 0.08 with the mean ± SD 


















Figure 3-3 Standard curves of HBB (left panel) and APP 
(right panel) obtained from serial dilutions of commercial 
genomic DNA.  
Regression coefficients (R2) are both ideal at 0.99. The lowest 
dilutions of 3 GE (copies) were amplified and detected. 
 
3.4 Discussion 
Multiplex QRT-PCR amplifies both the target and endogenous 
reference genes within the same tube. Coamplification minimises 
well-to-well variation and increases sample throughput. By using 
the mean ΔCT (HBB-APP), we were able to compare the gene 
expression levels of APP and HBB. This is known as RQ of gene 
expression. DS was accurately detected in 3 out of 85 amniotic fluid 
samples within one day of fetal sampling. Ideally, specific indication 
of the normality of the fetus should be available on the same day as 
the diagnostic invasive procedure. This would be possible if 
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analysis results of uncultured amniocytes after invasive testing 
were ready within hours of the procedure. In this study, the time 
taken from sample collection to reporting of results was 3 hours.  I 
had demonstrated that multiplex QRT-PCR of APP with HBB as the 
endogenous reference in amniotic fluid samples is a rapid and 
reliable alternative technique to other rapid molecular prenatal 
diagnostic tests such as FISH and QF-PCR. This technique can be 
modified for rapid prenatal diagnosis of other common 
chromosomal aneuploidies such as trisomy 18 (Edward’s syndrome) 
and trisomy 13 (Patau’s syndrome).  
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4 DETECTION OF FETAL DNA FROM MATERNAL 
PLASMA 
4.1 Introduction 
Fetal DNA in the maternal plasma samples were known to be 
elevated in pregnancy-related complications in previous studies. I 
optimised DNA isolation from maternal plasma and QRT-PCR of 
SRY and HBB using maternal plasma samples from mothers with 
pregnancy-related complications. The successful detection and 
quantitation of elevated amounts of fetal DNA from these samples 
allow subsequent utilisation of these optimised protocols in 
normotensive pregnancies. The levels of fetal DNA were quantified 
throughout gestation to determine the earliest week where fetal 
DNA can be detected in maternal plasma in normotensive 
pregnancies. 
4.2 Materials and methods 
Pregnancy-related complications. Two women were admitted at 
30 weeks (P1) and 27 weeks (P2) of gestation for preeclampsia 
(PE). P1 had hypertension and 24-hour urine total protein was 
reported to be 1.77 g/day. Her pregnancy was also complicated by 
intrauterine growth retardation (IUGR) and post-operative HELLP 
syndrome. After her emergency caesarean section, biochemistry 
results revealed thrombocytopenia (platelet count 25 x 109/L), 
elevated hepatic enzymes (AST 1446 U/L, ALT 1031 U/L, LDH 
(7419 U/L) and coagulopathy (prolonged prothrombin time and 
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activated partial thromboplastin time). This was preceded by normal 
blood results with platelet count of 131 x 109/L before the operation. 
Blood for our study were obtained before HELLP syndrome set in. 
P2 had severe preeclampsia based on blood pressure of more than 
160/110 and 24-hour urine total protein of 14.1 g/day. No evidence 
of HELLP syndrome was noted for P2. After written informed 
consent, 3 ml of peripheral blood was collected in EDTA tubes from 
both mothers before delivery. All peripheral blood samples were 
processed and DNA isolated as described in Chapter 2 with water 
being used as extraction internal negative controls to rule out 
contamination of extracted DNA samples. QRT-PCR analysis was 
done by Perkin Elmer Applied Biosystems 7000 Sequence Detector 
(Applied Biosystems). β-globin (HBB), a chromosome 11 locus, 
was used as endogenous control for total DNA quantitation. SRY 
was used for fetal DNA quantitation and fetal gender determination. 
Primers, probes sequences, dilution series for standard curves and 
cycling profiles were as described (Table 2-1). Each sample and 
standard was run in triplicates with both sample and standards 
running in parallel. Water used in preparation of PCR master mix 
and water used as an extraction internal negative control 
throughout DNA isolation were included in triplicates for each PCR 
run as amplification external and internal negative controls 
respectively. 
Normotensive pregnancies. Two millilitres of maternal blood was 
collected after written informed consent from 23 mothers 
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undergoing amniocentesis, ultrasound or termination of pregnancy 
(TOP) between 6+5 to 36+4 gestational weeks. Trophoblast tissues 
were collected from TOP for molecular genetic analysis of fetal 
gender. All blood samples were processed within 2 hours of 
sampling. DNA isolation from maternal plasma, trophoblast tissue, 
preparation of PCR master mix, cycling profile and primers and 
probes sequences were as described in Chapter 2. Fetal gender 
confirmation was done using FlashFish of trophoblast cells (in 
cases of TOP). Centromeric enumeration CEP® X/Y probe (Vysis 
Inc, Illinois, USA) was used to label the sex chromosomes for fetal 
gender analysis. QRT-PCR of fetal trophoblast cells was also 
performed to determine fetal gender. In samples collected from 3rd 
trimester pregnancies, fetal gender was determined by ultrasound 
and at birth. 
4.3 Results 
Qualitative analysis in pregnancy-related complications. Cell-
free total (both maternal and fetal) DNA concentrations in the 
maternal plasma were measured with HBB amplifications and 
quantitation while cell-free fetal DNA concentrations were 
measured with SRY amplifications and quantitation. The conversion 
factor of 6.6 pg of genomic DNA per cell was used for expression of 
results in genome equivalents (GE). The concentrations of cell-free 
total and fetal DNA in P1 maternal plasma with HELLP syndrome 
was 2064813.0 GE/ml and 632.2 GE/ml respectively. In P2 with 
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severe PE, cell-free total and fetal DNA concentrations in maternal 
plasma were 44659.4 GE/ml and 370.2 GE/ml respectively (Table 
4-1, Figure 4-1). When compared to the medians of cell-free total 
and fetal DNA concentrations of normotensive pregnancies in Birch 
et al., 2005, there were 2082.3- and 8.0- fold increased in cell-free 
total and fetal DNA in maternal plasma respectively in P1. In P2, 
the number of fold increased in cell-free total and fetal DNA as 
compared to median of normotensive were lower at 45.0- and 4.7- 
folds (Table 4-1). 
Table 4-1 Table showing fetal DNA (measured by SRY 
amplifications) and total DNA (measured by HBB 
amplifications) concentrations in maternal plasma of P1 and 
P2.  
Sample SRY (GE/ml) 
HBB 
(GE/ml) 
*No. of fold increase 
(fetal) 
*No. of fold increase 
(total) 
P1 
(HELLP) 632.2 2064813.0 8.0 2082.3 
P2 (PE) 370.2 44659.4 4.7 45.0 
*No. of fold increase compared with means of 3rd trimester samples 
where means of fetal and total DNA concentrations are 79.4 GE/ml 
and 991.6 GE/ml respectively (Birch et al., 2005). 
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Figure 4-1 Real-time PCR amplifications of HBB and SRY in 
HELLP syndrome (P1) and severe PE (P2) samples. 
 
Qualitative analysis of normotensive pregnancies. Of the 23 
maternal plasma samples analysed, 13 male fetuses were identified 
with the presence of SRY amplifications in cell-free DNA isolated 
from maternal plasma. Endogenous controls (HBB) amplified in all 





Figure 4-2 Figure showing HBB and SRY amplifications of 
cell-free total (HBB) & fetal (SRY) DNA from maternal plasma. 
 
For samples obtained from mothers undergoing amniocentesis, 
fetal genders were confirmed by cytogenetic karyotypes. QRT-PCR 
of HBB and SRY on DNA isolated from trophoblast cells and 
FlashFISH of CEP® X/Y probes on trophoblast cells obtained from 
TOP confirmed fetal gender (Figure 4-3), as well as ultrasound 




Figure 4-3 Fetal gender confirmations by QRT-PCR (I, II) and 
FlashFISH (A, B) of trophoblast cells showing female (I, A) and 













Figure 4-4 Ultrasound findings showing female genitalia (A) 
and male genitalia (B). 
(Reproduced with approval from A/P Biswas) 
 
Figure 4-3 shows QRT-PCR amplifications of HBB and SRY on 
DNA isolated from trophoblast cells (I and II). The lack of SRY 
amplifications in suggests female gender (I) while the presence of 
SRY amplifications suggests male gender (II). FlashFISH of 
CEP®X/Y probes of fetal trophoblast cell in A and B, obtained from 
the same samples confirmed the presence of two chromosomes X 
(red signals, A) which indicate a female karyotype. The trophoblast 
nucleus (B) shows the presence of one chromosome X (red signal) 
and one chromosome Y (green signal), indicating a male karyotype. 
Figure 4-4 shows the sonography markers for female (A) and male 
(B) fetuses at ≥ 20 gestational weeks. 
A B
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Table 4-2 Non-invasive identification of fetal gender using 







1 6+5 Female XX 
2 7+6 Female XX 
3 8+2 Male XY 
4 8+5 Female XX 
5 8+5 Male XY 
6 9+0 Male XY 
7 9+3 Female XX 
8 16+4 Male XY 
9 21+5 Female XX 
10 21+6 Female XX 
11 22+0 Male XY 
12 24+0 Male XY 
13 32+0 Female XX 
14 32+0 Male XY 
15 32+0 Male XY 
16 33+1 Male XY 
17 34+1 Male XY 
18 35+0 Male XY 
19 35+4 Female XX 
20 36+0 Female XX 
21 36+0 Male XY 
22 36+2 Male XY 
23 36+4 Female XX 
Table 4-2 shows the identification of male fetuses using fetal DNA 
from the maternal plasma by the presence of QRT-PCR 
amplification of SRY. Out of 23 maternal plasma samples 
(gestational weeks ranged from 6+5 to 36+4), 13 were determined as 
male while 10 were determined as female fetuses. Real-time PCR 
results were 100% concordant with confirmatory results obtained 
from FlashFISH, QRT-PCR and at birth (chi-square 23.0; Fisher’s 
Exact P<0.001). Total DNA concentrations in maternal plasma 
(measured by HBB amplifications) ranged from 355.4 - 4642.4 
GE/mL (median = 1653.0 GE/mL). Fetal DNA concentrations 
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determined from SRY amplifications ranged from 3.04 - 169.00 
GE/mL (median = 10.97 GE/mL) (Table 4-3). 
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Table 4-3 Table shows the comparisons of cell-free total (HBB) and fetal (SRY) DNA concentrations in maternal plasma 
obtained from normal pregnancies (n=13) and hypertensive pregnancies (n=2, P1 with HELLP syndrome and P2 with 
severe PE).   
  Normative Pregnancies (n=13) Hypertensive Pregnancies (n=2) 
      P1 P2 
  Gestation (weeks) 
1st Trimester (8 -9, 
n=3) 
2nd Trimester (16 – 
24, n=3) 
3rd Trimester (32 – 
36, n=7) 30 27 
Range 355.4 - 2544.1 722.4 - 2443.4 802.8 - 4642.4 2064813.0 44659.4 
Mean 1413.7 1424.3 2352.3 – – 
Median 1476.7 1171.2 2315.2* – – 
HBB 
No. of fold increase (*) – – – 891.9 19.3 
Range 11.0 - 26.2 3.0 - 129.2 67.4 - 121.6 632.2 370.2 
Mean 16.1 56.8 100.1 – – 
Median 11.1 38.0 84.8* – – 
SRY 
No. of fold increase (*) – – – 7.5 4.4 
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Both cell-free fetal total (HBB) and fetal (SRY) DNA concentrations 
increased as pregnancies advanced from 1st to 3rd trimester (6 - 36 
weeks). In hypertensive pregnancies (P1 and P2), cell-free total DNA 
increased 891.9-fold (in P1) and 19.3-fold (in P2), while cell-free fetal 
DNA increased 7.5-fold (in P1) and 4.4-fold (in P2) when compared 
with their respective median (*). HBB measures the total concentration 
of cell-free DNA while SRY measures the concentration of cell-free 
fetal DNA in the maternal plasma. All DNA concentrations shown are 
measured in genome equivalents (GE) where 1 GE is equivalent to 6.6 
pg of DNA. 
Sensitivities of SRY and HBB assays. The lowest serial dilutions of 
commercial male genomic DNA (1.5 GE for SRY and 3 GE for HBB) 
were amplified and detected by both SRY and HBB real-time PCR 
assays in all runs (Figure 4-5). 
Standard curves. Regression coefficients for all runs were at -0.99 
(ideal -1.00). For SRY standard curves, the mean ± SD slope was -
3.55 ± 0.16 with the mean ± SD intercept of 38.11 ± 0.49. For HBB 
standard curves, the mean ± SD slope was -3.52 ± 0.13 with the mean 





Figure 4-5 Figure showing HBB (left panel) and SRY (right 
panel) standard curves obtained from serial dilutions of 
commercial male genomic DNA. 
 
4.4 Discussion 
In the initial stages of optimising enrichment and detection protocols for 
cell-free fetal DNA in the maternal plasma, I used maternal plasma 
samples from pregnancies with hypertensive disorders (PE and 
HELLP) as cell-free fetal DNA levels were known to be highly elevated 
as compared to normotensive pregnancies. Results of the two 
pregnant women with HELLP syndrome (P1) and severe PE (P2) at 
term showed that there were significant increases of cell-free fetal and 
total DNA at the time PE was manifested in both cases. Significant 
increases in circulating cell-free total and fetal DNA concentrations in 
the maternal plasma of mothers with complications in pregnancy can 
be useful as screening markers. Data from the 13 normotensive male 
pregnancies in different trimesters shows increases in concentrations 
of total and cell-free fetal DNA in maternal plasma as pregnancy 
 120 
progresses. However, due to the small number of male pregnancies in 
our study (n=13), we compared the concentrations of cell-free total and 
fetal DNA of P1 and P2 with published data from a large study (Birch et 
al., 2005). In the case of HELLP syndrome (P1), fetal DNA increased 
8.0-fold while total DNA increased by 2082.3-fold when compared with 
respective means of normotensive 3rd trimester pregnancies (Birch et 
al., 2005). In the maternal plasma of mother, P2, who was affected with 
severe PE, amount of cell-free total DNA increased 45.0-fold while fetal 
DNA concentration increased by 4.7-fold when compared with 
respective means of normotensive 3rd trimester pregnancies (Birch et 
al., 2005) (Table 4-1). These significant increases in the numbers of 
copies of fetal and total DNA were observed at the time PE were 
manifested but before the onset of HELLP syndrome. Hence, 
increases in concentrations of cell-free total and fetal DNA in the 
maternal plasma maybe used as predictive markers for HELLP 
syndrome in mothers admitted with PE, allowing necessary procedures 
for clinical management of the at-risk mother and neonate. These 
elevated concentrations had been reported in several studies. In these 
studies of HELLP syndrome cases, both fetal and total DNA increased 
significantly prior to the diagnosis of HELLP syndrome and therefore, 
useful as markers for the non-invasive evaluation of the 
pathophysiological severity of eclampsia and HELLP syndrome. 
However, this system is limited to mothers carrying singleton male 
fetuses as detection of fetal DNA is based on the presence of SRY in 
the maternal plasma.  
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The aim of this study was to optimise DNA isolation and PCR protocols 
to detect cell-free fetal DNA from the maternal plasma. Using the same 
protocols, I proceeded to detect and quantify the levels of fetal DNA in 
maternal plasma of normotensive pregnancies. In this study, I showed: 
(1) 100% accuracy in fetal gender determination using maternal 
plasma in 3 trimesters in all cases (100%), fetal gender was 
concordant between SRY amplification and known fetal gender (chi-
square 23.0; Fisher’s exact P <0.001), (2) that cell-free fetal DNA in 
maternal plasma can be quantified in as early as 8+2 gestational 
weeks, (3) that fetal DNA concentration in maternal plasma increased 
as pregnancy progressed (from a median of 11.10 GE/mL in the first 
trimester to a median of 84.80 GE/mL in the third trimester) and (4) that 
with a detection limit of 1.50 GE/mL, the sensitivities of our SRY and 
HBB quantitative real-time PCR assays are high. The lowest fetal DNA 
concentration that we had quantified from maternal plasma was 3.04 
GE/mL.  
In conclusion, I had successfully isolated cell-free fetal DNA from 
maternal plasma in as early as 8 gestational weeks. Using QRT-PCR, I 
was able to amplify and quantify the isolated fetal DNA. Fetal gender 
was also determined with 100% accuracy. This would mean that fetal 
genetic material could be obtained in first trimester maternal plasma in 
as early as 8 gestational weeks for non-invasive prenatal genetic 
analysis of thalassaemia.  
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5 USE OF MICROSATELLITE MARKERS TO 
IDENTIFY HB BART’S IN FETAL DNA 
5.1 Introduction 
Microsatellite markers within the breakpoints of common alpha 
thalassaemia double gene deletions such as -SEA, -THAI and –FIL were 
analysed to identify Hb Bart’s simultaneously with the exclusion of 
maternal contamination. Using multiplex QF-PCR, two polymorphic 
microsatellite markers (16PTEL05, 16PTEL06) within the -SEA, -THAI and 
–FIL deletion breakpoints were amplified and analysed. Complete 
absence of these markers indicates deletions of both alleles as these 
microsatellite markers are located within the breakpoints. The 
polymorphic nature of these microsatellite markers enables 
discrimination between maternal and paternal alleles. This is useful for 
the exclusion of maternal contamination by determining the absence of 
maternal alleles that are not inherited by the fetus within fetal DNA 
samples. The additional cost and time required for a separate test to 
exclude maternal contamination are thus eliminated. The ability of this 
novel technique for the discrimination between maternally- and 
paternally- inherited alleles will be useful for subsequent exclusion of 
Hb Bart’s non-invasively using fetal DNA from the maternal plasma. 
5.2 Materials and methods 
Controls. DNA was isolated from three cell lines (GM10799, GM03037, 
GM03433), 3 mL EDTA-anticoagulated blood samples from two alpha 
thalassaemia (αα/--SEA) carriers (carrier-1, carrier-2) and two healthy 
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volunteers (normal-1, normal-2). The α-globin genotypes were 
determined by the α-thalassaemia 7-deletion multiplex PCR as 
previously described (Tan et al., 2001). DNA sequencing ensured that 
all target sequences of the primers were correctly amplified. 
Paired parental and fetal samples. In the blinded clinical validation 
study, 50 sets of stored DNA samples each consisting of maternal, 
paternal and fetal DNA were obtained from the DNA Bank of the 
Molecular Diagnosis Centre (MDC) at the National University Hospital 
for analysis. Usage of the banked DNA samples for this study complied 
with the regulations set by our Institutional Review Board, including 
informed patient consent and anonymization of source. DNA had been 
isolated from the peripheral blood of both parents and fetal DNA from 
one of the following sources: amniotic fluid (AF), chorionic villi (CV), or 
fetal blood (FB). Maternal contamination of the fetal DNA samples was 
monitored by PCR amplification of the D1S80 variable number of 
tandem repeat (VNTR) polymorphism (Budowle et al., 1991). In all 
prenatal samples, parental and fetal samples were haplotyped 
simultaneously to exclude maternal contamination. The α-globin 
genotypes of these samples had been previously determined using the 
method of Tan et al. (2001) in the diagnostic service routine (Tan et al., 
2001), but were not made known to the analysts conducting the clinical 
validation study for the new QF-PCR method.  
Unpaired amniotic fluid samples. DNA was isolated from 100 
amniotic fluid samples obtained from pregnant women undergoing 
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routine prenatal diagnosis to evaluate the polymorphisms of the 
microsatellite markers in the Singapore population. QF-PCR using the 
primer sequences for the microsatellite markers were performed (Table 
2-2). Heterozygosities and PIC (polymorphism information content) are 
calculated using the Promega PowerStats v12 freeware 
(promega.com). 
QF-PCR. Singleplex and multiplex QF-PCR were performed as 
described in Chapter 2. To calculate the heterozygosities of all three 
microsatellite markers for the determination of polymorphism, QF-PCR 
was performed singleplexed for each of the primer pairs. D16S539-F/R, 
16PTEL05-F/R and 16PTEL06-F/R primers were used together within 
a PCR reaction (single-tube multiplex-QF-PCR) for the remaining 
samples. PCR was done using 15 ng extracted DNA in a total volume 
of 25 µL, with 1X PCR buffer, 2.0 mM MgCl2, 0.8 mM each of 
deoxynucleotide triphosphates (PE Biosystems, Warrington, England) 
and 1 U of AmpliTaq Gold polymerase (Roche, Mannheim, Germany). I 
used 0.6 µM of each specific primer (Sigma-Aldrich, Proligo Primers 
and Probes Pty, Singapore) for singleplex QF-PCR. For multiplex QF-
PCR, I used 0.2 µM D16S539-F/R, 0.5 µM 16PTEL05-F/R and 1.5 µM 
16PTEL06-F/R. Thermal cycling was performed in a PTC-200 Thermal 
Cycler (MJ Research Inc., Waltham, USA) with an initial 5-min 
denaturation at 95°C, followed by 30 cycles of 95°C for 30 s, 66°C for 
30 s, and 60°C for 30 s, with a final extension of 60°C for 5 min, 
followed by a 1-hour incubation at 60°C. Two microliters of the 
amplified PCR products were mixed with 9.5 µL of deionised 
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formamide and 0.5 µL of GS-500 ROX standard (Applied Biosystems, 
Foster City, CA, USA). The mix was heated at 90°C for 2 min, followed 
by 4°C for 5 min before resolving on the ABI PRISM 310 Genetic 
Analyzer (Applied Biosystems). The resulting peaks were analysed 
using the GeneScan analysis software (Applied Biosystems). SPSS 
14.0 was used for statistical analysis.   
5.3 Results 
Controls. DNA sequences from the two healthy volunteers (normal-1, 
normal-2) were obtained and aligned with the reference sequence, 
AE006462 using the nucleotide-nucleotide BLAST (blastn, 
http://www.ncbi.nlm.nih.gov/BLAST/). BLAST results confirmed that all 
the amplified sequences are specific to their respective target primers 
in Table 2-2. In DNA samples isolated from carriers with α-
thalassaemia-1 trait (αα/--SEA) (carrier-1, carrier-2, GM10799), 
D16S539 alleles were amplified while only 1 allele was amplified for 
each of 16PTEL05 and 16PTEL06. Both alleles of D16S539 in the Hb 
Bart’s cell lines (GM03037, GM03433) were amplified and detected 
while none of 16PTEL05 or 16PTEL06 was detected. The absence of 
both 16PTEL05 and 16PTEL06 in samples GM03037 and GM03433 





Figure 5-1 Figure showing the electropherograms of multiplex 
QF-PCR (D16S539, 16PTEL05, 16PTEL06) of controls consisting 
of αα/--SEA (carrier-1, carrier-2, GM10799) and --SEA/--SEA (GM03037, 
GM03433). 
Filled coloured (blue/green) peaks are amplified microsatellite markers. 
Unfilled red peaks are ROX-500 size standard. 
 
Blinded study. Samples were identified as Hb Bart’s (--SEA/--SEA) when 
D16S539 were amplified in the absence of both 16PTEL05 and 
16PTEL06. The presence of only one allele in each of 16PTEL05 and 
16PTEL06 suggest two possible genotypes: (1) α-thalassaemia-1 
carriers (αα/--SEA) where one of the alleles had been deleted, or (2) 
normal homozygotes (αα/αα) where both alleles are of the same size 
and therefore cannot be resolved as two different alleles.  Normal 
samples (αα/αα) were identified when both alleles of either 16PTEL05 
or 16PTEL06 were amplified and detected. Using this analysis protocol, 
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11 fetal samples were identified as Hb Bart’s (--SEA/--SEA), 18 fetal 
samples as either alpha thalassaemia carriers (αα/--SEA) or unaffected 
homozygotes and the remaining 21 fetal samples were identified as 
unaffected (Table 5-1).  
Table 5-1 Microsatellite markers (16PTEL05 and 16PTEL06) 
analysis results and molecular analysis genotypes.  
  QF-PCR Results Genotype 
Family Type (Fetus) Fetus Fetus 
1 AF unaffected IVS 1 #5 (G>C) 
2 AF C/H αα/--SEA 
3 AF unaffected αα/αα 
4 FB --SEA/--SEA --SEA/--SEA 
5 CV unaffected Cd 41/42 
6 CV unaffected αα/αα 
7 AF C/H αα/--SEA 
8 CV --SEA/--SEA --SEA/--SEA 
9 CV unaffected normal 
10 CV unaffected Cd 41/42 
11 CV unaffected β-thal major 
12 CV unaffected αα/αα 
13 CV C/H αα/--SEA 
14 CV C/H αα/--SEA 
15 FB --SEA/--SEA --SEA/--SEA 
16 CV C/H αα/--SEA 
17 CV unaffected αα/αα 
18 CV C/H αα/--SEA 
19 CV --SEA/--SEA --SEA/--SEA 
20 AF C/H αα/--SEA 
21 CVS --SEA/--SEA --SEA/--SEA 
22 CVS C/H αα/--SEA 
23 CVS unaffected αα/αα 
24 CVS --SEA/--SEA --SEA/--SEA 
25 CVS --SEA/--SEA --SEA/--SEA 
26 AF C/H αα/--SEA 
27 CVS --SEA/--SEA --SEA/--SEA 
28 CVS C/H αα/--SEA 
29 CVS unaffected αα/αα 
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30 CVS C/H αα/--SEA 
31 CVS unaffected αα/αα 
32 AF C/H αα/--SEA 
33 AF unaffected αα/αα 
34 CVS unaffected αα/αα 
35 FBS --SEA/--SEA --SEA/--SEA 
36 CVS C/H αα/--SEA 
37 AF C/H αα/--SEA 
38 CVS --SEA/--SEA --SEA/--SEA 
39 CVS C/H αα/--SEA 
40 CVS unaffected αα/αα 
41 CVS C/H αα/--SEA 
42 CVS unaffected αα/αα 
43 CVS unaffected αα/αα 
*44 CVS unaffected αα/--SEA 
45 FBS --SEA/--SEA --SEA/--SEA 
46 AF unaffected αα/αα 
47 FBS C/H αα/αα 
48 CVS C/H αα/--SEA 
49 CVS unaffected αα/αα 
50 AF unaffected αα/αα 
C/H indicates either a carrier with α-1 thalassaemia trait (αα/--SEA) or a 
homozygote (αα/αα). 
*Fetus 44 was a carrier (αα/--SEA) misdiagnosed as unaffected. 
Figure 5-2 shows the electropherogram results of Family-1 consisting 
of unaffected parents (Father-1, Mother-1) with an unaffected fetus 
(Fetus-1). Both alleles of 16PTEL05 and 16PTEL06 were detected in 
all members of the family. Figure 5-3 shows Family-2 consisting of 
parents who are alpha thalassaemia carriers (αα/--SEA) with a carrier 
fetus (Fetus-2). The presence of two alleles for each of the 
microsatellite markers 16PTEL05 and 16PTEL06 in each member of 
the family conclude either carrier or homozygous alleles in all family 
members. Fetus-2 inherited the paternal unaffected allele and was 
excluded as having Hb Bart’s (--SEA/--SEA). Figure 5-4 shows Family-
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3 with α-thalassaemia-1 parents (Father-3, Mother-3) with an 
unaffected fetus (Fetus-3). The inheritance of each of the parent’s 
unaffected alleles by Fetus-3 is shown. In Figure 5-5, Family-4 consists 
of α-thalassaemia-1 parents (Father-4, Mother-4) with a fetus (Fetus-4) 
afflicted with Hb Bart’s. None of the microsatellite markers, 16PTEL05 
and 16PTEL06, can be detected in Fetus-4. The results were 
compared with their respective known genotypes documented at the 
MDC only after all the diagnostic calls had been made in a prospective 
and blinded manner (Table 5-1). From the known genotypes, 11 fetal 
samples were identified as Hb Bart’s, 18 fetal samples were diagnosed 
as αα/--SEA, and 21 fetal samples were diagnosed unaffected. Results 
were concordant in all cases discriminating between fetuses with and 
without Hb Bart’s (sensitivity 100%, lower 95% CI, 76.2%; specificity 
100%, lower 95% CI, 92.6%). One fetal sample with the known carrier 
genotype αα/--SEA was misdiagnosed by our multiplex QF-PCR as 
unaffected with the presence of 2 alleles in 16PTEL05 and 16PTEL06 
(Table 5-1, Fetus-44). Maternal contamination was excluded by the 







Figure 5-2 Family-1: Unaffected parents with an unaffected 
fetus.  
Multiplex QF-PCR (16PTEL05, 16PTEL06, D16S539) show the 
presence of both alleles each of 16PTEL05 (blue) and 16PTEL06 
(green) in both unaffected parents and unaffected fetus. 
Filled coloured (blue/green) peaks are amplified microsatellite markers. 
Unfilled red peaks are ROX-500 size standard. 
 
Figure 5-3 Family-2: Carrier parents with a carrier fetus.  
Multiplex QF-PCR (16PTEL05, 16PTEL06, D16S539) show the 
presence of one allele each of 16PTEL05 (blue) and 16PTEL06 
(green) in both carrier parents and carrier fetus. 
Filled coloured (blue/green) peaks are amplified microsatellite markers. 




Figure 5-4 Family-3: Carrier parents with an unaffected fetus. 
Multiplex QF-PCR (16PTEL05, 16PTEL06, D16S539) show the 
presence of both alleles each of 16PTEL05 (blue) and 16PTEL06 
(green) in the unaffected fetus.  
Filled coloured (blue/green) peaks are amplified microsatellite markers. 
Unfilled red peaks are ROX-500 size standard. 
 
 
Figure 5-5 Family-4: Carrier parents with a Hb Bart’s fetus. 
Multiplex QF-PCR (16PTEL05, 16PTEL06, D16S539) show the 
absence of 16PTEL05 (blue) and 16PTEL06 (green) with the presence 
of control D16S539 (blue) in the fetus affected with Hb Bart’s. 
Filled coloured (blue/green) peaks are amplified microsatellite markers. 




5.3.1 Assessment of maternal DNA contamination 
This multiplex QF-PCR assay was designed to amplify both targets 
(16PTEL05 and 16PTEL06) and control (D16S539) within a single tube 
for each sample. Maternal contamination can therefore be excluded 
with the absence of D16S539 non-inherited maternal alleles in fetal 
DNA samples simultaneously with diagnosis. The usefulness of the 
polymorphic microsatellites was shown in Figure 5-3. Fetal DNA 
(Fetus-2) shows the absence of maternal alleles; 85 bp (16PTEL05) 
and 118 bp (16PTEL06). Paternally-inherited alleles; 83 bp (16PTEL05) 
and 100 (16PTEL06), in the fetal DNA were amplified and detected as 
shown. Therefore, in family-2, maternal contamination was excluded 
without the use of maternal D16S539 alleles. Results showed that 
none of the fetal DNA samples was contaminated with maternal DNA 
and this was verified with variable number tandem repeat (VNTR) 
analysis at the D1S80 locus. 
5.3.2 Heterozygosity and PIC 
Table 5-2 shows the number of alleles and ranges of size fragments 
obtained for each microsatellite marker obtained from the 100 amniotic 
fluid samples. Previous experiments had shown that the polymorphism 
of 16PTEL05 derives from the (CA)n dinucleotide repeats and not the 
(AATA)n tetranucleotide repeats (data not shown). Therefore, to 
calculate heterozygosities of 16PTEL05, a primer pair of 16PTEL05 
(16PTEL05-F/R) which targets only the (CA)n repeats was used. Allele 
frequencies, PIC and heterozygosities were calculated using the 
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Promega PowerStats v12 freeware (Tereba, 1999). We found that the 
PIC values of all three markers ranged from 0.76 to 0.86. According to 
Bostein et al. (1980), a marker can be considered highly informative in 
a mapping population if it has an expected PIC greater than 0.5, with 
values of between 0.5 and 0.25 considered to be reasonably 
informative (Botstein et al., 1980). Therefore, all 3 microsatellite 
markers (D16S539, 16PTEL05 and 16PTEL06) are highly informative. 
Table 5-2 Table showing STR analysis results of the 100 










D16S539 (GATA)n 7 145 – 169 0.76 0.79 0.83 
16PTEL05 (CA)n 7 77 – 89 0.80 0.82 0.74 
16PTEL06 (CA)n 22 100 - 142 0.86 0.87 0.82 
5.4 Discussion 
The basis of PCR diagnosis of a fetus affected with homozygous α-
thalassaemia-1 is the absence of all four alpha-globin genes. PCR is 
highly sensitive and requires a very small amount of DNA to make a 
diagnosis. However, this high sensitivity will also detect few copies of 
contaminating alpha-globin genes that may be present in the sample. 
Therefore, low level of maternal DNA contamination may result in 
misdiagnosis. Current established PCR-based methods require a 
separate test to exclude maternal contamination. D1S80 testing is 
commonly used to exclude maternal contamination. It is a VNTR which 
consists of a 16 bp repeat with at least 29 alleles ranging in size from 
369 to 801 bp corresponding to 14 and 41 repeats, respectively (Kasai 
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et al., 1990; Cetus Corp 1991). PCR efficiency is reduced with the 
amplification of large repeats such as D1S80. Differential amplification 
may also result in dropout of the larger allelic product and 
misclassification of a heterozygous individual as homozygous for the 
over-amplified smaller allele. Therefore, in cases where results of 
D1S80 analysis are inconclusive, further tests using STR analysis are 
required. In order to obtain sufficient DNA for diagnosis and exclusion 
of maternal contamination, amniotic fluid samples need to be cultured. 
Ten milliliters of amniotic fluid are usually required and culture takes up 
to 2 weeks. This increased length of time and amount of sample 
needed for a separate test so as to exclude maternal contamination is 
undesirable. I had developed a novel prenatal diagnostic test by using 
QF-PCR to detect Hb Bart’s as well as to exclude maternal 
contamination in a single assay. The SEA type deletion was 
specifically investigated because it is the most common double gene 
deletion in Southeast Asia. My results support the hypothesis that Hb 
Bart’s (--SEA/--SEA) can be diagnosed by analysing microsatellite 
markers within the breakpoints. These microsatellite markers 
(16PTEL05, 16PTEL06) are highly polymorphic with PIC of 0.80 and 
0.86 respectively, allowing differentiation between paternally- and 
maternally-inherited alleles. Figure 2-2 shows the locations of these 
markers and the breakpoints of various types of other alpha 
thalassaemia double gene deletions, such as --MED, --FIL and --THAI. As 
shown in the figure, the markers (16PTEL05 and 16PTEL06) also lie in 
the breakpoints of --FIL and --THAI. Of these double gene deletions, 
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fetuses carrying --MED or --SEA deletions on both alleles can survive to 
late trimester and will present as Hb Bart’s. Fetuses that inherit the --FIL 
or --THAI deletions in both alleles do not survive beyond 8 gestation 
weeks due to the lack of zeta-globin chains synthesis. PCR 
amplifications of these polymorphic microsatellite markers are efficient 
as they consist of short repeating units of 2-4 bp. Multiplex QF-PCR 
amplifications of both targets (16PTEL05 and 16PTEL06) and control 
(D16S539) enable Hb Bart’s to be diagnosed simultaneously together 
with the exclusion of maternal contamination. The absence of both 
16PTEL05 and 16PTEL06 suggests Hb Bart’s (--SEA/--SEA). The 
presence of one allele for each of 16PTEL05 and 16PTEL06 suggest 
either of α-thalassaemia-1 (αα/--SEA) or the normal homozygote (αα/αα). 
As D16S539 is located outside the breakpoint region, it is used as a 
control to confirm the presence of DNA and to exclude maternal 
contamination.  
QF-PCR of all primer pairs yield consistent results in DNA isolated 
from the cell lines. No amplification of 16PTEL05 and 16PTEL06 was 
detected in the cell lines of Hb Bart’s (GM03037 and GM03433). In the 
blinded study, Hb Bart’s were diagnosed when the microsatellite 
markers (16PTEL05, 16PTEL06) were not detected, in the presence of 
D16S539. Maternal contamination was excluded in all cases, as 
evidenced by the absence of non-inherited maternal alleles in fetal 
DNA samples.  
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In conclusion, by amplifying target microsatellite markers found within 
the breakpoint region of –SEA deletion, Hb Bart’s can be accurately 
identified with the absence of amplifications. The target microsatellite 
markers are highly polymorphic as demonstrated by the heterozygosity 
and PIC calculations of 100 amniotic fluid samples. Since these 
microsatellite markers are highly polymorphic, maternally- and 
paternally-inherited alleles can be differentiated and identified in fetal 
DNA samples. The ability of our novel QF-PCR method to differentiate 
between maternally- and paternally-inherited alleles will also be used in 
the analysis of fetal DNA in maternal plasma. The detection and 
identification of the paternally-inherited fetal alleles in the maternal 
plasma may be useful to exclude Hb Bart’s and forms the basis of non-
invasive testing in this thesis. 
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6 USE OF MICROSATELLITE MARKERS TO 
EXCLUDE HB BART’S NON-INVASIVELY 
USING FETAL DNA FROM MATERNAL 
PLASMA 
6.1 Introduction 
The highly sensitive QF-PCR technique is used to amplify and detect 
the small amounts of fetal paternally-inherited microsatellite markers in 
the maternal plasma. As these polymorphic microsatellite markers 
(16PTEL05 and 16PTEL06) are located within the breakpoints of the -
SEA deletion, the presence of these fetal paternally-inherited 
microsatellite markers in the maternal plasma confirm the fetal 
inheritance of the unaffected paternal allele, and Hb Bart’s hydrops 
fetalis can be excluded non-invasively. This will allow at-risk mothers 
carrying unaffected fetuses to avoid unnecessary invasive prenatal 
diagnostic procedures. This non-invasive method to exclude Hb Bart’s 
will encourage more at-risk couples to uptake prenatal testing.  
If none of the microsatellite markers (16PTEL05 and 16PTEL06) of the 
unaffected paternal allele is detected, the fetus could either had 
inherited the paternal affected allele and the maternal unaffected allele 
to be an alpha thalassaemia heterozygous carrier (αα/--), with the fetal 
maternally-inherited microsatellite marker being masked by the 
maternal alleles, or the affected alleles from both parents to have Hb 
Bart’s (--/--). Whether the fetus has inherited the maternal affected or 
unaffected allele will not be known due to the contaminating maternal 
DNA masking the fetal maternally-inherited alleles. Therefore, in the 
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absence of the paternal microsatellite markers in the maternal plasma, 
invasive prenatal diagnosis will be required to exclude false negative 
results by the determination of fetal genotype by conventional methods. 
6.2 Materials and methods 
Patients. Sample collection for research was approved by the National 
Healthcare Group Domain Specific Review Board in Singapore, and all 
volunteers gave written informed consent. Two millilitres of amniotic 
fluid (n=19) and 6 mL umbilical cord blood (n=11) samples were 
collected from 19 mothers undergoing amniocentesis (15+6 – 17+3 
gestational weeks) and 11 mothers undergoing delivery (33+4 – 41+2 
gestational weeks) respectively. Six millilitres of peripheral blood were 
collected from mothers (n=30) and fathers (n=30) in EDTA vacutainer 
tubes. DNA isolation from buffy coat, plasma and amniotic fluid 
samples were as described in Chapter 2. Singleplex QF-PCR of 
16PTEL05, 16PTEL06 and D16S539 were performed on DNA isolated 
from buffy layers from parental peripheral and fetal umbilical cord blood 
samples, amniotic fluid and maternal plasma samples. Parental 
genotypes were determined by the single-tube α-thalassaemia 
multiplex PCR that detects --THAI, --FIL, --SEA, -α3.7 and –α4.2 deletions 
(Tan et al., 2001). Fetal genotypes were determined in cases where 
both parents carry alpha-globin double gene deletions (αα/--). 
Sensitivity of singleplex QF-PCR.  Efficacy of using QF-PCR to 
detect small amounts of spiked target DNA (A:B) in the following 
dilutions; 1:1, 1:2, 1:10, 1:20, 1:50 where both A and B were isolated 
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from the peripheral blood of healthy volunteers (αα/αα) and diluted to 5 
ng/µL before spiking. As proof-of-principle to demonstrate the 
reproducibility of our optimised protocol to detect low amounts (3-6%) 
of non-deleted fetal alleles carrying the microsatellite markers in the 
maternal plasma of alpha thalassaemia carriers (αα/--; labelled as ‘X’ 
and ‘Y’), QF-PCR was performed for spiked alpha thalassaemia DNA 
samples at a detection limit of 2% (at the lowest 1:50 dilution). Table 6-
1 shows the combinations of different X and Y samples for this spiking 
experiment where 2% of samples X (αα/αα, αα/--SEA, --SEA/--SEA, αα/--FIL) 
was diluted in samples Y (αα/--SEA, αα/--SEA, αα/--SEA, αα/--THAI) 
respectively. 
Table 6-1 Table showing the genotypes of spiked alpha 
thalassaemia samples in 1:50 dilution where X is the target DNA 
and Y is the diluent DNA. 
 Target DNA, X Diluent DNA, Y 
A αα/αα αα/--SEA 
B αα/--SEA αα/--SEA 
C --SEA/--SEA αα/--SEA 
D αα/--FIL αα/--THAI 
 
6.3 Results 
Singleplex QF-PCR of spiked controls. The series of spiking 
experiment to investigate the sensitivity of singleplex QF-PCR were 
designed to detect 2% fetal DNA in the maternal plasma. I set the 
detection limit to 2% as it had been shown that the amount of fetal 
DNA in the maternal plasma throughout pregnancy is at 3-6% (Lo et al., 
1998b). In principle, by achieving the 2% detection limit, fetal DNA in 
maternal plasma will be detectable throughout pregnancy. QF-PCR of 
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the microsatellite markers (D16S539, 16PTEL05 and 16PTEL06) were 
performed on a series of spiked DNA dilutions, 1:1, 1:2, 1:10, 1:20 and 
1:50 (50% down to 2%), obtained from healthy volunteers (A:B). DNA 
obtained from Hb Bart’s (--SEA/--SEA) and alpha thalassaemia carriers 
(αα/--SEA, αα/--FIL and αα/--THAI) were spiked in 1:50 dilution (2%) to test 
the reproducibility (Table 6-1). Figure 6-1 shows the QF-PCR 
electropherograms of D16S539, 16PTEL05 and 16PTEL06 on DNA 
sample A spiked in varying dilutions in sample B (1:1, 1:2, 1:10, 1:20 
and 1:50). The targeted alleles of samples A (as indicated by arrows) 
can be detected in all dilutions for all markers including the lowest 1:50 
dilution. The bottom panel shows electropherograms with an amplified 
Y-axis scale to demonstrate the presence of target allele(s) of sample 
A clearly. Neat DNA sample B shows the absence of alleles of sample 
A. In Figure 6-2  where (A) αα/αα spiked in αα/--SEA, (B) αα/--SEA spiked 
in αα/--SEA, (C) --SEA/--SEA spiked in αα/--SEA, and (D) αα/--FIL spiked in 
αα/--THAI, at dilutions of 1:50, arrows show the presence of target 
allele(s) of sample X spiked in sample Y. The non-deleted 
microsatellite markers (16PTEL05 and 16PTEL06) (arrows) of the 
target (X) DNA samples with αα/αα or αα/-- genotypes can be detected 
in all 2% spiked samples Y (αα/--). The bottom panels show the 
electropherograms with a different y-axis scale to enlarge the target 
peak(s) of samples X more clearly. All non-spiked samples Y showed 
absence of samples Y alleles. The presence of “paternal identifier”, 
D16S539, acts as a control to exclude PCR amplification failure in the 
absence of 16PTEL05 and 16PTEL06 amplification. 
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Figure 6-1 Figure showing the sensitivity of singleplex QF-PCR 
to detect 2% target DNA in spiked normal controls. 
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Figure 6-2 Figure showing QF-PCR electropherograms of 
16PTEL05, 16PTEL06 and D16S539 of spiked DNA samples (X:Y).  
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The presence of fetal paternally-inherited microsatellite markers (either 
16PTEL05 or 16PTEL06, or both) in maternal plasma will exclude Hb Bart’s 
while the absence of both would require invasive prenatal diagnosis to 
exclude false negatives. After testing the reproducibility of my protocols in the 
amplification and detection of 2% target alleles, the optimised singleplex QF-
PCR was performed on DNA isolated from parental peripheral blood, fetal 
samples (either amniotic fluid obtained at amniocentesis, n=19, or umbilical 
cord blood obtained at delivery, n=11) and maternal plasma samples from 30 
families in a blinded non-invasive study. In the analysis of maternal plasma 
samples, 10 fetuses were excluded of Hb Bart’s with the respective maternal 
plasmas showing the presence of non-deleted paternally-inherited fetal alleles 
carrying either 16PTEL05 or 16PTEL06 (n=5), or both (n=10) in as early as 
15+6 gestational weeks.   
Table 6-2 shows the comparison of results obtained from (a) maternal plasma 
study, (b) fetal DNA analysis by QF-PCR, and (c) genotypes of 30 couples 
and their fetuses. In the analysis of fetal DNA (b), 27 samples were 
considered unaffected with the presence of either 16PTEL05 and/or 
16PTEL06. These markers are not deleted and therefore, exist in the genome 
of these fetuses. Two fetuses were concluded as either carriers or 
homozygous (C/H) with the presence of one allele of 16PTEL05 and 
16PTEL06. Hb Bart’s was confirmed in one fetus with the absence of both 
16PTEL05 and 16PTEL06. In the gel-based genotyping test that detects --
THAI, --FIL, --SEA, -α3.7, and -α4.2 deletions (c), nine mothers were found to 
be alpha thalassaemia carriers (seven αα/--SEA and two αα/-α3.7). In 3 
couples (as shown in Table 6-2, families 2, 7 and 14) both parents of families 
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2 and 7 carried αα/--SEA. In family 14, the father carried αα/-α3.7 while the 
mother carried αα/--SEA. The gel-based genotyping test was performed in fetal 
samples from these families and Hb Bart’s (--SEA/--SEA) was detected in the 
fetus of family 7. The fetuses of families 2 and 14 were identified as normal 
and αα/--SEA respectively. Figure 6-3 shows the gel-based genotyping results 
of fetal DNA from families 2, 7 and 14 as αα/αα, --SEA/--SEA and αα/--SEA 
respectively. LIS1 is a control locus in 17p13.3.  
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Table 6-2 Table showing the results from (a) maternal plasma study, (b) fetal DNA analysis by QF-PCR, and (c) 
genotypes of 30 couples and their fetuses. 
FDMP denotes Fetal DNA in the Maternal Plasma. Hb Bart’s were excluded in 10 families (highlighted) with the detection of 
paternally-inherited fetal alleles (16PTEL05 and/or 16PTEL06) in FDMP. 
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Figure 6-3 Figure showing alpha thalassaemia multiplex PCR 
genotyping results (αα/αα, --SEA/--SEA and αα/--SEA) of fetuses from 
families 2, 7 and 14 respectively.   
 
M: 1 kb DNA ladder, B: water blank, Controls: αα/--THAI, --FIL/-α3.7, αα/-α4.2 and 
αα/--SEA, Samples: 2, 7 and 14 obtained from umbilical cord blood of families 2, 
7 and 14 respectively. 
 
Figure 6-4 Figure shows the singleplex QF-PCR for maternal plasma 































































As shown in (A), the non-deleted fetal paternally-inherited alleles (16PTEL05 
and 16PTEL06) were amplified and detected in maternal plasma (arrows) and 
Hb Bart’s was excluded in this fetus. Parental genotypes showed that both 
parents are normal (αα/αα). In (B), fetal paternally-inherited allele was absent 
in the maternal plasma and therefore, Hb Bart’s was not excluded in this fetus 
from family 7. Parental genotypes showed both parents carrying the --SEA 
deletion and subsequent fetal genotyping confirmed Hb Bart’s (--SEA/--SEA). 
Fetal genotyping confirmed --SEA/--SEA. Using this strategy, Hb Bart’s can be 
excluded by the detection of paternally-inherited fetal microsatellite markers 
(either 16PTEL05 or 16PTEL06, or both) in the maternal plasma. In a mixed 
population of unaffected (n=21) and at-risk (n=9) mothers, Hb Bart’s was 
correctly excluded in 10 out of 30 fetuses. Of the at-risk mothers, one mother 
was found to be carrying a fetus with Hb Bart’s. The sensitivity for diagnosis of 
an affected case was 100%, the specificity was 37.5%, and the negative 
predictive value was 100%. 
Statistical analysis. The sample size in this proof-of-principle study is small. 
Of the thirty families recruited, nine mothers were alpha-thalassaemia carriers 
and the remainder were unaffected volunteers. In this exclusion study, the 
presence of a distinct paternal STR excludes Hb Bart’s in the fetus; this will be 
treated as ‘test negative’. The absence of a distinct paternal STR will be 
treated as ‘test positive’. The sensitivity, specificity and negative predictive 
value will be reported only for the at-risk mothers (n=9). By chance, one out of 
the nine fetuses was Hb Bart’s, which alters the prevalence of this disease in 




Diagnosis of Hb Bart’s affecting fetuses of carrier parents required invasive 
prenatal testing. This study showed that non-deleted paternally-inherited fetal 
microsatellite markers located within the alpha thalassaemia double-gene 
deletion region can be detected within the maternal plasma. I explored the 
possibility of using these markers to non-invasively exclude Hb Bart’s in the 
fetus of carrier parents. Results suggest that in 1 in 3 cases this test could 
eliminate the need for invasive diagnostic sampling. Fetal DNA comprises 
between three to six percent of total DNA in maternal plasma (Lo et al., 
1998b). During the optimisation phase using spiked DNA samples, I set our 
detection threshold target to two percent for QF-PCR. In spiked samples I 
could readily amplify and detect target DNA in diluent DNA down to the lowest 
dilution of 1:50. Use of polymorphic microsatellite markers allow the 
identification of paternally-inherited alleles amplified from within maternal 
blood (González-González et al., 2003; 2005). Within the cell-free DNA 
fraction of maternal plasma, presence of a distinct microsatellite marker 
matching the unaffected paternal allele suggests inheritance of the undeleted 
alpha-globin cluster from the father. This excludes Hb Bart’s in the fetus. In 
contrast, if a distinct paternal allele is not detected, the fetus could be either (1) 
heterozygous or (2) homozygous for the double gene deletion and have Hb 
Bart’s. In the former case, the fetus would have inherited the affected paternal 
allele but the unaffected maternal allele. The fetal maternally-inherited normal 
allele would be indistinguishable from the mother’s own alleles within her cell-
free DNA in plasma. In the latter case, the fetus would have inherited the 
affected alleles from both parents and be afflicted with Hb Bart’s. In the 
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absence of a distinct paternal microsatellite marker in the maternal plasma, 
invasive prenatal testing would be necessary to identify a false positive result 
(carrier fetus), or diagnose Hb Bart’s in the fetus (true positive). 
As proof-of-principle that this technique could detect non-deleted paternally-
inherited fetal alleles within the maternal plasma, I studied 30 families 
consisting of both unaffected (n=21) and at-risk (n=9) mothers. In one third of 
the cases (10 out of 30), I could readily detect the paternally-inherited fetal 
microsatellite marker. Invasive fetal testing could potentially be avoided in 
such cases. This test would be useful only in cases where both parents are 
known carriers of the alpha-thalassaemia double gene deletion syndromes. Of 
the nine at-risk mothers in this case series, I could readily detect the 
paternally-inherited fetal microsatellite marker in three cases, suggesting that 
in a third of at-risk cases invasive prenatal testing could be avoided. Of the 
remaining six at-risk mothers who would have required invasive testing, one 
fetus was affected with Hb Bart’s. In this small series, the sensitivity for 
diagnosis of an affected case was 100%, the specificity was 37.5%, and the 
negative predictive value was 100%, but the true accuracy of this test and the 
confidence intervals will need to be determined in a larger clinical study. 
Technical issues limit the accuracy of this test which detects paternal 
inheritance in only one-third of the 30 analysed cases. First, if both parents 
carry the same microsatellite markers, it is not possible to distinguish the 
paternally-inherited fetal allele(s) within maternal plasma cell-free DNA. More 
microsatellite markers are required in order to improve the informativeness of 
this test. However, we could only find two polymorphic microsatellite markers 
(16PTEL05 and 16PTEL06) located within the 2 kb deletional region. The use 
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of single nucleotide polymorphisms (SNPs) which are present in abundance in 
the human genome as compared to microsatellite markers (1 in every 100 - 
300 bases) will be useful. Being bi-allelic, SNPs are not as polymorphic as 
STRs (Butler et al., 2007). However, the abundance of SNPs is significant in 
improving the informativeness and therefore, detection rate of our test. In 
addition, with a smaller target region, efficiencies of amplification/ detection of 
short fragments (<500 bp) of cell-free fetal DNA in maternal plasma can be 
improved (Hromadnikova et al., 2006). Second, amplification of non-specific 
stutter peaks that occurs due to polymerase slippage mispairing during PCR 
of STRs can mask the presence of paternally-inherited fetal microsatellite 
markers that may be present in the maternal plasma. These technical 
challenges lead to uninformative results in two out of three cases. The 
combined use of size-fractionation to enrich fetal DNA from the maternal 
plasma together with MALDI-TOF MS for SNP detection may enhance the 
resolution of detecting paternally-inherited fetal alleles in the maternal plasma. 
In conclusion, the detection of paternally-inherited fetal microsatellite markers 
in cell-free fetal DNA in the maternal plasma is useful to exclude Hb Bart’s 
non-invasively. Although the accuracy of this study cannot be determined due 
to the small sample size, I had shown that more than one-third of at-risk 
mothers carrying unaffected fetuses can be excluded of Hb Bart’s non-
invasively. These mothers will avoid unnecessary invasive procedures that 




For couples where both parents carry the --SEA deletion, there is a 1 in 4 
chance that the fetus will inherit both the parents’ deleted alleles, and be 
affected with Hb Bart’s. Almost all fetuses with Hb Bart’s are stillbirths or die 
shortly after birth. Therefore, efforts should be directed to identify couples at 
risk and provide them with genetic counselling and prenatal diagnosis so that 
they can make an informed choice (Leung et al., 2005). The aim of prenatal 
diagnosis is to provide an accurate and rapid result as early in the pregnancy 
as possible. Current prenatal diagnostic tests require pure fetal DNA to be 
obtained for analysis. Prenatal diagnosis is performed using pure fetal DNA 
isolated from chorionic villi, amniocytes or fetal blood samples. These 
samples are obtained from chorionic villus sampling (CVS) or amniocentesis. 
Fetal blood samples for haemoglobin studies are obtained from cordocentesis. 
These invasive methods carry a 1-4% risk of procedural-related miscarriage 
unacceptable to some couples. Therefore, alternative non-invasive methods 
of prenatal diagnosis will encourage more couples to undergo early screening 
and analysis. Screening for alpha thalassaemia mutations is crucial in our 
population due to its high prevalence. 
Recent studies have demonstrated the presence of cell-free fetal DNA 
circulating in the maternal plasma of pregnant women (Lo et al., 1997). This 
represents an alternative source of fetal genetic material for non-invasive 
prenatal diagnosis of genetic diseases. However, although fetal DNA amounts 
to 3-6% of the total DNA in maternal plasma during pregnancy (Lo et al., 
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1998b), the ability to diagnose fetal genetic disease in the overriding maternal 
DNA is a technical challenge. The diagnostic reliability depends on the 
sensitivity and specificity of the analytical system for the detection of fetal-
specific markers. In principle, any fetal DNA sequence that differs from 
maternal DNA sequence can be identified in maternal plasma, thus allowing 
non-invasive prenatal testing of paternally-inherited genetic diseases. 
7.2 Hypotheses 
The aim of this thesis was to examine whether Hb Bart’s can be excluded 
non-invasively using cell-free fetal DNA from the maternal plasma. I 
hypothesized that: (i) QRT-PCR can detect and quantify fetal DNA from the 
maternal plasma, (ii) Hb Bart’s can be identified simultaneously with maternal 
contamination exclusion using microsatellite markers within deleted regions, 
(iii) QF-PCR of these microsatellite markers will exclude Hb Bart’s non-
invasively using fetal DNA from the maternal plasma  
7.3 Findings 
7.3.1 Sensitivity and specificity of real-time PCR (QRT-PCR) 
The sensitivity and reliability of QRT-PCR was tested by gene dosage 
quantitation to detect DS. The relative quantitation real-time multiplex PCR 
was designed to amplify both the target (APP) and endogenous reference 
(HBB) genes within the same tube. By using the mean ΔCT (HBB-APP) to 
compare the gene expression levels of APP and HBB, 3 DS out of 85 
amniotic fluid samples were identified accurately. QRT-PCR is accurate in 
gene dosage discrimination between 2 and 3 copies in normal and DS 
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samples respectively. QRT-PCR amplified the lowest standard curve serial 
dilution of 1.5 copies in all reactions. 
7.3.2 Detection of fetal DNA from maternal plasma 
Pregnancy-related complications. Cell-free fetal DNA isolated from 
maternal plasma of two pregnant women with pregnancy-related 
complications (PE, HELLP) were amplified using QRT-PCR of SRY and HBB. 
Significant increases in fetal and total plasma DNA concentrations (measured 
by SRY and HBB amplifications respectively) were observed as compared 
with normal 3rd trimester pregnancies (Birch et al., 2005). These elevated 
concentrations maybe useful as markers for the non-invasive evaluation of the 
pathophysiological severity of pre-eclampsia and HELLP syndrome. However, 
this system is limited to mothers carrying singleton male fetuses as detection 
of fetal DNA is based on the presence of Y-chromosome specific sequences 
(e.g. SRY) in the maternal plasma.  
Normotensive pregnancies. I showed that cell-free fetal DNA can be 
detected and quantified in as early as 8+2 gestational weeks in unaffected 
pregnancies. Using QRT-PCR of SRY, fetal gender can be determined with 
100% accuracy in fetal gender determination throughout the 3 trimesters. 
Fetal DNA concentration in maternal plasma increased as pregnancy 
progressed (from a median of 11.1 GE/mL in the first trimester to a median of 
84.8 GE/mL in the third trimester).  
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7.3.3 Use of microsatellite markers to identify Hb Bart’s from fetal DNA 
Microsatellite markers within the common alpha thalassaemia breakpoints 
(16PTEL05, 16PTEL06) were analysed for polymorphism with DNA from 100 
amniotic fluid samples. The heterozygosities of all these markers were high, 
with polymorphism information content of >0.5 (0.76 - 0.86) (Table 5-2). 
Therefore, they can be suitably used to exclude maternal contamination and 
at the same time, diagnose Hb Bart’s. Eleven of the fifty fetuses tested were 
correctly identified as Hb Bart’s. Twenty were verified as unaffected and the 
remaining 18 were identified as either carriers (αα/--SEA) or unaffected 
homozygotes. One carrier was misdiagnosed as unaffected by my multiplex 
QF-PCR. Sensitivity for diagnosis of Hb Bart’s was 100% (lower 95% CI, 
76.2%), and specificity was 100% (lower 95% CI, 92.6%). None of the 
samples tested showed any traces of non-inherited maternal alleles, 
eliminating any false positives due to contamination by maternal DNA. In 
conclusion, these polymorphic microsatellite markers are able to discriminate 
between maternally- and paternally- inherited alleles, which could be useful 
for the detection of fetal paternally-inherited alleles in the maternal plasma. 
The presence of fetal paternally-inherited alleles in the maternal plasma would 
exclude Hb Bart’s non-invasively. 
7.3.4 Use of microsatellite markers to exclude Hb Bart’s non-invasively 
using fetal DNA from maternal plasma 
Hb Bart’s was excluded with 100% accuracy using cell-free fetal DNA in 
maternal plasma by the analysis of the same microsatellite markers 
(16PTEL05, 16PTEL06). I excluded Hb Bart’s in 10 of 30 (33.3%) at-risk 
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mothers who carried alpha-globin gene deletions, 7 αα/--SEA, 2 αα/-α3.7 (3 of 9), 
and unaffected (7 of 21) mothers with the presence of paternally-inherited 
fetal alleles carrying either 16PTEL05 or 16PTEL06 (n=5) or both (n=5). Of 
the 6 at-risk mothers who were not excluded, Hb Bart’s (--SEA/--SEA) was 
detected in one fetus as confirmed with the genotyping test. All 10 mothers 
who were excluded of Hb Bart’s were confirmed to be unaffected. Thus, in 
one-third of a general population that consist of at-risk and unaffected 
mothers, Hb Bart’s can be excluded non-invasively using our method. More 
than one-third (37.5%, 3 out of 8) of at-risk mothers carrying unaffected 
fetuses would had avoided unnecessary invasive tests and any risk of fetal 
loss eliminated. In conclusion, the use of two highly heterozygous 
microsatellite markers in my method allowed me to exclude 33.3% (7 out of 
21) unaffected and 37.5% at-risk mothers of carrying Hb Bart’s fetuses. With 
this non-invasive method for prenatal screening of Hb Bart’s, invasive testing 
with its attending fetal loss rates is avoided for one-third of the population. My 
method of detecting paternally-inherited fetal microsatellite markers within 
deleted regions in maternal plasma could also be useful for non-invasively 
excluding other deletional mutations such as DiGeorge syndrome. 
7.4 Limitations 
Due to the very small amounts of fetal DNA present in the maternal plasma, 
the number of amplification cycles in QRT-PCR and QF-PCR need to be 
increased. This increase in the number of amplification cycles increases the 
sensitivity. The high sensitivity of the technique means that foreign 
contaminating DNA or amplicons will be amplified and detected as false 
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positives or negatives. Therefore, the use of external and internal negative 
controls is crucial to exclude false positives/ negatives results. External 
controls, which are essentially water instead of maternal plasma samples, are 
included in every DNA isolation process of the maternal plasma. Internal 
negative controls are water blanks used in place of DNA during the setup of 
PCR reactions. DNA sample preparation, setup of PCR reactions and PCR 
process were performed in separate areas. A laminar flow safety cabinet 
(Gelman BH Class II Series, Singapore) equipped with a UV lamp was used 
for the preparation of PCR reaction mixtures. Fresh gloves were worn for DNA 
isolation and each reaction setup. The reagents were aliquoted into small 
portions and stored in designated PCR areas separately from other DNA 
samples. In cases where the external negative controls were contaminated, 
DNA isolation was repeated on stored samples. In cases where internal 
negative controls were contaminated, the PCR had to be repeated. 
 Another major limitation of this project is the presence of stutter and pull-up 
peaks. Stutter peaks differ in size from the main alleles with multiple repeating 
units. They arise from polymerase slippage mispairing which occurs with the 
dissociation of polymerase from the single strand DNA template before the 
complete synthesis of the complementary strand. This result in a 
complementary strand that is short of 1 repeat unit. These incomplete 
amplicons act as the template in subsequent cycles and with the completion 
of PCR, a series of amplicons, which are shorter than the true allele result. 
These are known as ‘stutter peaks’. Pull-up peaks are short peaks that are 
one repeating unit larger than the true allele. These peaks result from the high 
intensity of the true peak and appear as ‘pull-up’ from the preceding true peak. 
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Dinucleotide repeats are prone to polymerase slippage mispairing (Schlotterer 
and Tautz, 1992; Murray et al., 1993; Walsh et al., 1996; Hashem and Sinden, 
2005). As the microsatellite markers (16PTEL05 and 16PTEL06) consist of 
STRs that are made up of dinucleotide repeating units (CA)n, stutter peaks 
are inevitable. The increase in the number of cycles in order to amplify and 
detect the small amounts of fetal DNA in the maternal plasma amplified the 
stutter peaks concurrently. As these amplified stutter peaks are smaller size 
fragments than true alleles, fetal paternally-inherited alleles which are smaller 
than the maternal allele are therefore masked. In addition, the presence of the 
‘pull-up’ peak will also mask fetal paternally-inherited allele that is one repeat 
unit larger than the true allele. 
To minimise the occurrences and intensity of stutter peaks, the cycling profile 
was optimised with the highest annealing temperature (TA = 66°C) and lowest 
extension temperature (TE = 60°C) possible. I extended the extension time to 
90 seconds instead of 30 seconds to ensure maximum association of the 
polymerase with the single strand DNA template for complete synthesis of the 
complementary strand. This increase in extension time was necessary as the 
height of the stutter peaks decreases, allowing a better resolution of the true 
alleles. The final optimised QF-PCR protocol minimises the number of stutter 
peaks that accompanies each true allele to not more than 4. Therefore, 
smaller fetal paternally-inherited alleles that fall within 4 repeating units less 
than the maternal allele will be masked by stutter peaks of the maternal 
alleles. In addition, fetal paternally-inherited allele that is one repeat unit larger 
than the true allele will also be masked by the ‘pull-up’ peak. As shown in 
Figure 7-1, the true allele (orange) with n repeating units. Accompanying the 
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true peak are the smaller (n-1, n-2, n-3, n-4) stutter peaks (blue) and one 
larger (n+1) ‘pull-up’ peak (yellow).  
Figure 7-1 Stutter peaks.  
Figure shows the true allele (orange) with n repeating units. Accompanying 
the true peak are the smaller (n-1, n-2, n-3, n-4) stutter peaks (blue) and one 
larger (n+1) ‘pull-up’ peak (yellow).  
 
Thirdly, if both parents carry the same microsatellite markers, it is not possible 
to distinguish the paternally-inherited fetal allele(s) within maternal plasma 
cell-free DNA. These technical challenges lead to uninformative results in two 
out of three cases.  
Enzymes with high processivity, high fidelity, high strand displacement activity 
and low slippage were ideal in eliminating and/or minimising polymerase 
slippage mispairing (Viguera et al., 2001). ProofStart DNA Polymerase 
(Qiagen) which was originally isolated from a novel hyperthermophilic 
Pyrococcus spp and cloned into E. Coli was tested. This recombinant 90 kDa 
DNA polymerase contains a 3’ → 5’ exonuclease activity (proofreading activity) 
which functions by recognising and removing incorrectly incorporated 








was no amplification of positive controls. As AmpliTaq Gold™ DNA 
polymerase (ABI) produced consistent results despite the presence of stutter 
peaks, I studied the effects of varying Mg2+ concentrations in affecting the 
fidelity of AmpliTaq Gold DNA polymerase. The high concentrations of Mg2+ 
showed no reductions in the number of stutter peaks but instead, limited the 
yield of amplicons. I concluded that the fidelity of polymerase was not 
probably relevant in stutter peaks as stutter peaks are caused by polymerase 
slippage and not due to misincorporation of nucleotides. Final MgCl2 
concentration in all PCR reactions was thus, left unchanged at 2.0 mM. 
Finally, due to limiting availability of samples, the earliest that fetal paternally-
inherited allele was detected in the maternal plasma is 15+6 weeks of 
gestation. Although prenatal exclusion of Hb Bart’s is useful in the second 
trimester, early prenatal exclusion of Hb Bart’s is more desirable in the first or 
early first trimester for at-risk couples. This will alleviate the anxiety in cases 
where Hb Bart’s are excluded, while in cases where Hb Bart’s are not 
excluded, confirmatory prenatal diagnosis that requires invasive procedures 
(ie. CVS, amniocentesis, FBS) can be performed. In cases where Hb Bart’s 
are diagnosed, genetic counselling can be offered to couples early in 
pregnancy. Maternal morbidities such as preeclampsia and haemorrhage, as 
well as the adverse psychological impact of carrying a hydrops fetalis to term 
only to result in a stillbirth can therefore be prevented. 
7.5 Directions for future research 
Despite these limitations, the high sensitivity of detection as demonstrated 
during the optimisation and reproducibility tests with 2% detection limit allows 
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the detection of low amounts of fetal DNA in the maternal plasma. This 
strategy is useful in countries where the population is at high risk of carrying a 
fetus with Hb Bart’s. In Singapore, the predicted frequency of alpha 
thalassaemia carriers with double-gene deletions is 3%. With the yearly birth 
rate of 40,000, the number of at-risk mothers who are carriers and require 
invasive testing for alpha thalassaemia will be projected at 1200. SNPs have 
been shown to be another novel strategy that can distinguish paternally-
inherited fetal alleles within maternal plasma as SNPs occur more frequently 
in the human genome (Dhallan et al., 2007). One of the future directions in 
this research is to explore the possibility of using sensitive SNP analysis 
platforms such as MALDI-TOF to enhance the accuracy of the non-invasive 
prenatal exclusion of Hb Bart’s. In addition to -SEA type deletion, this technique 
is also applicable to screening parents who are alpha thalassaemia carriers of 
αα/--THAI or αα/--FIL as these microsatellite markers lie within the breakpoints of 
-THAI and -FIL. By offering this technique for the non-invasive prenatal exclusion 
of Hb Bart’s, screening for alpha thalassaemia double-gene deletions will 
become more effective as couples will find non-invasive testing more 
acceptable than current invasive procedures. 
7.6 Conclusions  
Cell-free fetal DNA and fetal cells in the maternal circulation provides a non-
invasive source of fetal genetic material for prenatal diagnosis. Fetal cells are 
rare and technically challenging to obtain for prenatal diagnosis. Cell-free fetal 
DNA present in larger amounts (3-6%) in the maternal plasma and is more 
feasible for prenatal diagnosis, as shown by the establishment of fetal Rhesus 
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status testing worldwide. The major limiting factor in using cell-free fetal DNA 
in the maternal plasma is that fetal genetic sequences need to differ from 
maternal genetic sequences to enable differentiation from the overwhelming 
contaminating maternal DNA. In this thesis, I utilised polymorphic 
microsatellite markers to differentiate between fetal and maternal genetic 
sequences. I have shown that these polymorphic microsatellite markers are 
able to discriminate between fetal paternally-inherited alleles from maternal 
alleles. In addition, these microsatellite markers lie within the breakpoints of 
common alpha thalassaemia double gene deletions such as –SEA, -FIL and –
THAI, and therefore, presence of fetal paternally-inherited alleles will exclude 
Hb Bart’s that were caused by these deletions. 
In conclusion, I have achieved the main aim of my thesis to develop a non-
invasive prenatal test to exclude Hb Bart’s using cell-free fetal DNA in the 
maternal plasma. This non-invasive test will encourage more at-risk couples 
to uptake prenatal testing and allow at-risk mothers carrying unaffected 
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